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1. Introduction 
 
  1.1 The transcriptional control by RNA polymerase II 
 
Transcription is a complex process that relies on the collective action of the 
sequence-specific factors along with the core RNA polymerase II (RNAPII) 
transcriptional machinery (Figure 1). The control of this process is predominantly 
mediated by a network of thousand sequence-specific DNA binding transcription 
factors that interpret the genetic regulatory information and that bind to the proximal 
promoter and distal transcriptional regulatory regions such as activators and 
repressors (named enhancers and silencers) (Kadonaga,2004). In fact, it has 
demonstrated that the transcriptional activators recruit the RNAPII-containing 
transcription initiation apparatus to promoters of protein-coding genes (Lee and 
Young 1998). The binding of RNAPII depends on an associated multi-subunit 
complex TFIID, which is composed of TBP and TBP-associated factors (TAFs). In 
particular, TFIID binds TATA via TBP and interacts with regulatory elements through 
different TAFs. As shown in figure 2, the cis-regulatory DNA elements of eukaryotic is 
highly structured and exhibits a modular organization consisting of enhancer and 
silencer and discrete core promoter. It should be considered that exist different 
protein complexes that interact with these regulatory DNAs. In particular there are 
three major strategies for regulating the binding and function of RNAPII complex at 
the core promoter. First, divergent TFIID complexes bind specific sequence elements 
within the core promoter and recruit RNAPII. Second, multi-subunit transcription 
complexes that are related to the yeast Mediator complex also facilitate the binding 
and function of RNAPII. Third, there are enzymatic complexes that remodel or modify 
chromatin (for example acetylation) (Levine and Tjian, 2003).  
Target of diverse mammalian activators is the Mediator complex, which is an 
evolutionary-conserved complex that contains approximately 25–30 subunits and has 
multiple roles in transcriptional regulation (Conaway et al.,2005). Based upon its 
ability to support activated, but not basal, transcription in vitro, the Mediator complex  
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is often referred to as a coactivator. However, several Mediator subunits are required 
for transcription of almost all genes and it has been proposed to be an activator  
 
 
 
 
 
 
 
 
Figure 1:  Rapresentation of the eukaryotic promoter and its transcriptional control modules. 
 
The molecular apparatus controlling transcription in human cells consists of three kinds of components: the 
numbered proteins alone with RNA PolymeraseII, the basal transcription factors which are essential for 
transcription and the task falls to regulatory molecules known as activators and repressors. Activators, and 
possibly repressors, communicate with the basal factors through coactivators-proteins that are linked in a tight 
complex to the TATA-binding proteins, the first of the basal transcription factors to land on the core promoter. 
 
 
 
 
 
 
 
Figure 2:  The multi-subunit general apparatus 
 
The eukaryotic transcriptional apparatus can be subdivided into three broad classes of multi-subunit 
ensembles that include the RNAPII core complex and associated general transcription factors  (TFIIA-B-D-E-
F-and H), multi-subunit cofactors (Mediator) and various chromatin modifying or remodeling complexes 
(SWI/SNF, RSF and so on).  
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target. Several studies have now conclusively shown that distinct subunits of the  
mammalian Mediator complex are essential and selective targets of different 
transcriptional activators. This complex is tightly associated with RNAPII molecules 
that lack phosphate on their Carboxy-Terminal repeat Domain (CTD); in contrast, the 
elongator complex and various RNA processing factors become associated with 
RNAPII molecules with hyperphosphorylated CTDs (Lee and Young, 2000).  
Purified eukaryotic RNAPII typically has 10 to 12 subunits and is capable of DNA–
dependent RNA synthesis in vitro, but is incapable of specific promoter recognition in 
the absence of additional factors. It contains, in the largest subunit of RNAPII, a 
unique Carboxy-Terminal repeat Domain (CTD) that consists of tandem repeats of a 
consensus heptapeptide sequence (Tyr-Ser-Pro-Tyr-Ser-Pro-Ser). The CTD 
consensus sequence is highly conserved in eukaryotes, although the number of 
heptapeptide repeats varies from 26 in S. Cerevisiae to 52 in humans. It is known 
that the functions of the CTD are closely associated with the phosphorylation state of 
the domain. In fact, the switch in CTD phosphorylation states that occurs between 
transcription initiation and elongation and it appears to cause the RNAPII molecule to 
switch cofactor. Moreover, genetic studies have shown that the CTD is essential for 
the function of RNAPII because deletions that remove only a fraction of the 
heptatpeptide repeats can be lethal (Nonet, Sweetser and Young, 1987). Therefore, 
the RNA polymeraseII transcription, could be summarized in a “cycle of events” 
divided into a number of distinct step (Figure 3). In order for RNAPII to transcribe a 
gene, it needs to be recruited to the promoter, assemble with the general 
transcription factors (GTFs) and then initiates the transcript (pre-initiation complex 
assembly, open complex formation and initiation). Because regulation of transcription 
obviously occurs in the context of chromatin and the DNA template is embedded in 
chromatin, RNAPII transcription thus also entails recruitment of chromatin-remodeling 
complexes, such as ATP-dependent chromatin remodelling machines and histone-
modifying enzymes to facilitate the process. After this, the polymerase needs to 
escape the ties that bind it to the promoter and become engaged in processive 
mRNA production (promoter clearance) (Svejstrup, 2003). As transcript elongation 
proceeds, the RNA transcript is matured by capping and splicing, and these events 
as well as termination-coupled processes leading to m-RNA poly-adenylation all 
happen co-transcriptionally, that is coupled in the progress of RNAPII through the  
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gene (Proudfoot et al., 2002). Finally, the transcription terminates and RNAPII is 
recycled for utilization in new rounds of transcription. 
 The elongation stage of eukaryotic mRNA transcription represents an important 
regulatory step in the control of gene expression (Bentley 1995). Studies during the 
past several years have demonstrated that the regulation of transcription elongation 
by RNAPII is not a simple process as once considered to be. Perhaps, the regulation 
of the RNAPII elongation is a multifaceted and complicated step, as the transcription 
initiation. The transcription elongation complex, once thought to be composed of 
merely the DNA template, RNAPII and the nascent RNA transcript, have been 
studied during the past years have resulted in the discovery of a diverse collection of 
transcription elongation factors that are either directly involved in the regulation of the 
rate of the elongating RNAPII or can modulate mRNA processing and transport 
(Shilatifard, 2004). A requirement for phosphorylation of the CTD in elongation by 
RNAPII  was initially proposed on the basis of evidence  that CTDs of actively 
elongating polymerase are highly phosphorylated and that polymerase containing 
hypophosphorylated CTDs preferentially enter the preinitiation complex, where they 
are subsequently phosphorylated during or shortly after initiation (Serizawa, 
ConawayJW and Conaway RC, 1993). Phosphorylation of CTD occurs on both 
Serine2 (Ser2) and Serine5 (Ser5) (Figure 4).  
Two kinases have been identified that can phosphorylate the CTD and, based partly 
their tight association with the initiation apparatus, are almost certainly involved in 
regulation of transcription initiation. In particular, Ser5 phosphorylation by TFIIH-
associated CDK7/cyclinH kinase occurs at or near the promoter, while Ser2 
phosphorylation by CDK9-componet of P-TEFb elongation factor, is seen primarily on 
polymerase molecules that have moved away from the promoter region and are 
engaged in transcript elongation (Komarnitsky and Buratowski, 2000). During the 
transcription cycle concomitant with or following the termination of transcription 
dephosphorylation of the CTD must occurs in order to regenerate the non-
phosphorylated form of the enzyme that appears to be recruited to promoters 
(Majello and Napolitano, 2001). While several RNAPII CTD kinases have been 
described, has been demonstrated that transcription initiation requires Fcp1/Scp1-
mediated dephosphorylation of phospho-CTD. Fcp1 and Scp1 belong to a family of 
Mg2+-dependent phosphoserine/phosphothreonine-specific phosphatases.  
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gene silencing that bound to mono- and diphosphorylated peptides encompassing 
the CTD heptad repeat (Y1S2P3T4S5P6S7). This combined structure-function analysis 
Termination 
Transcriptional 
Cycle 
Transcript elongation 
Initiation  
Figure 3: The transcriptional cycle 
Figure 4: Transcription elongation - The Pol II CTD phosphorylation cycle 
After RNAPII has been recruited into a pre-initiation complex, the CTD repeat is phosphorylated on Ser 5 by the 
CDK-7 subunit of the GTF TFIIH. This phosphorylation is required for Pol II to transcribe beyond the immediate 
promoter region (clearance), and for recruitment of the mRNA capping enzyme. Subsequently, phosphorylation of 
CTD Ser 2 by CDK-9 facilitates elongation and is required for mRNA termination, cleavage, a d proces ing . CDK-
9 is a subunit of the GTF P-TEFb (positive transcription elongation factor b)  
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Recently Zhang et al. showed that Scp1 is an evolutionarily conserved regulator of 
neuronal discloses the residues in Scp1 involved in CTD binding and its preferential 
dephosphorylation of P.Ser5 of the CTD heptad repeat (Zhang et al., 2006).  Thus it 
seems reasonable to assume that perturbation of transcript elongation or RNA 
processing events will also turn out to impact on initiation events at the promoter. 
 
 1.2 The P-TEFb complex 
 
Over the past decade, the identity of positive elongation factor (P-TEFb) was 
revealed. Numerous cellular proteins have been reported to interact with P-TEFb and 
many studies, demonstrated that about 50% of P-TEFb is present in active form and 
the other half of P-TEFb exists in a calitically inactive form (Ngujen et al., 2001; Yang 
et al., 2001, Michels et al., 2003 ). In particular, the small complex is a heterodimeric 
complex and is catalitically active and it comprises two subunit, cyclin-dependent 
kinase-9 (CDK9) and Cyclin T1, T2 or K. In contrast, the large complex is inactive 
and contains 7SK small nuclear RNA (7SKsnRNA) and HEXIM1 (Michels et al, 2003; 
Yik et al, 2003; Chen et al, 2004; Nguyen et al, 2001; Yang et al, 2001) or HEXIM2 
protein (BlazeK et al., 2005).  
Therefore It has demonstrated that P-TEFb is maintained in a functional equilibrium 
through alternately interacting with its positive and negative regulators (JIang et al. 
2005) although the physiological significance of this phenomenon has not been 
demonstrated clearly. It has shown that active and inactive P-TEFb complexes are in 
rapid equilibrium, and as shown in figure 5, either a transcriptional arrest, genotoxic 
insults and UV or RNAse treatments, triggers dissociation of 7SK and HEXIM1 from 
CDK9/Cyclin T resulting in a subsequent accumulation of kinase active P-TEFb 
complex (Nguyen et al, 2001; Yang et al, 2001; Michels et al, 2003).  Moreover, it has 
demonstrated the Hexametylene bis acetamide (HMBA) induced dissociation of 
HEXIM1/7SK from P-TEFb; it is also reminiscent of the situations seen with HeLa 
cells treated with certain stress-inducing agents that globally disrupt transcription and 
suppress cell growth (Chen et al.,2004; Michels et al.,2003; Nguyen et al., 
2001;Yang et al., 2001; Yik et al., 2003).Thus, that pharmacological inhibition of P-
TEFb kinase activity by 5,6-di-chloro-1-b-D-ribofuranosyl-benzimidazole (DRB) 
causes a rapid dissociation of 7SK from P-TEFb (Nguyen et al., 2001 and Michels et 
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al.,2003) as well as Actinomycin D that distrupts P-TEFb/HEXIM1 by transcription 
arrest (Michels et al., 2003).   
In particular, HEXIM1 (HMBA-inducible protein 1), is a human protein isolated in 
smooth muscle cells and it is induced following exposure to hexamethylene bis 
acetamide (HMBA) (Ouchida et al, 2003). It consists of 359 aa and is divided into four 
regions (as depicted in figure 6): a variable N-terminal region (1–149) that is 
suggested to have a self inhibitory function; a central nuclear localization signal (NLS, 
150–177) that interacts with the nuclear transport machinery and directly binds to 
7SK snRNA; a region of highest homology (185–220), including a negatively charged 
cluster that might be involved in P-TEFb inhibition; and a C-terminal Cyclin T binding 
domain (TBD) (255–359) that leads to dimerization of HEXIM1 molecules (Yik et al., 
2004; Michels et al., 2004; Shulte et al., 2005; Barbonic et al., 2005). It has been 
reported by Michels et al., 2004 the importance of two domains of HEXIM1 protein, 
involved in such interactions. Specifically, the HEXIM1 C-terminal domain (181–359) 
is involved in the binding to P-TEFb through direct interaction with CyclinT1 by the 
evolutionarily conserved motif (PYNT aa202–205) and the RNA-recognition motif 
(KHRR) that was identified in the central region of the protein (aa 152–155), involved 
in a direct binding of 7SK snRNA. Therefore, it has shown that HEXIM1 can form a 
stable homo and hetero-oligomers with a protein named HEXIM2. HEXIM2 is a 
protein strongly related to HEXIM1, but smaller, 286 instead of 359 amino acids, and 
coded by a distinct gene in the same locus (Dulac et al., 2005) which altogether with 
HEXIM1 may nucleate the formation of the 7SKsn RNP. Despites their similar 
functions, HEXIM1 and HEXIM2 exhibit distinct expression patterns in various human 
tissues and established cell lines. Notably, in HEXIM1-knocked down cells, HEXIM2 
can functionally and quantitatively compensate for the loss of HEXIM1 to maintain a 
constant level of the 7SK/HEXIM1-bound P-TEFb. Moreover, it has demonstrated 
that the HEXIM1 and/or HEXIM2 proteins, in homo- or heterodimeric forms  (Dulac et 
al., 2005; Yik et al., 2005), bind to distal region of 5’-hairpin of 7SKsnRNA (Egloff et 
al., 2006). Another important component of the inactive P-TEFb complex is the 
human 7SKsnRNA. It is an abundant, RNA polymeraseIII-syntetized, small nuclear 
RNA which functions is a key of cellular mRNA production by controlling the activity 
of the P-TEFb (Garriga and Grana 2004). Thus it has reported that docking of 7SK 
induces a conformational change in HEXIM1 protein that enables their acidic C-
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terminal region  to interact with CyclinT1 (Michels et al., 2004; Yik et al., 2004; 
Barboric et al., 2005). 
 
High Kinase Activity Low Kinase Activity
I II
• Stalled transcription
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• Genotoxic insults
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7SKsnRNA
HEXIM1
 
 
 
 
 
 
 
Figure 5: Active and inactive complexes of P-TEFb 
P-TEFb is regulated by its reversible association with HEXIM1 and 7SK RNA. When P-TEFb is in this RNA-
protein complex , its kinase activity is inhibited.  
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Figure 6: Regulatory domain of HEXIM1 protein 
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Therefore, recruitment and activation of P-TEFb in vivo, necessitates another RNA-
protein interaction formed between the 3’-hairpin of 7SK snRNA and CycT1 (Egloff et 
al., 2006). 
 Notably, the core active P-TEFb complex, is likely also associated with the positive 
regulator bromodomain Brd4 (Jang et al., 2005; Yang et al., 2005). In fact, besides 
7SK and HEXIM1, a bromodomain protein, Brd4 has recently been identified as a 
major factor associated with CycT1/CDK9 heterodimer (Jang et al., 2005). Like all 
components of 7SK snRNA, Brd4 is also ubiquitously expressed (Shang et al., 2004). 
It belongs to the conserved BET family of proteins that carry two tandem 
bromodomains and an extra terminal domain (Yang et al., 2005). The bromodomain 
has been recognized as a functional module in helping decipher the histone code 
through interacting with acetylated histones (Zeng and Zhou, 2002). Consistent with 
this view, Brd4 has been shown to bind to acetylated euchromatin through acetylated 
histones H3 and H4 (Dey et al., 2003). Moreover, the demonstrated binding of Brd4 
to CycT1/CDK9 prompted us to investigate a potential role for Brd4 in P-TEFb-
dependent transcription. In fact, it has been shown that Brd4 and HEXIM1/7SK 
existed in two mutually exclusive CycT1/CDK9-containing complexes and stress 
treatment caused a quantitative conversion of the 7SK snRNA into the complex 
containing Brd4 bound to CycT1/CDK9 (as shown in figure 7). Importantly, the 
association with Brd4 contributed to general transcription through its recruitment of P-
TEFb to transcriptional templates in vivo and in vitro. Moreover, the P-TEFb complex 
holds an important role as kinase. It has demonstrated to phosphorylate the C-
terminal domain (CTD) of the large subunit (Rpb1) of RNAPII (Marshall and Price 
1995) capable to play a pivotal role in productive elongation of nascent RNA 
molecules by RNAPII. In fact, because transcription of pre-mRNAs is blocked shortly 
after initiation by the DRB sensitivity-inducing factor (DSIF) assisted by the negative 
elongation factor (NELF) (Yamaguchi et al, 1999), the release from this block 
involves phosphorylation of the carboxyl-terminal domain (CTD) of RNAPII and 
phosphorylation of negative factors as the Spt5 subunit of DSIF by P-TEFb (Wada et 
al,1998; Ping and Rana, 2001) which results in a productive transcription. Moreover, 
components of the inactive P-TEFb complex (7SK RNA and HEXIM1) contribute to 
the regulation of gene transcription. However, the individual contribution of HEXIM1 
and 7SK RNA to the inhibition of P-TEFb kinase activity has remained unclear.  
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 Figure 7: An equilibrium model for Brd4-P/TEFb interactions  
  P-TEFb occurs either complexed with Brd4 or the inhibitory subunit. The Brd4 bound P-TEFb is recruited to a 
promoter in acetylated chromatin and stimulates RNA polymerase II dependent transcription   
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1.3 The role of P-TEFb complex in  HIV-1 transcription 
 
Many studies shown that P-TEFb is not only essential for the expression of 
most protein-encoding genes, but also it is indispensable for the replication of human 
immunodeficiency virus type 1 (HIV-1) (Jones et al., 1997; Cullen et al., 1998). 
Transcription of HIV-1 proviral DNA by RNAPII is controlled primarily at the  level of 
elongation by the viral Tat protein (Barboric and Peterlin 2005). In fact, many studies 
revealed that HIV-1 gene transcription and replication require the viral transactivation 
factor Tat. The important role of Tat protein is manifested on elongating transcription 
complexes where it alleviates an apparent block to RNAPII processivity at the HIV-1 
Long Terminal Repeat promoter (LTR). In absence of Tat, LTR transcripts terminate 
prematurely: RNAPII clears the HIV-1 promoter but soon arrests due to actions of the 
negative transcription elongation factor (N-TEF), yielding predominantly short viral 
transcripts that contain the transactivation response element (TAR) at their 5’ ends 
(Figure 8). Thus, Tat promotes the transition of abortive complexes to processive, 
elongation-competent complexes, thereby increasing the number of full-length 
transcripts elongated from the HIV-1 LTR promoter (Flores et al., 1999). This is 
proposed to be necessary to activate transcription elongation from the HIV-1-LTR 
promoter (Bienaisz et al., 1998); in fact, during HIV-1 transcription, P-TEFb travels 
with the transcription elongation complex as it moves along the HIV-1 transcription 
unit (Ping et al., 1999).  
The highly cooperative interactions between Tat, TAR and P-TEFb recruit P-TEFb to 
the paused transcription complex, where it phosphorylates the C-terminal domain 
(CTD) of the largest subunit of RNAPII and the components of N-TEF (Negative 
Transcription Elongation Factor). These events convert N-TEF into a positive 
elongation factor and recruit pre-m-RNA splicing and 3’polyadenilation machineries to 
the phosphorylated CTD, resulting in efficient elongation and co-transcriptional 
processing of nascent pre-m-RNA  (Barboric and Peterlin 2005).  Tat is a protein 
encoded by HIV-1, transcribed from multiply spliced viral RNA molecules expressed 
at early stages of viral gene expression. It is composed of the two exons of the viral 
Tat gene and encodes a protein of approximately 101 amino acids and in the late 
stage of the infection cycle, a carboxy-terminally truncated, encoded for Tat protein of 
72 aminoacids also sufficient to transactivate the HIV-1 promoter.  
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Although this protein is able to transactivate the HIV-1 promoter in the absence of 
any viral encoded protein (Jones et al., 2004), a considerable body of evidence 
indicates that Tat interacts with cellular proteins as well as either a highly structured 
RNA element, transactivation-responsive TAR RNA, which is located at the 5’ end of 
nascent viral transcripts or human CycT1 subunit of P-TEFb, which recruits the 
kinase complex to the RNAPII elongation machinery (Bieniasz et al, 1998) (Figure 9). 
As shown in figure 10, Tat binds CyclinT1 by a conserved domain cysteine-rich 
region, which is part of trans-activating domain. An equally cis-region is essential for 
direct contact of Tat with TAR RNA cooperatively and induces phosphorylation of the 
C-terminal domain of RNAPII by CDK9  (Hetzer et al., 2006). Tat stimulates 
transcription elongation through interaction with a transactivation-responsive element 
(TAR) located at the 5’ end of nascent transcripts (Berkhout et al., 1989) and it is 
unique among transcriptional activators in eukaryotic cells in that it functions via RNA 
rather than DNA promoter elements (Barboric and Peterlin 2005). Tat it is the first 
demonstration of a RNA element of a RNA enhancer element. Neither CycT1 nor the 
P-TEFb complex binds TAR RNA in the absence of Tat, signifying that binding to 
RNA is highly cooperative for both Tat and P-TEFb (Chiu et al., 2004). Since most of 
the P-TEFb are sequestered in the catalytically inactive and active complexes in 
cells, Tat could in principle modulate their configurations to increase the pool of P-
TEFb for efficient HIV-1 transcription. 
 Notably, Tat recruits P-TEFb to the HIV-1 LTR independently of Brd4 (Yang et al., 
2005). However, it is unclear whether Tat affects the inactive 7SK snRNA. Because it 
exists an apparent similarities in the molecular RNA protein configurations between 
the HIV-1 TAR-Tat-P-TEFb and the inactive 7SK snRNA, it has demonstrated that 
Tat disrupts 7SK snRNA in cells and releases P-TEFb from it via its activation 
domain. This disruption could be attributed to a direct competition between Tat and 
HEXIM1 for binding to CycT1. Thus, it appears that HIV-1 has evolved an efficient 
mechanism that alleviates the negative regulation of P-TEFb by hijacking it from the 
inactive 7SK snRNP to activate HIV-1 transcription. 
HIV-1 proviral DNA is organized into a higher order chromatin structure in vivo, which 
regulates viral expression by restricting access of the transcriptional machinery to the 
HIV-1 LTR. The LTR acts as a very strong promoter when analyzed as naked DNA in 
vitro (Parada and Roeder, 1996), while it is almost silent when integrated into the 
cellular genome. Hence, chromatin conformation essentially represses transcription 
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from the integrated promoter (Marzio et al., 1998). The viral LTR promoter has a 
structure typical of promoters activated by cellular transcription factors and its “core 
promoter” which contains three in tandem binding sites for the constitutively 
expressed Sp1 transcription factor immediately upstream of a TATA box, is 
necessary for basal levels of LTR-directed RNA synthesis (Figure 9).  
Functional analysis of LTR-driven reporter constructs have shown that the mutation 
of individual or pairs Sp1 sites has a little effect on the basal or Tat-transactivated 
levels of expression (Harrich et al., 1990) but markedly reduces the response of Tat 
(Berkhout and Jeang, 1992). In particular, maximal activation of the LTR requires the 
concerted action of Tat and cellular proteins binding to the enhancer region, which 
lies immediately upstream of the core promoter. The region contains two tandemly 
arranged binding sites (kb-sites) for the dimeric transcription factors composed of 
several combinations of members of the Rel/NF-kb family of polypeptides (Liu et a., 
1992). The predominant complex that binds to the LTR-kb sites in activated cells is 
NF-kb (p50/p65 heterodimer). Furthermore, independent of the viral integration site, 
five nucleosomes (nuc-0 to nuc-4) are precisely positioned within the 5' LTR as 
shown in figure 11. In the transcriptionally silent provirus, these nucleosomes define 
two large nucleosome-free regions spanning nt -255 to -3 and +141 to +265. One 
nucleosome, nuc-1, is located between these two regions. The first nucleosome-free 
region in U3 contains many promoter/enhancer elements which are already occupied 
by transcriptional factors including repressors (Coull et al., 2002). Chromosomal 
integration, an essential step in the viral life cycle, leads to the packaging of the 
proviral DNA into an array of precisely positioned nucleosomes. These nucleosomes 
define two open regions of chromatin where transcription factors bind DNA (Verdin 
1991). Since, as depicted in figure 12, Kaehlcke et al., proposed that Tat also 
induces chromatin remodelling of a single nucleosome nuc-1 positioned at the HIV-1 
promoter stimulating transcriptional elongation of HIV-1 both increasing the intrinsic 
ability of the RNAPII complex to elongate efficiently and by recruiting histone-
modifying enzymes to remodel the elongation block caused by nuc-1 (Kaehlcke et al., 
2003).  
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 Figure 8: Model for HIV-1 Tat transactivation involving the human P-TEFb complex. 
  
 
 
 
 
 
Figure 9: Model for HIV-1 Tat transactivation involving the human P-TEFb complex.   
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 Figure 10: Structure of the HIV genome, the viral promoter and TAR RNA. 
  The viral promoter has a structure typical of promoters activated by RNA polymerase II. Immediately 
upstream of the TATA box are two tandem NF-kB binding sites and three tandem SP-1 binding 
sites. Immediately downstream of the start of transcription is the transactivation response region 
(TAR). TAR encodes an RNA that can fold into the stem-loop structure shown at left.   
 
 
 
 
 
 
 
 
Figure 11: Acetylated Tat associates with a chromatinized HIV-1 promoter near nuc-1  
 
Diagram of nucleosomes positioned on the integrated HIV-1 genome. The transcription start site is indicated 
as +1. Critical transcription factor binding sites (NF-κB, Sp1, and TBP) are indicated. Location of nuc-0 
through nuc-4 are indicated above the diagram. 
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 1.4 The importance of  Acetylation in HIV-1 transcription 
 
The nucleosome remodelling in HIV-1-LTR promoter is thought to remove an 
obstacle to RNAPII elongation. The molecular mechanism of this Tat-induced 
nucleosome-remodeling event has remained unclear. Notably it has demonstrated 
that the chromatin remodeling of nuc-1 that occurs at the HIV-1 promoter in response 
to Tat, suggests that Tat may recruits also an ATP-dependent chromatin-remodeling 
complex at HIV-1 LTR to facilitate transcription.  
The chromatin remodeling of nuc-1 that occurs at the HIV-1 promoter in response to 
Tat suggests that Tat may recruit an ATP-dependent chromatin-remodeling complex 
to the HIV-1-LTR to facilitate transcription . An attractive candidate for the regulation 
of HIV-1 transcription and chromatin remodelling is a core subunit of SWI/SNF 
chromatin-remodeling complex (Wang et al., 1996). This complex in a component of 
a class of chromatin-modifying proteins that use the energy from ATP hydrolysis to 
change the location or conformation of nucleosomes, resulting in increased DNA 
accessibility within a nucleosomal array. Another group of chromatin modifying 
complexes are factors that mediate covalent modifications of histones. The N-
terminal tails of histone proteins are subject to extensive post-transcriptional 
modifications, including phosphorylation, methylation and acetylation. The interaction 
of Tat with a number of histone acetyltransferase (HAT) complexes, such as 
p300/CBP and PCAF, and their relevance to Tat-mediated activation of the HIV-1 
promoter have been estabilished (Marzio et al., 1998; Kiernan et al., 1999). Thus, the 
complexes acetylate the N-terminal tails of histones of nucleosomes at the HIV-1 
promoter, inducing destabilization of histone-DNA contacts and facilitating 
transcription.  
Moreover, Tat itself is subject to modification by acetyltransferase ( Ott et al., 1999;; 
Deng et al., 2000). In fact, Mahmoudi et al. demonstrated that Tat recruits the 
SWI/SNF complex to the HIV-1 promoter and is necessary for Tat-mediated 
activation of the HIV-1 promoter (Mahmoudi et al., 2006). Other Tat cofactors include 
a number of transcriptional coactivators with intrinsic histone acetyltransferase 
activity, including p300/CBP, p300/CBP associated factor (PCAF) and Tip60 
(Barboric et al., 2005). Notably, chromatin can be remodelled either via the activity of 
multiprotein chromatin remodelling complexes or the activity of histone 
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acetyltransferase (HAT) or via the combined activities of both (Becker and Horz., 
2002). Several transcriptional coactivators with intrinsic HAT activity interact with Tat, 
including p300/CBP (Marzio et al., 1998), Tip60 (Kamine et al., 1996) and TAFII250 
(Weiss-man et al., 1998).  
Histone acetyltransferases reversibly catalyze the transfer of acetyl groups on 
Lysines in the N-terminal tails of histone H2A, H2B, H3 and H4, which form the core 
of nucleosomes. The level of acetylation of each lysine in the histone tail reflects the 
competing activities of HATs and histone deacetylases (HDACs) and plays a 
fundamental role in transcriptional regulation (Kornberg and Loerch., 1999). It has 
reported that the HAT activity of p300 acetylates the Tat protein directly at a highly 
conserved lysine (K50) in the ARM region (Kiernan et al., 1999; Ott et al., 1999). 
Kaehlcke et al., demonstrated that acetylated Tat interacts with the bromodomain of 
p300/CBP-PCAF (Mutjaba et al., 2002). The interaction between K50-acetylated Tat 
and PCAF bromodomain is required for Tat transactivation (Dorr et al., 2002). Thus, 
acetylation of K50 occurs as a critical step during HIV-1 transcription that regulates 
cofactor binding to Tat, both by dissociation of CyclinT1 and association of 
modification-specific cofactors, such as PCAF (Kaehlcke et al., 2003).Therefore, It 
has suggested that Tat and P-TEFb can also recruit TAF-independent transcription 
complexes to the HIV LTR (Raha et al., 2005). Possibly, this assembly reflects 
interactions between CycT1 and the unphosphorylated CTD of RNAPIIa (Taube et 
al., 2002). The assembly and disassembly of the complex between PTEFb, Tat, and 
TAR is a regulated process in vivo. Whereas the phosphorylation of CDK9 
strengthens this complex (Garber et al., 2000) and the acetylation of the lysine at 
position 50 in Tat weakens it (Kiernan et al., 1999). Upon this disruption, as depicted 
in figure 12, acetylated Tat is liberated from P-TEFb and recruits the p300/CREB-
binding protein– associated factor (P-CAF) to the elongating RNAPII, most likely 
facilitating chromatin remodeling. Moreover, it has demonstrated that acetylated Tat 
is deacetylated by SIRT1 (Pagans et al., 2005). In this way, Tat can reassemble with 
P-TEFb on TAR. 
 Clearly, P-TEFb plays a key role in the control of transcriptional elongation. 
Although Tat was the first activator known that could recruit P-TEFb to initiating 
RNAPII, additional members of this group were soon identified. They include the 
androgen receptor, c-Myc, the class II transactivator (CIITA), myoblast determination 
protein (MyoD), and nuclear factor kB (NF-kB). The last one is of great interest as it 
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explains how the HIV genome can be transcribed before the synthesis of Tat 
(Barboric et al., 2001).Finally the Tat remodeling of nuc-1 is thought to remove an 
obstacle to RNAPII elongation. Both Tat activities, P-TEFb recruitment and nuc-1 
remodeling, are thought to synergize in enhancing the ability of RNAPII to elongate. 
The molecular mechanism of this Tat-induced nucleosome-remodelling events has 
remained unclear (Mahmoudi et al., 2006). In fact, it has demonstrated that the 
structure of HIV-1 provirus is altered by external stimuli or inhibitors of HDACs activity 
(Van Lint et al., 1996) which modulate chromatin dynamics (Minucci et al., 2006). 
 
 
 
 
 
 
 
            Figure 12: Cycles of Tat acetylation and deacetylation regulate HIV transcription 
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1.5 The role of HDACs inhibitors in HIV-1 transcription 
 
Nucleosomes the fundamental unit of chromatin structure, provides the first 
order and, at least in part, the higher-order packaging and compaction of the DNA 
about 10,000 fold. The nucleosome core particle consists of a highly conserved basic 
proteins, histone around which 146 bp of DNA are wrapped. Over the past decade, 
extensive genetic, biochemical and cytological studies have revealed that in addition 
to their structural role, the histones proteins are also involved in regulation of gene 
expression. As the maintenance of health depends on the coordinated and tightly 
regulated expression of genetic information, this becomes a very important function 
of histones (Kramer et al., 2001). Post-translational modifications of histone tails, 
such as acetylation, phosphorylation and methylation has emerged as common 
denominators in regulating several biological functions. Acetylation is probably the 
best understood of these modification reactions. The enzymes involved in this 
process are Histone acetyl transferases (HATs) and Histone deacetylases (HDACs). 
Hyperacetylation leads to over expression of a particular gene where as 
hypoacetylation leads to its repression. Thus HAT and HDAC activity control the level 
of acetylation and in turn, can regulate the gene expression and its biological 
functions.  
HDACs inhibitors (HDACi) are currently being tested in clinical trials as anti cancer 
agents (Marks et al. 2004). Numerous pharmacological inhibitors of HDACs activity 
have been identified as given in the classification of HDACs inhibitors. These agents 
are mainly act by inducing the apoptosis in the cancerous cell. Animal studies have 
demonstrated that these drugs have little unwanted toxicity and that are an elegant 
example of how drugs that target cell cycle checkpoints that are defective in tumour 
cell scan provide the selective toxicity desired in chemotherapeutic agents.HDACs 
inhibitors are small molecules and restore the acetylation to normal level, induce cell 
cycle arrest, differentiation, and apoptosis, suggesting their promising anticancer 
activity (De Schepper et al., 2003). A number of small-molecule HDACs inhibitors 
have been described, showing the capacity to interfere with HDACs activity (Minucci 
et al., 2006). Among then, valrpoic acid (VPA) has received considerable attention. 
VPA is an estabilished drug in the long-term therapy of epilepsy, and it has recently 
reported the treatment of four HIV-positive patients with therapeutic doses of VPA. 
Infection of CD4 T-cells decreased in all patients (Lehrman et al., 2005). The results 
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of this pilot study suggest that VPA may be a promising addition to HIV-1 treatment.  
It is currently unknown the molecular mechanism by which VPA reduces the 
frequency of latently infected, resting CD4T-cells. Most likely, through inhibition of 
HDACs, VPA allows transcription from silent proviral LTR leading to production of 
viral proteins and virions and cell death due to virally induced cytotoxicity. However, it 
is pertinent to note that VPA does not activate resting CD4T-cells, thus making it 
unclear the molecular mechanisms underlying VPA capacity to activate viral promoter 
transcription. In my study I demonstrated that HDACs inhibitors such as VPA and 
Trichostatin-A (TSA) as well as Hexamethylene bisacetamide (HMBA), enhance Tat 
transactivation capability and activate basal transcription driven by a HIV-LTR 
promoter. Therefore, TSA is a natural product isolated by Streptomices 
hygroscopicus, that was initially used as an antifungal antibiotic with the activity of  
inhibitor of histone deacetylase (Yoshida et al., 1987). Consequently, it has been 
suggested that inhibition of HDACs activity would allow outgrowth of HIV-1 from 
latently infected resting CD4T-cells. In my works has been showed that HDACs 
inhibitor such as VPA and TSA as well as the cell differentiation inducer HMBA, 
enhance Tat transactivation capability and activate basal transcription drive by a HIV-
LTR promoter. Although HMBA do not inhibit HDACs (Ylisastigui et al., 2004), the 
shared properties of HMBA and the inhibitors of HDACs to activate HIV-LTR 
expression are indicative of similarities in their modes of action. In contrast to VPA 
and TSA, HMBA did not alter the steady-state levels of acetylation, phosphorylation, 
or methylation at specific sites in the N-terimini of core histones (Ylisastigui et al., 
2004). 
  It has been suggested that HMBA may non-covalently interact with transcriptional 
machinery to produce a molecular environment equivalent to that produced by 
hyperacetylation of histones. HMBA is a hybrid polar compounds that alters factors 
controlling the G1-S cell cycle phase transition, leading to G1 arrest and inhibition of 
DNA synthesis. The hybrid polar compounds are potent inducers of differentiation of 
a wide variety of transformed cells, and HMBA can induce differentiation of neoplastic 
cells in patients. Taken together, our present knowledge suggests that these agents 
may be effective in treating cancers (Marks et al., 1994). HMBA, a low molecular 
weight synthetic compound, induces terminal differentiation and apoptosis in 
transformed cells in culture (Richon et al., 1996). Moreover, it has reported that VPA 
like TSA, inhibits HDACs activity in vitro and cause accumulation of hyperacetylated 
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histone H4 in cultured cells, whereas HMBA do not. Suboptimal antitumour activity at 
clinically tolerable doses has impeded the further development of HMBA (Andreef et 
al., 1992). HMBA is known to activate HIV expression in chronically infected cell lines 
(Antoni et al.,1994;) and in cell lines stably transfected with long terminal repeat 
(LTR)-reporter gene constructs (Zoumpourlis et al., 1992). While HMBA is structurally 
related to HDACs inhibitors, it does not inhibit it or induce histone hyperacetylation 
(Richon et al., 1998). Indirect evidence suggests that HMBA and HDACs inhibitors 
induce cell differentiation by different pathways (Richon et al., 1996). Tumour cell 
lines resistant to the differentiation-inducing activity of HDAC inhibitors are not 
resistant to HMBA (Richon et al., 1996). Klicho et al., find that HMBA increases both 
initiation and elongation of the HIV-1 LTR in the absence of Tat. Surprisingly, HMBA 
increased DNA accessibility and induced nucleosome remodelling without histone 
acetylation. However, unlike mitogen activation, HMBA did not increase cell 
susceptibility to HIV infection or the expression of cell surface markers of activation. 
In fact, HMBA down-regulated the surface expression of the HIV receptor, CD4 T-
cells. As a likely result of this effect, HMBA did not enhance de novo cell infection, 
and it suppressed HIV propagation in ex vivo primary blood mononuclear cell 
(PBMC) cultures. In summary, recent findings suggest that HMBA is a novel 
prototype for therapeutics designed to interrupt latent HIV infection (Klicho et al., 
2006).Therefore, a number of small-molecule HDACs inhibitors have been described, 
showing the capacity to interfere with HDACs activity (Minucci et al., 2006).  
 
1.6  P-TEFb and the cell cycle control 
 
Since several years there has been an explosion in the number of publications 
about the mechanisms that control the cell cycle and how their deregulation can lead 
to cellular atypia and potentially carcinogenesis. The cell cycle is a ubiquitous, 
complex process involved in the growth and proliferation of cells, regulation of DNA 
damage repair and diseases such as cancer.The cell cycle involves numerous 
regulatory proteins that direct the cell through a specific sequence of events 
culminating in mitosis and the production of two daughter cells. Central to this 
process are the cyclin-dependent kinases (cdks) and the cyclin proteins that regulate 
the cell’s progression through the stages of the cell cycle referred to as G1, S, G2 
and M phases (Fig.13). The cell cycle can be morphologically subdivided into 
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interphase and stages of M (mitotic) phase, which include prophase, metaphase, 
anaphase, and telophase. The G1 and G2 phases of the cycle represented the 
“gaps” in the cell cycle that occur between the two obvious landmarks, DNA 
synthesis and mitosis. In the first gap, G1 phase, the cell is preparing for DNA 
synthesis. S phase cells are synthesizing DNA and therefore have aneuploid DNA 
content between 2N and 4N. The G2 phase is the second gap in the cell cycle during 
which the cell prepares for mitosis or M phase. G0 cells are not actively cycling. G0 
has since been loosely, and probably incorrectly, used to also include terminally 
differentiated cells, such as those of the outer layers of the epidermis and adult 
neurons (Shafer 1998). 
The core of the cell cycle machinery consists of cyclin dependent kinase (cdk) 
complexes, the activation of which is strictly regulated during the cell cycle. Each cell 
cycle phase exhibits a unique pattern of active cdks which conduct the cycle by co-
ordinately phosphorylating their substrates (Hamel and Hanley-Hide, 1997). Cdks are 
partly activated by binding to cyclin subunits, the levels of which oscillate in the 
course of the cell cycle promoting periodic Cdk-functions. Therefore, inactivation of 
Cdks takes place partly by phosphorylation of Tyrosine and Threonine residues at the 
catalytic cleft (Lew and Kornbluth, 1996). Additionally, inactivation of Cdks may occur 
by binding of cdk-inhibitors of the INK4 family (p15, p16, p18 and p19) or the p21 
family (p21 Cip1/Waf1, p27kip1 and p57 Kip2) (Sherr, 1996).  
Notably, cycling cells are continuously monitoring both internal and external 
conditions and, if required, their cell cycle progression can be halted at so-called cell 
cycle checkpoints by arresting signals from outside or from inside the cell (Sherr, 
1996). Therefore, in addition to extracellular signals, changes in the internal milieu 
and the genome also regulated cell cycle progression (Sherr, 1996).  
One of the best-known sensors and regulators of the internal cell cycle control 
pathway is the tumour suppressor p53 whose upregulation  after DNA damage leads 
to growth arrest at least partly via induction of p21 (El-Deiry et al., 1993). 
p21 was initially characterized as a subunit of Cdk/cyclin/PCNA complexes with an 
unknown function (Xiong et al., 1993). p21 is upregulated by p53 tumour suppressor 
(El-Deiry et al., 1993) as well as to inhibit the activity of various Cdks and to arrest 
cells in the G1 phase. Although the normal cell signalling machinery may not be 
functional, the cell must immediately activate the transcription of a subset of genes 
involved in the individual stress response, while simultaneously repressing numerous 
 27
other genes. It has been demonstrated that long before the presence of a cellular 
stress, cells have already assembled paused RNAPII on the p21 promoter. In 
response to DNA damaging agents and p53 activation, the paused, initiating form of 
RNAPII is converted to its elongating form and transcription of the p21 gene by 
RNAPII rapidly ensues (Espinosa et al. 2003).  
In order to study the mechanisms of p53-dependent transcriptional activation of the 
p21 gene, Gomes et al. established a high-resolution quantitative ChIP assay that 
enables to generate detailed maps of protein occupancy on the p21 locus at different 
stages of the transactivation process. The gene map in Figure 14 shows the most 
relevant features of this locus, including the two upstream p53-binding sites (high-
affinity BS1 and low-affinity BS2), the transcription start site (+1), the exon–intron 
organization, the start (ATG) and stop codons (TAA) (Gomes et al., 2006). p21 is 
expressed at high levels in almost every human tissue examined and independently 
of the cell cycle stage (Harper et al., 1993). Therefore, p21 levels are regulated 
during the cell cycle. After initial peak by serum stimulation, p21 amounts decrease 
towards the S phase. In addition to G1 arrest, p21 is known to retard S-phase 
progression and arrest cells in the G2 phase (Ogryzko et al., 1996). It has 
demonstrate that p21, after an initial peak  by serum stimulation, it amounts decrease 
towards the S phase (Li et al., 1996) and in most cases it seems to be required for 
the initial growth arrest but not for the later stages of differentiation. Coinciding with 
the identification of p21 as a Cdk inhibitor, p21 was found to be transcriptionally 
induced by the p53 tumour suppressor gene product (El-Deiry et al., 1993) which is 
thought to be a central regulator of growth arrest and apoptotic responses after 
cellular stress and DNA damage (Levine 1997). Finally, p21, as several genes 
involved in the DNA damage response pathway contain p53-binding elements 
upstream of their promoters. In response to chemical or irradiation-induced DNA 
damage, binding of p53 to target genes occurs rapidly to shut off cell cycle 
progression and allow for recovery.There are a variety of p53-dependent pathways 
that can maintain cell cycle blocks (Agami and Bernards 2000; Gartel and Tyner 
2002). Once p21 (a potent inhibitor of cyclin-dependent kinases) is expressed, the 
cells become arrested (Agami and Bernards 2000).  
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Figure 13: The different phases of the cell cycle. 
 
 In the first phase (G1) the cell grows. When it has reached a certain size it enters the phase 
of DNA-synthesis (S) where the chromosomes are duplicated. During the next phase (G2) the 
cell prepares itself for division. During mitosis (M) the chromosomes are separated and 
segregated to the daughter cells, which thereby get exactly the same chromosome set up. 
The cells are then back in G1 and the cell cycle is completed. 
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Figure 14: p21 locus 
 
Linear up-to-scale map of the p21 locus showing the location of p53-binding sites (p53BS1 and 
p53BS2), the transcription start site (+1), exons and introns, the start codon (ATG), the stop 
codon (TAA), and the polyadenylation signal (AATAAA). 
 
 
 
p53 is one of the most important tumour suppressors in the cell and often  referred to 
as “ the guardian of the genome” (Lane 1992). In unstressed cells, p53 is maintained 
at very low levels. However, also in unstressed cells, some p53 activities involved in 
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the “routine” maintenance of genomic integrity rely on p53 interactions with genomic 
DNA, particularly at sites of active metabolic processes that render DNA vulnerable 
or prone to potential structural re-arrangements (figure 15). In response to various 
intracellular and extracellular stresses, such as DNA-damage to its integrity, hypoxia 
and oncoprotein expression, p53 is rapidly stabilized and activated. The transcription 
activity of p53 is critical to its function such as tumour suppressor, and this is 
highlighted by the fact that approximately 50% of human cancers contain a mutation 
of p53 gene. Among them, more than 80% are located in the p53 DNA-binding 
domain (DBD), which abrogates the p53 transcriptinal activity (Hainaut et al., 1998). 
Therefore, the activated p53 mainly functions as a sequence specific DNA-binding 
transcription factor to regulate a large number of target genes. These genes mediate 
cell-cycle arrest, apoptosis, senescence, differentiation, DNA repair, inhibition of 
metastasis and other p53-dependent activities (Harms et al.2004). It has 
demonstrated that recognition and binding affinity of the various p53 DNA 
interactions are determined by the presence of specific sequence motifs (sequence-
specific DNA binding, p53-SSDB). However, Gomes at al. present evidence that CTD 
kinase activities and RNAPII phosphorylation are differentially required for expression 
of distinct p53 target genes and that RNAP II is regulated at a post-initiation stage on 
the p21 gene. Paused RNAP II assembles on the p21 promoter before cellular stress 
and is converted to the elongating form upon stress-induced p53 activation (Espinosa 
et al. 2003). This process is accompanied by recruitment of several positive 
elongation factors and changes in CTD phosphorylation. Moreover, ChIP assays 
reveal important differences in the site of recruitment and distribution of the 
elongation factors NELF, DSIF, P-TEFb, TFIIF, TFIIH, and FACT (Facilitates 
Chromatin Transcription) on the p21 locus. 
All these evidence produced several interesting observation: (1) P-TEFb activity is 
differentially required for activation of distinct p53 target genes; at least two distinct 
Ser5 kinases act consecutively on the p21 locus based on DRB sensitivity and site of 
action; CTD kinases are required for recruitment of the elongation factor FACT to the 
p21 locus; (4) P-TEFb kinase activity, Ser2 phosphorylation, and FACT recruitment 
are dispensable for p21 mRNA transcription, processing, and accumulation in 
response to stress-induced p53 activation; and (5) global inhibition of transcription 
triggers a stress response that leads to p53-dependent apoptosis. Thus, the tumour 
suppressor protein p53 regulates transcriptional programs that control the response 
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to cellular stress. Espinosa et al., showed that distinct mechanisms exist to activate 
p53 target genes as revealed by marked differences in affinities and damage-specific 
recruitment of transcription initiation components. p53 functions in a temporal manner 
to regulate promoter activity both before and after stress. Before DNA-damage basal 
levels of p53 are required to assemble a poised RNAPII is converted into an 
elongating form shortly after stress but before p53 stabilization (Espinosa et al., 
2003). In fact it has demonstrated that significant differences in the abundance of 
poised RNAPII exist at p53 target promoters before activation, in fact, after DNA 
damage, increased p53 activity leads to the transactivation process by stimulating 
elongation of arrested RNAPII. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15:   
 
 Summary of the various stress factors that active the p53 tumor suppressor protein and 
the opposite functions played by the cdk inhibitor p21 in nucleus and the cytoplasm. 
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1.7 The cellular stress 
 
In highlight of the studies driven by Espinosa et al., the DRB have an important 
role on P-TEFb and elongation phase. It has been suggested that this transcription 
machinery may play an important role in sensing DNA damage and activating DNA 
repair and stress response pathways when stalled at blocking lesions. There are 
many different types of DNA lesions that can act on transcription elongation. In fact, it 
has been shown that the induction of p53 (Yamaizumi et al., 1994) and apoptosis 
(Ljiungman et al., 1996) following UV-irradiation depends on persistent lesions 
localized in the transcribed strand of active genes. Furthermore, a number of agents 
that interfere with RNAPII-mediated transcription have been shown to induce p53 and 
apoptosis suggesting that blockage of transcription may act as a trigger for stress 
response activation (Liungman 2005;  Ljungman et al.1999). It has been shown that 
UV light induced apoptosis is linked to blockage of transcription (Ljungman 1999). 
Furthermore, treatments with various agents that inhibit RNAPII have been shown to 
efficiently induce apoptosis in many cell types (McKay et al., 2001), such as two 
transcription inhibitors named DRB (5,6-dichloro-ribofuranosylbenzimidazole) and 
ActinomycinD  (ActD). These compounds have different mechanisms of action. ActD 
inhibits transcription but has been reported to inhibit initiation of protein synthesis by 
interfering with the binding of mRNA to ribosomes ( Singer and Penman 1972). DRB 
inhibits synthesis of mRNA by targeting polymerase II transcription (Yankulov et al. 
1995). In particular, DRB has received a great deal of attention during the last 
decade and the elucidation of its mechanism of action is of considerable interest. An 
interesting feature of DRB is its capability to interfere with early transcription events. 
There is evidence for an effect on transcription initiation as well as for an involvement 
in premature termination of transcripts. While the biological effects of DRB are 
extensively studied, there is only limited amount of information available concerning 
its mode of action and the identification of possible metabolic steps preceding actual 
transcription block on the chromosomal level (Egyhazi et al., 1999). DRB was 
originally discovered as an inhibitor of the synthesis of heterogeneous nuclear RNA 
in human, murine, avian, and insect cells (Sehgal et al. 1976). Many of these studies 
showed that DRB inhibits the synthesis of full-length RNA transcripts by enhancing 
the pausing or premature termination of transcription by RNAPII. Although it was 
originally proposed to inhibit transcription initiation (Sehgal et al. 1976) specifically at 
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the level of elongation. DRB-mediated transcription inhibition appears to result from 
the inhibition of one or more protein kinases necessary for transcription. The other 
compound involved in transcriptional block is ActD. It is generally thought to 
intercalate into DNA thereby preventing the progression of RNAPII (Sobell 1985). 
Moreover, Dubois et al. demonstrated that the average phosphorylation of RNAPII-
CTD increases in cells exposed to UV, DRB and ActD (Dubois et al, 1994).  
Moreover, the cellular stress is also responsive to DNA damage; there are several 
compounds that induce cellular stress such as Mitomycin C (MMC), Camptothecin 
(CPT), Apigenin (APG) and Doxorubicin (DXR). In particular, MMC is a DNA 
alkylating agent that leads to a gradual formation of DSBs in chromosomal DNA, a 
slowdown of DNA synthesis (Mladenov et al., 2006) and a G2 phase of cell cycle 
arrest (Franchitto et al., 1998). CPT is a cytotoxic alkaloid  with a strong antitumuor 
activity against a wide range of experimental tumours (Gallo et al.,1971) It also 
inhibits both DNA and RNA synthesis in mammalian cells. The inhibition of RNA 
synthesis results in shortened RNA chains and is rapidly reversible upon drug 
removal (Abelson et al., 1972). The inhibition of DNA synthesis, on the other hand, is 
only partially reversible upon drug removal (Kessel et al., 1972). It is a much stronger 
inhibitor of DNA synthesis than RNA synthesis (Gallo et al.,1971) and another 
prominent effect of CPT is the rapid and reversible fragmentation of cellular DNA in 
cultured mammalian cells (Horwitz et al, 1971). Moreover Flow cytometry (FACS) 
analyses showed that CPT can induce G1 arrest in cells with normal p53. This G1 
arrest was markedly reduced in the p53-deficient cells. These results demonstrate a 
critical role of p53 as a G1 checkpoint regulator after CPT-induced DNA damage and 
suggest a rationale for the selectivity of CPT toward tumours with p53 mutations 
(Gupta et al., 1997). Another candidate agent is APG which have been shown to 
have antitumour effects in several human adult tumour cell lines, including those 
derived from various cancers (Casagrande et al., 2001). APG also inhibits UV-
induced tumour promotion and the mechanism whereby APG acts, seems to involve 
p53; it modulates p53 protein levels and accumulation in the nucleus and induce the 
expression of the p53 target protein p21 (Torkin et al., 2005). Therefore, APG inhibits 
various cancer cell growth in vitro through G2/M phase cell cycle arrest associated 
with decreased cyclin B-cdc2 activity. Another compound that provokes DNA damage 
is DXR. It is a compound, similar to DRB, that affects on DNA damage, but it not 
affects total RNAPII phosphorylation, whereas DRB treatments leads to a clear shift 
 33
towards the unphosphorylated form because effectively it blocks CDK9 activity 
(Gomes et al., 2007). One such compound, Caffeine, uncouples cell-cycle 
progression from the replication and repair of DNA. Caffeine therefore serves as a 
model compound in establishing the principle that agents that override DNA-damage 
checkpoints can be used to sensitize cells to the killing effects of genotoxic drugs 
(Blasina et al., 1999). Caffeine may very be the most frequently ingested neuroactive 
drug in the world. It has been reported that CAF affects cell cycle function, induces 
programmed cells death or apoptosis and perturbs key regulatory proteins as well as 
p53 (He et al., 2003). Although the effects of caffeine have been investigated, much 
of the research data regarding caffeine’s effect on cell cycle and proliferation seems 
ambiguous. One important factor may be that CAF has been used in many cell types 
and under a variety of conditions and concentrations. In fact, it has found that at low 
concentration (1mM) it induces p53 posphorylation  and p53-dependent apoptosis, 
whereas at 1-2mM concentration  appeared  induces G1 arrest and at high 
concentration (2-5mM) appeared to block G1 arrest and induce apoptosis (Bode and 
Dong, 2007).  Previous results demonstrated that CAF overrides the cell cycle effects 
of various chemicals such as protease inhibitors, preventing apoptosis  inhibits 
cellular DNA repair mechanisms, but notably Mladenov et al. has been demonstrated 
that caffeine is capable to delay and reverse effect of MMC. Finally, a compound 
named Pifithrin-α, that is a neuroprotective drug based on p53 inhibitors, enhances 
cell survival after genotoxic stress such as UV irradiation and treatment with 
Doxorubicin, ectopoxide etc, and a reversible inhibitor of p53 mediated apoptosis and 
p53-dependent gene transcription as p21 and Mdm2 (Gudkov et al., 2005). 
Finally, several studies demonstrated that the transcriptional block provoked by 
cellular stress agents such as DRB, UV and ActD, induces a rapid dissociation of P-
TEFb complex. Thus I performed a number of experiments to check if treatments with 
other compounds that provoke cellular stress by DNA damage and activation of 
ATM/ATR-p53 pathway, could affect the ratio of P-TEFb complexes. Moreover, I 
sought to determinate such effect of P-TEFb may represent a general event after the 
cellular response to genotoxic stress. 
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 2. The aim of this study 
 
An essential factor for regulation of transcriptional gene expression is the 
positive elongation factor (P-TEFb). Which is present in vivo in two mutually exclusive 
forms, (Michels et al, 2003; Yik et al, 2003; Chen et al, 2004; Nguyen et al, 2001; 
Yang et al, 2001).  
A number of studies have shown that P-TEFb complex is co-factor of the HIV-1 Tat 
protein. In fact, the Tat activity involves direct interaction with P-TEFb complex 
(Garriga and Grana, 2004) binding to the transactivation response (TAR) element in 
the nascent HIV-1 transcript (Price et al., 2000). In highlight of these studies, in the 
first part of my thesis, I focalized my attention on the role of the P-TEFb complex in 
HIV-1 transactivation and the effect of alteration of gene expression, as well as the 
changes in acetylation state on HIV-1 activation by Tat protein. 
In a second part of my studies I focused my attention on the physical and functional 
interaction between P-TEFb and p53. Finally, the transcriptional block involves a 
modification in P-TEFb complex equilibrium versus active form, whilst the DNA 
damage provokes an activation of p53 pathway. I investigated the shift of the P-TEFb 
complex from inactive to active form upon several stress agents, to understand if P-
TEFb activation could be represent an early response to cellular stress and if this 
effect could be p53-dependent. 
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3. Results 
 
 
3.1 Correlation between P-TEFb and HIV-1 
 
3.1.1 Tat activity is inhibited by HEXIM1 
 
  The current model for recruitment of P-TEFb to the HIV-1-LTR predicts 
the formation of Tat-P-TEFb complex, which efficiently binds TAR, allowing 
CDK9 to phosphorylate the CTD of RNAPII, thereby enhances processivity of 
the polymerase to produce full-length m-RNAs (Garriga et al., 2004; Mancebo 
et al., 1997; Garber et al.,1998). Tat activity involves direct interaction with P-
TEFb complex. However two different P-TEFb complexes exists in vivo in 
human cells (Nguyen et al., 2001; Yang et al., 2001). One is active and 
restricted to CDK9 and CyclinT1, the other is inactive and contains HEXIM1 
or 2 and 7SK snRNA in addition to P-TEFb (Michels et al., 2004; Yik et al., 
2004). It has shown that Tat interacts only with the active P-TEFb complex 
(Michels et al., 2002). Because the two complexes exchange rapidly, I sought 
to determine the functional consequences of the over-expression of HEXIM1 
and 7SK snRNA on Tat activity. To this end, I performed transient transfection 
in human 293T cells using HIV-1-LTR-Luc reporter (figure 16 panel A) in the 
presence of increasing amounts of Flag-tagged HEXIM1 (F:HEXIM1) or 7SK 
snRNA respectively. I found that Tat-mediated transactivation of the HIV-1-
LTR was inhibited by the over expression of F:HEXIM1 in a dose dependent 
manner; moreover, I found that ectopic expression of 7SK did not significantly 
affected HIV-1-LTR-Luc basal transcription as well as Tat-activation either 
alone or in a combination with F:HEXIM1 (figure 16, panel B). As control to 
test the specific ability of HEXIM1 to repress Tat transactivation, the same 
experiment was performed using murine CHO cells in which endogenous 
mouse CycT1 is unable to interact with Tat protein (figure 16, panel C). 
Finally, like in human cells, it was shown that ectopic expression of 7SK 
snRNA did not have any significant effect on Tat activity. Notably, the 
HEXIM1 effect on Tat activity were validated for also its paralog named 
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HEXIM2 (data no shown and Fraldi et al., 2005). These data are consistent 
with a role of HEXIM1 as negative regulator of HIV-1-1 activity. 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
Luc gene 
+1 
TAR element -19 +81Sp1          
TATA  
-83HIV LTR luc 
Figure 16 – HEXIM1 is a negative regulator of HIV-1 activity 
On top the relevant HIV-LTR luc reporter is depicted (panel A). In the panel B, HIV-Luc reporter was transfected into 
293T cells in the presence of pSV-Tat along with increasing amounts of F:HEXIM1 and 7SK RNA as indicated. In the 
panel C, CHO cells were transfected with HIV-LTRE-luc-reporter in the presence of pSV-Tat and togheter with CMV-
hCycT1, in the presence of increasing amounts of F:HEXIM1 and 7SK. Each histogram bar represents the mean of 
at least three independent transfections after normalization to Renilla luciferase activity to correct for transfection 
efficiency with the activity of the reporter without effect set to one. 
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 3.1.2 Definition of the HEXIM1 regulatory domains involved in repression 
 
The following experiments delineated the important structural domains of 
HEXIM1 required for repression of Tat. It was been reported that the HEXIM1 C-
terminal domain (181–359) is involved in the binding to P-TEFb through direct 
interaction with CyclinT1 (as well as for homo and hetero-dimerization with 
HEXIM2) and the evolutionarily conserved motif (PYNT aa202–205) is important 
for such interactions. Notably, it was found that the PYND point mutant is 
impaired in repression and binding either P-TEFb or 7SK RNA in vivo, albeit it 
retains the ability to bind 7SK in vitro. In addition, it was determined that HEXIM1 
binds 7SK snRNA directly and the RNA-recognition motif (KHRR) was identified 
in the central region of the protein (aa 152–155). In fact, the HEXIM1-ILAA 
mutant fails to interact in vivo and in vitro with 7SKsnRNA (Michels et al., 2004). 
It has been demonstrated that the artificial recruitment of P-TEFb to the HIV-1 
promoter is sufficient to activate the promoter in absence of Tat (Majello et al., 
1999; Taube et al., 2002). Consistent with these studies, I addressed the 
importance of these motifs HEXIM1-mediated repression of Tat activity using a 
transcriptional system consisting of chimeric Gal4-CycT1 protein and the 
plasmid reporter G5-83-Luc, which contains five Gal4 DNA binding sites 
positioned upstream of the HIV-1 long terminal repeat (HIV-1- LTR), followed by 
the luciferase (Luc) reporter gene. As expected Gal4-CycT1 chimera activates 
G5-83-Luc in 293T cells, whereas co-expression of the wild-type F: HEXIM1 
protein decreased this activity in a dose dependent manner (figure 17, panel A). 
Similarly, Tat-mediated activation was repressed by HEXIM1 (figure 17, panel 
B). To confirm  the importance of the integrity of HEXIM1 C-terminal domain that 
would be impaired for P-TEFb binding, I performed the same experiments with  
point mutants in this domain: the PYNT motif (aa 202–205) in the C-terminal 
domain that was targeted because it has been conserved throughout evolution 
from insects to mammals (Michels et al., 2002) and PYND mutant in which 
threonine 205 was replaced by aspartate (Michels et al., 2004). I found that, 
unlike wild-type HEXIM1, both mutants were unable to respress Tat as well as 
Gal4-CycT1 activities (figure 18, panel A and B), albeit they were expressed at 
levels comparable to the wild-type protein (figure 18, panel C). 
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Thus it appears that HEXIM1 inhibition is strictly dependent upon the 
integrity of the protein to interact with P-TEFb. Moreover, because the point 
mutant in the central part ILAA abolished HEXIM1 repression on Tat, it can be 
concluded that HEXIM1-mediated inhibition of Tat required the formation of the 
P-TEFb/HEXIM1/7SK complex.  
 
 
 
 
 
 
Figure 17 – HEXIM1-mediated inhibition of Tat required the formation of the P-TEFb/HEXIM1/7SK 
complex. 
 
On top the relevant HEXIM1 functional domains are depicted. Position of the point mutants ILAA and PYND 
are indicated. G5-HIVLuc reporter was transfected into 293T cells along with Gal4-CycT1. Panel A, or pSV-
Tat. Panel B: along with increasing amounts of Flag:HEXIM1 wilt type and mutants as indicated. Each 
histogram bar represents the mean of three independent transfections after normalization to Renilla 
luciferase activity. Panel C: western-blot with anti-HEXIM1 antibody demonstrated that the HEXIM1 effectors 
were expressed at comparable levels. 
 
 
3.1.3 P-TEFb activity in the presence of enhanced expression of HEXIM1 
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To test whether enhanced expression of HEXIM1 might directly affect the 
P-TEFb activity, it was performed a time course kinase assay using as a 
substrate the CTD4 peptide consistent of four repeats of the RNAPII CTD (data 
no shown and Fraldi et al., 2005). It was shown by  Fraldi et al. that over-
expression of HEXIM1 resulted in a modest reduction of P-TEFb activity, thus 
the inhibition of Tat activity in unlikely due to a global reduction of cellular P-
TEFb activity. To further investigate the mechanism of inhibition of Tat mediated 
transcription by HEXIM1, we tested the relative levels of transfected Tat protein 
in the presence of F:HEXIM1. I found that ectopic expression of HEXIM1 did not 
affected Tat expression (figure 18, panel A). Next, I sought to determine whether 
exogenous expression of HEXIM1 might result in a decrease in Tat-bound 
CycT1. To this end 293T cells were transfected with pSV-Tat in the presence or 
absence of F:HEXIM1 using the same transfection conditions used in the 
Luciferase assays. Cells extracts were immunoprecipitated with CycT1 antibody 
and the immunoprecipitates were analyzed by immunoblotting for evaluation of 
Tat, CycT1 and HEXIM1 proteins, respectively. In two different experiments I 
found a modest, but reproducible decrease in Tat-bound cyclin T1 (fig. 18, panel 
B).  
Collectively, these data demonstrated that over-expression of HEXIM1 
resulted in a modest reduction of P-TEFb activity, thus the inhibition of Tat 
activity is unlikely due to a global reduction of cellular  P-TEFb activity, rather 
over-expression of HEXIM1 appears to influence Tat-P-TEFb interaction. 
 
3.1.4 Activation of HIV-1 LTR promoter by HDACs inhibitors and HMBA 
 
The integrated HIV-1 provirus is assembled into an ordered chromatin 
structure altered by external stimuli or inhibitors of HDAC activity (Van Lint et al., 
1996; Williams et al., 2006). One of the most important mechanisms responsible 
for chromatin remodeling is the post-translational modifications of histone tails. 
Histones are subject to dynamic covalent modifications that modify gene 
expression, including acetylation, methylation, ubiquitylation, and ADP-
ribosylation. Dynamic changes in gene expression may affect chromatin 
structure and, consequently, the interaction of chromatin with regulatory factors. 
A class of compounds that modulate chromatin dynamics are the HDACs 
inhibitors. Several studies suggested that treatment of cells with the antiseizure 
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drug valproic acid (VPA, 2-propylpentanoic acid) results in histone 
hyperacetylation, growth arrest, and cell differentiation in several tumor cell lines 
(Minucci et al., 2006).  
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To investigate the effect of VPA on the expression of a reporter gene under 
the control of a defined HIV-1 promoter, I performed firefly Luciferase assay that 
F:HEXIM 1 
F:HEXIM 1 
CycT1 
Tat 
HEXIM 1 
B
Figure 18 – Tat- CycliT1 binding in the presence of HEXIM1. 
Tat-CyclinT1 binding in the presence of HEXIM1. Panel A: 293T cells were transfected with pSV-Tat in the 
presence or absence of F:HEXIM1as indicated and at 48 hrs after transfection cell extracts were probe by 
Western blotting with anti-Tat. For accurate comparison increasing amounts of material (μl) were loaded on the 
gels. Panel B: 293T cells were transfected as in panel A, and cell extracts were immunoprecipitated with anti-
CycT1. Immunocomplexes were analyzed on Western blots as indicated. I, input, B; bound, FT; flow through. 
This experiment was performed two times with similar results. 
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was followed in lysates from huHL6 cells exposed to VPA or HMBA, in the 
presence or absence of pcDNA3-Tat-101-flag, respectively. huHL6 cells is a 
clonal human cell line bearing an integrated HIV-1-LTR-Luc reporter derived 
from HeLa cells co-transfected with pHIV-1LucA41 and pRSVtkneo. I found that 
both VPA and HMBA activates basal as well Tat-mediated HIV-1-LTR 
expression (fig 19, panel A). To further substantiate these findings I also tested 
the effect of HMBA and the HDACs inhibitors (VPA and TSA) in transient 
transfection assays. To this end, I transfected human 293T cells with –83HIV-1-
Luc reporter along with pcDNA3-Tat101 in the presence or absence of TSA, 
VPA and HMBA, respectively. The –83HIV-1-Luc reporter contains the LTR 
sequences spanning from –83 to +82, thus bearing the three Sp1 binding sites, 
the TATA element and TAR sequences. As shown in figure 19 panel B, both 
HMBA, TSA and VPA induced a robust increase of basal and Tat-activated 
expression of the –83HIV-1-Luc reporter in transient transfection. Because Tat 
activity is mainly dependent upon the interaction with catalytic active P-TEFb 
(Brady et al., 2005), I monitored the relative amounts of P-TEFb (CDK9 and 
CycT1 proteins) as well as the P-TEFb-bound inhibitor HEXIM1 upon VPA, TSA 
and HMBA treatment, respectively. As reported in figure 19, panel C, the relative 
amounts of CDK9 and CyCT1 proteins remained largely unaffected. In contrast, 
treatments with HMBA as well as in the presence of HDACs inhibitors a slightly 
enhancement of the HEXIM1 protein levels were observed.  
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Figure 19 – Enhancement of HEXIM1 as a result of HMBA and HDACs inhibitors. 
 
HuHL6 cells harboring an integrated HIV-LTR-Luc reporter were transfected with pcDNA3-Tat vector as 
indicated, and after 24 h mock and Tat-tranfecsted cells were treated with VPA and HMBA for additional 24 hr. 
Cell lysates then prepared were analyzed for luciferase activities. Each histogram bar represents the mean of at 
least three independent transfections with the activity of the untranfected huHL6 cells without Tat without effect 
set to one. (B). Human 293T cells transfected with –83HIV-Luc reporter in the presence or absence of co-
transfected pcDNA-Tat vector as indicated. Cells were then were treated (24 hr after transfection) with VPA, 
TSA and HMBA for additional 24 hr. Cell lysates then prepared were analyzed for luciferase activities and 
immunoblottings with the indicated antibodies (panel C). Each histogram bar represents the mean of at least 
three independent transfections with the activity –83HIV-Luc reporter without Tat vector set to one.  
 
 
 
 
 
 
 
 
3.1.5  HEXIM1 represses VPA and HMBA activation of HIV-1-LTR promoter 
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HMBA-treatment of virtually any cell line tested results in induction of 
HEXIM1 protein (Yik et al., 2005; Turano et al., 2006). However, induction of 
HEXIM1 is not restricted to HMBA treatment. Rather, it has  recently found that 
HEXIM1 is up-regulated by various chemical inducers, such as Retinoic acid and 
DMSO (Turano et al., 2006) as well as HDACs inhibitors (VPA  and TSA) as 
reported in figure 19 panel C.  
Paradoxically, high levels of Tat transctivation were detected in cells 
treated by HMBA and VPA, albeit a modest increase of endogenous HEXIM1 
protein was seen. Subsequently, I sought to determine the effect of over-
expression of HEXIM1 protein of the HIV-1 promoter activity in the presence of 
HDACs inhibitors and HMBA respectively. I co-transfected Flag-taggeted 
HEXIM1 expression vector (F:HEXIM1) into 293T cells together with –83HIV-1-
Luc reporter (Majello et al., 1999, 2005) along with pcDNA3-Tat-101-flag and 
transfected cells were then treated with the HDACs inhibitors and HMBA, 
respectively. I found that over-expression of exogenous F:HEXIM1 inhibits the 
stimulatory effect exerted by the HDACs inhibitors (VPA or TSA) as well as by 
HMBA treatment (fig. 20 panel A and B).  
Because both Tat and VPA stimulate basal transcription, the inhibitory 
function of F-HEXIM1 might be due to interfering with Tat function and/or to 
inhibition of VPA action. To address this point I determined the functional 
consequences of F:HEXIM1 expression in the absence of Tat.  293T cells were 
co-transfected with –83HIV-1-Luc reporter along with F:HEXIM1 and luciferase 
activity was followed in lysates from cells exposed to VPA and HMBA, 
respectively. As shown in figure 21 (panels A and B), F:HEXIM1 effectively 
debilitates the activity of HDACs inhibitors in a Tat-independent manner.  
The identification of HEXIM1 as a P-TEFb-associated factor and P-TEFb 
as a principal target of HEXIM1 (Yik et al., 2004; Michels et al., 2004) suggest 
that P-TEFb plays a key role in HIV-1 LTR activation mediated by HDACs 
inhibitors in the absence of Tat. To further substantiate the role of P-TEFb in 
VPA-induced activation, I carried out co-transfection assays using another 
specific inhibitor of P-TEFb activity. It has previously described an effective  
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Figure 20 – Over-expression of F:HEXIM1 inhibits the stimulatory effect of HMBA and HDACS 
inhibitors 
 
293T cells were co-transfected with –83HIV-Luc reporter together with pcDNA3-Tat vector , in the 
presence or absence of F:HEXIM1 vector as indicated. After 24 hr cells were treated with VPA, TSA 
and HMBA for additional 24 hr as indicated. Cell lysates were then prepared and analyzed for 
luciferase activities (A) and immunoblotting with the anti-HEXIM1 antibody (B). Each histogram bar 
represents the mean of at least three independent transfections with the activity of the cells 
transfected with Tat alone set to one. 
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 protocol to achieve functional ablation of CDK9 in vivo using a strategy named 
oligomerization protein inactivation (OCR). This strategy relays on the ability of the 
coiled-coil (CC) region of the nuclear factor promyelocytic leukemia (PML) to form self-
associating oligomeric complexes (Contegno et al., 2002). It was demonstrated that 
fusion of “CC domain” to CDK9 triggers the formation of large molecular weight hetero-
complexes leading to a functional inactivation of the CDK9/Cyclin T1 transcription 
regulatory properties (Napolitano et al., 2003). 293T cells we transfected with –83HIV-1-
Luc reporter in the presence or absence of flag-cc-CDK9, then transfected cells were 
treated with VPA and HMBA, respectively. We determined that expression of cc-CDK9 
molecules effectively inhibits VPA as well as HMBA activities (figure 21 panel C and D).  
Collettively, the data presented in figures 19, 20, 21, strongly suggest the crucial 
role of P-TEFb in HMBA or VPA induced activation of HIV-1-LTR promoter in the 
absence of Tat. 
Several studies have highlighted the role of cis-acting DNA elements  within the 
Long Terminal Repeat (LTR) in Tat transactivation. Although Tat stimulates mainly chain 
elongation, it requires cellular DNA-bound activators  to stimulate transcription efficiently. 
In fact, mutation of cis-acting regulatory elements within HIV-1-LTR, such as Sp1 DNA-
binding sites, strongly affect Tat transactivation (Cullen et al., 1993; Jones et al., 1994; 
Southgate et al., 1991).  To monitor the role of cis-acting sequences in HMBA or VPA 
activation of HIV-1-LTR expression, I performed the luciferase assay in 293T cells 
transfected with three different HIV-1-LTR-Luc reporters: G5-83-Luc, in which Gal4-
binding domain is fused to wild-type HIV-1-LTR inserted upstream to luciferase gene, 
G5-38 in which HIV-1-LTR have the Sp1 binding sites deleted and finally G5-83ΔTAR-
Luc that was made deleting TAR region (Majello et al., 1998). I transfected 293T cells 
with these reporters (which structure is depicted in figure 22 panel A) and I exposed 
these cells to  HMBA and VPA treatments for 24 hours. I found that  both HMBA and 
VPA activates all three reporters either wild-type than LTR mutants, albeit the relative 
basal levels of each reporter were significantly different. Thus, HMBA and VPA activate 
basal transcription in a TAR-independent manner. 
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Figure 21 – HEXIM1 debilitates the activity of HDACs inhibitors in a Tat independent manner. 
 
293T cells were transfected with –83HIV-Luc reporter in the presence or absence of F:HXIM1 (panel A) or 
FLAG-CC-CDK9 (panel C) as indicated. After 24 hr cells were treated with VPA, and HMBA. Cell lysates 
then prepared and analyzed for luciferase activities (panels A and C) and immunoblotting with the anti-
HEXIM1 antibody (B) or anti-FLAG (D). Each histogram bar represents the mean of at least three 
independent transfections with the activity of the cells transfected with -83HIV-Luc reporter set to one.  
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Figure 22 – HIV1-LTR wild-type and mutants in response to HMBA and HDACs inhibitors treatment. 
 
On top the HIV-LTR reporter mutants are depicted (A). HIV-Luc reporter  mutants was transiently transfected into 293T 
cells, 24 hr after tranfstection cells treated with VPA and HMBA (B). 293T cells were transiently co- transfecetd with   
HIV-Luc reporter and PCDNA3-tat-101-flag; 24 hr after tranfstection cells treated with VPA and HMBA.
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 3.1.6  VPA induces recruitment of P-TEFb in the absence of Tat 
 
 Chromatin structure is modulated by the covalent modifications of the N-termini of 
the core histones in nucleosomes and by the action of ATP-dependent 
chromatin remodeling complexes. In particular, histone acetylation at the promoter of 
genes, mediated by histone acetyltransferases (HAT), has been shown to be 
necessary, albeit not sufficient, for transcriptional activation (Berger et al., 2002;; Narlikar 
et al., 2002). Each HAT has its own lysine specificity within the tails of histones H3 and 
H4, leading to the notion of a `histone code' that determines the epigenetic control of 
transcription (Strahl and Allis, 2000). Experiments performed both in vivo (Verdin et al., 
1993; Van Lint et al., 1996; El Kharroubi et al., 1998) and in vitro using the HIV-1 
promoter reconstituted into chromatin (Van Lint et al., 1996; El Kharroubi et al., 1998) 
have shown that, independent from the integration site, nucleosomes in the 5’ LTR are 
precisely positioned with respect to cis-acting regulatory elements. In the transcriptionally 
silent provirus, these nucleosomes define two large nucleosome-free areas. The first one 
is composed of the core promoter, containing three tandem Sp-1 binding sites and the 
TATA box sequence, and of the LTR enhancer, which is the target for the p50/p65 NF-kB 
heterodimer; the second open area spans the primer binding site immediately 
downstream of the 5’ LTR. These two open regions are separated by a single 
nucleosome called nuc-1 that is specifically and rapidly destabilized during transcriptional 
activation. The position of nuc-1 in the close proximity of the transcription start site and its 
displacement during transcriptional activation suggest that chromatin plays a crucial role 
in the suppression of HIV-1transcription during latency and that nuc-1 disruption is 
necessary for transcriptional activation (Verdin et al., 1993; Van Lint 1996). The Tat 
mediated recruitment of HAT proteins most likely explains the changes in chromatin 
conformation observed at the LTR upon transactivation (Verdin et al., 1993; Van Lint et 
al., 1996). Moreover, changes in chromatin conformation were also upon treatment with 
HDACs inhibitors (Wade 2001). 
Based on these consderations I sought to determine the presence of histone acetylation 
as well as presence of RNA-polymerase II and P-TEFb on HIV-1-LTR in the presence of 
HMBA and VPA, respectively. To this end 293T cells were transfected with –83-HIV-1-
Luc reporter and cells were treated for 24 hours with HMBA and VPA. As expected I 
found activation of transcriptional activity on HIV-1-promoter (figure 23, panel A). In 
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parallel, I carried out the powerful approach of chromatin immunoprecipitation (chIP) to 
map the presence of specific transcription factors at HIV-1-LTR promoter in the presence 
or absence of HMBA and VPA, respectively. 
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Figure 23 – Either HMBA and VPA induces Tat-independent recruitment of CDK9 to the HIV-1 
promoter. 
 
–83HIV-Luc reporter was transiently transfected into 293T cells, 24 hr after tranfstection cells treated 
with VPA and HMBA (A). After additional 24 hr cells extracts were subjected to ChIP assays using 
the indicated antibodies (B). The percentage of DNA immunoprecipitated relative to input is 
indicated with the data referring to the average of two independent experiments (C). 
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Aliquots of untreated, HMBA and VPA-treated 293T cells transiently transfected with 
HIV-1 promoter  were formaldehyde crosslinked, sonicated chromatin fragments from 
these cells were immunoprecipitated using antibodies directed against CDK9 and RNA 
Polymerase II. In addition, to test possible increase in histone acetylation at viral 
promoter I performed chIP using antibodies directed against the N-terminal tails of 
acetylated histone H3 (AcH3) and histone H4 (AcH4). As shown in figure 23 panel B and 
C,  I found that VPA treatment leads to a clear increase of histone acetylation markedly 
in AcH3, whereas HMBA did not significantly modulates histone acetylaton of  HIV-1-
LTR. Moreover, after HMBA and VPA treatments resulted in a modest increase of 
Polymerase II recruitment. In contrast, in the absence of treatments there was no 
detectable association of CDK9. However, following HMBA and VPA treatment, there 
was a robust increase in association of CDK9. 
These findings are consistent which the possibility that either HMBA or VPA induces a 
Tat-independent recruitment of CDK9 to the HIV-1 promoter. 
 
3.1.7. HMBA induces cell growth arrest and up-regulation of p21 
 
The results reported above strongly suggest that HMBA induces expression of HIV-
1-LTR driven gene expression independently from Tat. Thus, in the following section I 
sought to determine whether HMBA might modulated expression of cellular genes as 
observed for viral LTR. 
Hexamethylbisacetamide (HMBA) was originally developed as an anticancer drug 
(Reuben and Marks, 1981), while HMBA is structurally related to HDACs inhibitors, it 
does not inhibits HDACs or induces histone hyperacetylation (Richon et al., 1998) as 
shown in figure 23. Indirect evidence suggests that HMBA and HDACs inhibitors induce 
cell differentiation by different pathways (Richon et al., 1996). It has demonstrated that 
HMBA induces cell cycle arrest, differentiation and/or apoptosis in various cell types 
(Marks et al., 1987). Treatment with HMBA blocks cell cycle progression in G1 (Byers et 
al., 2005).  As shown in figure 24, treatment of huHL6 cells with HMBA induced a G1 
arrest. It is  known that cycling cells are continuously monitoring both internal and 
external condition, and, if required, their cell cycle progression can be healted at so-
called cell cycle checkpoint by arresting signals from outside or from inside the cells 
(Wade 2001). One of the best-known sensors and regulators of the internal cell cycle 
control pathway is the tumor suppressor p53 whose upregulation after DNA-damage 
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leads to growth arrest al least partly via induction of p21 (El Kharroubi et al., 1998). 
Consistent with this observation, I found by Western blot analysis, a concomitant 
increase of p21 expression, whereas levels of p53 were modestly affected (figure 25). As 
expected, HEXIM1 expression was induced by HMBA, whereas did not produce 
significant differences in the expression of the core P-TEFb subunits.  
Collectively, my data strongly suggest that HMBA treatments lead to activation of 
HIV-1-LTR and cellular p21 gene expression. It is pertinent to note that HIV-1-LTR-
driven transcription, as well as p21 gene expression, are mainly regulated at post 
initiation step (Espinosa et al., 2003); consequently I sought to determine a putative role 
of P-TEFb in HMBA-induced p21 expression. An approach to investigate this role, were 
represented by inhibition of P-TEFb complex i.e. co-expression of F:HEXIM1 and cc-
CDK9 in cells expressing either HIV-1 or p21 promoters.  
As shown in figure 26 panel A, HMBA treatment activates both p21 and HIV-1 
promoters transiently transfected in 293T cells; however, co-expression of F:HEXIM1 
effectively debilitated the activity of HMBA on both promoters constructs (figure 26 panel 
B). Furthermore, 293T cells where transfected with p21-Luc or the HIV-1-Luc reporters in 
the presence or absence of F:cc-CDK9 (that triggers the formation of large molecular 
weight hetero-complexes leading to a functional inactivation of the CDK9/CyclinT1 
(Napolitano et al., 2003)) , then cells were treated with HMBA. With this approach I 
determined that expression of CC-CDK9 molecules effectively inhibits HMBA activity as 
shown in figure 26 panel C.  
Despite of inherent limitations of transient transfections, which relay on the use of 
over-expressed proteins, these observations are indicative of the crucial role of P-TEFb 
in HMBA induced activation of HIV-1 and p21 gene expression. 
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Figure 24 – Treatment of huHL6 cells with HMBA induces a G1 phase cell cycle arrest. 
 
Panel A: Immunoblots were performed in 293T cells transfected with G5-83luc reporter to 
measure levels HEXIM1 after HMBA treatment after 24hrs. As control it performed a western blot 
for  β-actin protein level.  
Panel B: Sub-confluent 293T cells were treated for 24 hr with HMBA and VPA as indicated cells 
were collected and their DNA content was determined by FACS analyses. Pie charts display the 
percentage of cells in each stage of the cell cycle. The experiment was performed twice and 
resulted in similar dataSub-confluent HL6 cells were treated for 24 hr with HMBA as indicated; 
cells were collected and used for FACS analyses. The experiment was performed twice and 
resulted in similar data. 
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 Figure 25 – HMBA induces an increase of p21 expression, whereas levels of p53 were 
modestly affected.  
 huHL6 cells extracts were prepared after HMBA treatments for indicated times (hr) and analyzed by Western blots with indicated antibodies . 
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 Figure 26 – The role of P-TEFb in HMBA induced activation of HIV-1 and p21 gene expression.
 293T cells were transientely transfected with p21-Luc and HIV-luc reporter, respectively. Cells were 
then trated (24hrs after transfection) with HMBA (10mM) for additional 24hr. The levelof induction  in 
luciferase activity compared to that in untreated cells set to one is shown (panel A). In panel B and 
C, p21-Luc and HIV-Luc reporters were transfected into 293T cells in the presence or absence of 
FLAG-HEXIM1 (panel B) or FLAG-CC-CDK9 (panel C )as indicated. After 24hrs cells were treated 
with HMBA for additional 24hr. Cell lysate were analyzed for luciferase activities and immunoblotting 
with the anti-HEXIM1 (B) or anti-FLAG (C). Each histogram bar represents the mean of at least 
three independent transfections. 
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3.1.8 HMBA affects association between P-TEFb and HEXIM1 
 
HMBA-treatment of virtually any cell line tested results in induction of HEXIM1 
protein (Price et al., 2000). Paradoxically, HMBA treatment of huHL6 cells induces 
expression of HEXIM1 with a concomitant up-regulation of P-TEFb-dependent promoter 
activity. Because HEXIM1 togheter with 7SK RNA sequesters the core active P-TEFb in 
an inactive 7SK-HEXIM1/P-TEFb complex, I examined the association of HEXIM1 to P-
TEFb by co-immunoprecipitation. Cell extracts prepared from huHL6 cells, were 
immunoprecipitated with anti-CDK9 and the presence of the associated CycT1 and 
HEXIM1 was evaluated by western blotting. HMBA treatment for 16 or 24 hours did not 
result in detectable differences in CDK9-associated proteins (figure 27, panel A). In 
contrast, cell extracts prepared after a short treatment with HMBA (1,2 and 4 hours) 
caused a significant reduction of HEXIM1 associated with the immunoprecipitated CDK9 
(Fig.27, panel A). 
Notably, the CDK9-Cyct1 complex was unaffected. Thus, HMBA treatment 
specifically induces a rapid and transient dissociaton of HEXIM1/P-TEFb complex, 
without altering the CDK9/CycT1 heterodimer stability. 
Moreover, in collaboration with Dr.G.Napolitano, increased kinase activity was only 
seen in samples derived from short period of HMBA treatment (1 and 2 hrs) (data not 
shown and Napolitano et al., 2007). Altogheter, the results demonstrate that HMBA leads 
to a rapid and transient dissociation of HEXIM1 from P-TEFb with a concomitant 
enhancement of CDK9 kinase activity. 
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Figure 27 – HMBA leads to a dissociation of HEXIM1 from P-TEFb with a concomitant 
enhancement of CDK9 kinase activity. 
 
Cell extracts prepared from huHL6 cells were immunoprecipitated with anti-CDK9 and the 
presence of CycT1 and HEXIM1 was evaluated by western blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57
 3.1.9  p53 interacts exclusively with “core” active CycT1/CDK9 complex 
 
As presented above, HMBA treatment leads to activation of p21 locus and G1 
arrest. Because it is well documented the activation of the p53-p21 axis in response to a 
variety of stimuli leading to cell cycle arrest, we investigated whether p53 might mediate 
the P-TEFb recruitment at p21 locus following HMBA treatment. A prerequisite for such 
hypotesis is the interaction between p53 and P-TEFb. To test such premise, p53-/- 
H1299 cells were transiently transfected with CMV-p53 and CMV-CycT1 expression 
vectors and the cell extracts were prepared and subjected to co-immunoprecipitation 
(Co-IP) with anti-CycT1 or anti-p53, respectively. As reported in figure 28, panel A, in 
addition to the expected CDK9 and HEXIM1 proteins, p53 was found in the 
immunoprecipitated CycT1 materials. Reciprocally, anti-p53 antibody co-precipitated 
CycT1 and CDK9 proteins, however, no HEXIM1 protein was detectable in the p53-
containing complex. Next, to ascertain whether endogenous p53 interacts with P-TEFb, 
co-IP analysis was carried out with cell extracts from p53 expressing U2OS cells. In 
figure 28, panel B, anti-p53 antibody co-precipitated CycT1 and CDK9, but preimmune 
serum did not. Reciprocally, anti-CycT1 co-precipitated endogenous p53, as well as the 
expected partners CDK9 and HEXIM1, whereas control IgG did not. 
The absence of HEXIM1 protein in both endogenous and p53-over-expressed 
associated materials suggest that p53 interacts only with catalytic active P-TEFb “core” 
complex, a situation which is reminiscent of that observed with other P-TEFb-interacting 
factors such as tat and Brd4 (Yang et al., 2005; Jang et al., 2005). 
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 Figure 28: p53 interacts only with the catalytic active P-TEFb “core complex”. 
 (A) Cell extracts from H1299 cells transiently transfected with p53 and CycT1 constructs were 
immunoprecipitated with anti p53 or anti CycT1, as indicated, and inoputs and precipitates (IP) were 
analyzed by immunoblotting with the indicated antibodies. (B) U2OS cellular extracts were precipitated with 
anti p53 or anti CycT1, as indicated; inputs and precipitates (IP) were analyzed by immunoblotting with the 
indicated antibodies. 
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 3.1.10  HMBA enhances recruitment of p53 and CDK9 at p21 locus 
 
The foregoing observations suggest that HMBA-activation of p21 expression 
involves P-TEFb. Thus, we sought to investigate the presence of P-TEFb at the target 
promoter using chromatin immunoprecipitation (chIP). After treatment of huHL6 cells with 
HMBA for 10 hrs, chromatin was prepared and subjected to chIP assays with antibodies 
specific for CDK9 and p53. 
Precipitated DNA was analyzed by PCR with primers spanning four p21 
sequences, i.e. the affinity p53-binding site (-2283), two regions proximal to the 
transcription start site (-20 and +182) and the distal amplicon at + 5794. The 
semiquantitative nature of these assays was taking in account by performing PCR 
amplificatioj using serial dilutions of DNA  template as well as by repeating the 
expeiments (3-4 times) using different chromatin preparations. Normal serum and input 
DNA values were used to substract/normalize the values from chIP samples. ChIPs from 
trated cells reveal p53 recruitment at the major p53-binding site (-2283), while p53 
recruitment increases only modestly at proximal core promoter (-20), and it was absent 
at the 3’portion of the gene. As compared to untreated cells, chIP experiments indicated 
that CDK9 levels rise significantly around the core promoter (-20 and +182 amplicons). 
Moreover, accordingly with previous studies, the presence of CDK9 in the distal region 
(+5794) is suggestive of the presence of P-TEFb throughout the active transcription unit 
(figure 29). 
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Figure 29 – HMBA enhances recruitmant of p53 and CDK9 at p21 locus. 
On top, schematic representation of the p21 amplicons used in the ChIP experiments. ChIP assays 
were performed with extracts obtained from huHL6 cells before or 10 hr after HMBA treatment with 
antibodies recognizing p53 and CDK9, and the relative levels of ChIP enriched DNA are shown. 
Values are expressed as percentage of input DNA immunoprecipitated. The results shown are the 
average of at least two separate immunoprecipitations from three independent cell cultures. All 
standard deviations were <15%. 
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3.2 Correlation between P-TEFb and cell cycle control 
 
3.2.1 Relationship between P-TEFb –HEXIM1 and genotoxic insults 
 
  It has demonstrated that P-TEFb is maintained in a functional equilibrium 
through alternately interacting with its positive and negative regulators (Jang et al. 2005) 
although the physiological significance of this phenomenon has not been demonstrated. 
Nevertheless, the tight coupling of the P-TEFb equilibrium with the global control of the 
cell growth and differentiation agrees with the demonstrated growth-regulatory functions 
of the P-TEFb-associated factors, such as Myc, p53 and NF-kb (He et al., 2006). 
In the previous sections I presented evidences that HMBA induces transient dissociation 
of HEXIM1/7SK from P-TEFb, such circumstance is also reminiscent of the situation 
seen with HeLa cells treated with certain stress-inducing agents that globally disrupt 
transcription and suppress cell growth (Chen et al.,2004; Michels et al.,2003; Nguyen et 
al., 2001;Yang et al., 2001; Yik et al., 2003). These studies have shown that treatment  
of cells with the kinase inhibitor DRB causes a rapid dissociation of 7SK from P-TEFb 
(Nguyen et al., 2001 and Michels et al.,2003). Moreover, P-TEFb/HEXIM1 complex is 
also distrupted upon transcription attest mediated by ActinomycinD treatment (Michels et 
al.,2003). To extend such findings I sought to look for the role of others compounds to 
induce P-TEFb/HEXIM1 dissociation. First, I used Doxorubicin (DXR) which induces 
DNA damage, but unlikely DRB, does not affect total RNAPII phosphorylation. To 
determine whether the DNA damage agent DXR might affect the association between 
HEXIM1 and P-TEFb, I performed a co-immunoprecipitation assay using a-CycT1 
antibody and cell extracts were prepared from huHL6 cells treated with  DRB, DXR and 
ActinomycinD in a dose dependent manner for two hours. The presence of HEXIM1 and 
CDK9 in the Cyct1-IP materials was evaluated by western blotting (figure 31). I found 
that all treatments (DRB, DXR and ActD) affect CycT1-HEXIM1 association. In fact, less 
HEXIM1 was always observed in CycT1-IP from treated cells, while similar amounts of 
CDK9 were found in all extracts. Thus, all three agents: DRB, ActD and DXR reduce the 
relative amounts of HEXIM1 bound to Cyct1, suggesting that these agents dissociated P-
TEFb from its inhibitory subunit. 
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Figure 30 – DRB, Doxorubicin and Actinomycin release the active P-TEFb  complex. 
 
Cell extracts from huHL6 cells were prepared at 2 hrs after treatment with several 
compounds which concentrations are indicated in figure (on left). The cell extracts were 
immunoprecipitated with anti-CycT1, as indicated, and inputs and precipitates (IP) were 
analyzed by immunoblotting with the indicated antibodies. 
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Figure 31 -  Genotoxic insults shift the P-TEFb complex to inactive form and the different role of 
Pifithrin−α 
 
Nuclear extracts prepared from HeLa cells treated with compounds indicated on legend, were subjected 
to glycerol gradient sedimentation analysis . The panels show the western detection of CycT1, HEXIM1 
and Cdk9 in gradient fractions. 
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3.2.2 Genotoxic insults affect the P-TEFb forms in vivo 
 
To address whether treatments with genotoxic insults could affect the ratio between 
small active and large-inactive P-TEFb complexes, I performed glycerol gradient assays. 
This assay has been commonly used to separate different P-TEFb  complexes by 
molecular weight. 
huHL6 cells were then treated with each of the following agents: DRB, DXR, ActD, 
Apigenin (APG), Mitomycin C (MMC), Camptothecin (CPT)  and cell extracts were 
prepared after 2 hours of treatments and subjected to linear glycerol gradient assays. 
Untreated and RNAse treated cells extracts, which completely released P-TEFb from 
HEXIM1 (Michels et al., 2004) were used as control. 
According to previous studies, P-TEFb complexes can be detected in two major forms, 
the kinase active CDK9/CycT1 complex in fraction 3-4 and the large inactive 
CDK9/CycT1/HEXIM1/7SK complex in fraction 7-8. 
As expected, inclusion of RNase disptrupts the large complex (Fig.32 A, row R). 
Notably, I found that  all these  treatments, regardless their specific mode of action (see 
Discussion), induced dissociation of P-TEFb large complex (Fig 32, panel A, B,C,D).  
Both transcriptional block induced by  DRB and ActD, and genotoxic insults provoked 
by  DXR, APG, MMC and CPT agents  result in  a P-TEFb dissociation. Since it is known 
that when DNA damage occurs, p53 is activated by ATM/ATR pathway to mediate cell 
cycle arrest and induce apoptosis (Banin et al., 1998), I can hypotize a possible 
functional correlation between the ATM/ATR-p53 pathway  and P-TEFb activation. 
To address this point,  I treated huHL6 cells with two different  compounds named 
Pifithrin-α and Caffeine that inhibit p53 pathway affecting transcription of p53-dependent 
genes (p21 and Mdm2) and  ATM/ATR pathway respectively. 
Firstly, I performed glycerol gradient assay with extracts of huHL6 cells treated with 
Pifithrin-α for two hours. Pifithrin-α, is a neuroprotective drug based on p53 inhibitors (for 
details see Discussion), enhances cell survival after genotoxic stress such as UV 
irradiation and treatment with Doxorubicin, etpoxide, etc, It is and a reversible inhibitor of 
p53 mediated apoptosis and p53-dependent gene transcription as p21 and Mdm2 
(Gudkov etal., 2005; Downer et al., 2007).  As shown in figure 32 (panel C, row PFT), no 
effects on P-TEFb active/inactive equilibrium were seen. Thus, I sought to look if  the P-
TEFb equilibrium could shift in response to  the other chemical agent with similar 
property of Pifithrin-α, the Caffeine molecule (CAF). Caffeine is a natural stimulatory 
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compound that has been reported to affect cell cycle function (for details see Discussion) 
and to induce programmed cells death or apoptosis and perturbs key regulatory proteins 
as well as p53 (He et al., 2003; Ito et al., 2003). Most of the research literature supports 
that Caffeine treatments provoke an inhibition of ATM/ATR (Zhou et al., 2000) thus 
inhibiting p53 phosphorylation in response to DNA damage, resulting in p53 inactivation 
(Bode and Dong 2006; Banin et al., 1998; Kastan et al., 1991). As shown in figure 33, 
treatments of huHL6 cells with CAF do not affect P-TEFb equilibrium. To understand if 
ATM/ATR-p53 pathway is involved in P-TEFb activation in response to transcriptional 
block, I treated cells with Caffeine and ActinomycinD togheter. I  sedimented cellular 
extracts in a linear glycerol gradient and the resulting fractions were collected from the 
top of the tube analyzing  the results by western blot assay using antibodies direct 
against CDK9. As shown in figure 18, I found a P-TEFb dissociation in the presence of 
both Caffeine and ActinomycinD. These results strongly suggest that P-TEFb activation 
in response to transcriptional block is independent on ATM/ATR-p53 pathway. 
In conclusion, the results here reported strongly suggest that P-TEFb is activated in 
response to  DNA damage and transcriptional block. In fact, treatments of  cells with 
genotoxic insults ( DXR, APG, MMC and CPT) that provoke DNA damage and activation 
of  ATM/ATR-p53 pathway, and treatments with Actinomycin D that completely block 
transcription, affect the ratio of P-TEFb complex versus the small-active one; 
furthermore, treatments with chemical compounds involved in inhibition of ATM/ATR-p53 
pathway (Pifithrin-α and Caffeine), do not affect P-TEFb complex equilibrium.  
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Figure 32: The effect of Caffeine of P-TEFb equilibrium after genotoxic 
insults. 
 
   Nuclear extracts prepared from HeLa cells treated with compounds indicated on 
legend, were subjected to glycerol gradient sedimentation analysis . The panels 
show the western detection of Cdk9 in gradient fractions. 
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4.Discussion 
 
Several two past decades revealed that some of the most important mechanisms 
regulating eukaryotic gene expression target the movements of RNA polymerase II 
(RNAPII). The control of this process is predominantly mediated by an assortment of co-
regulators that bridge the DNA binding factors to the transcriptional machinery, a number 
of chromatin-remodeling factors that mobilize nucleosomes and a variety of enzymes 
that catalyze the covalent modification of histones and other proteins (Kadonaga, 2004). 
Similar to the regulation of transcriptional initiation, it is likely that control of elongation 
occurs through the combinatorial use of elongation factors. Specifically, the elongation 
control of nascent transcripts seems to be have a central role in the regulation of 
expression of most cellular gene and the key regulatory steps controlling the entry of the 
RNAPII into processive elongation. This step is represented by phosphorylation state of 
the CTD conserved domain of RNAPII as shown in figure 33 (Majello and Napolitano, 
2001). The CTD domain of RNAPII is the specific target for kinases that phosphorylate 
the RNAPII at the transition from initiation to elongation; Price and colleagues isolated a 
DRB positive factor P-TEFb, as an elongation factor that stimulates a shift from 
production of short to long transcripts (Marshall et al., 1995). P-TEFb is also an important 
RNAPII elongation factor involved in pathogenesis of HIV-1 (Price et al., 2000). In fact, it 
has been shown that P-TEFb is a significant co-factor of the HIV-1 Tat protein and that 
Tat activity involves direct interaction with P-TEFb complex (Garriga and Grana, 2004) 
binding to the transactivation response (TAR) element in the nascent HIV-1 transcript 
(Price et al., 2000).  
Moreover, several studies demonstrated that CTD kinase activities and RNAP II 
phosphorylation are also differentially required for expression of distinct p53 target genes 
(Gomes et al., 2006); in fact, paused RNAPII assembles on the p21 promoter before 
cellular stress and converting the elongating form upon stress-induced p53 activation 
(Espinosa et al. 2003). This process is accompanied by recruitment of several positive 
elongation factors and changes in CTD phosphorylation.  
 
 
Many evidences, indicates P-TEFb as a complex implicated in so many different 
diseases (summarized in Fig. 34). It should be pointed out that various diseases may be 
directly or indirectly caused by dysregulation of transcription elongation which is tightly 
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regulated by P-TEFb/HEXIM1 (Dey et al. 2007).Therefore, P-TEFb complex is an 
important elongation factor involved either HIV-1 Tat transactivation or p53 pathway 
representing an attractive target for the development of novel anti-viral and in cancer 
therapy respectively. 
In highlight of these observations, I sought to investigate the P-TEFb role in these 
pathway. 
 
 
 
 
 Figure 33: RNA Polymerase II Elongation Control  
RNA polymerase II comes under the control of negative elongation factors (DSIF and NELF) shortly after 
initiation. P-TEFb mediates a transition into productive elongation by phosphorylating the CTD of the large 
subunit of RNA polymerase II and DSIF 
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Figure 34: Role of HEXIM1 in various disease 
Various disease may be directly or indirectly caused by dysregulation of transcription elongation which is 
tightly regulated by P-TEFb/HEXIM1 
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4.1 P-TEFb and HIV-1 
 
The current model for recruitment of P-TEFb to the HIV-1-LTR predicts the 
formation of Tat-P-TEFb complex, which efficiently binds TAR, allowing CDK9 to 
phosphorylate the CTD of RNAPII, thereby enhances processivity of the RNA 
polymerase II to produce full-length m-RNAs (see figure 35) (Garriga and Grana, 2004; 
Mancebo et al., 1997; Garber et al.,1998). However, two different P-TEFb complexes 
exist in vivo in human cells (Nguyen et al., 2001; Yang et al., 2001): one is active and 
restricted to CDK9 and CyclinT1, the other is inactive and contains HEXIM1 or 2 and 
7SK snRNA in addition to P-TEFb (Michels et al., 2004; Yik et al., 2004). It has shown 
that Tat interacts only with the active P-TEFb complex (Zhang et al., 2000), that HEXIM1 
is responsive to the P-TEFb inactive complex and the presence of HEXIM1/7SK snRNA 
in P-TEFb complexes prevents Tat binding to P-TEFb (Michels et al., 2003). In highlight 
of these findings, I determined the functional consequence of HEXIM1 over-expression 
on Tat activity and the importance of 7SKsnRNA in Tat/P-TEFb inactive complex 
functional interaction. I demonstrated that HEXIM1 inhibits Tat-mediated transactivation 
of HIV-1-LTR in a dose dependent manner and that the ectopic expression of 7SK did 
not significantly affect HIV-1-LTR basal transcription as well as Tat-activation either 
alone or in a combination with HEXIM1; moreover, the specific ability of HEXIM1 to 
repress Tat transactivation is not affected by 7SK (figure 31). These data are consistent 
with a role of HEXIM1 as a negative regulator of HIV-1 activity. Moreover, I 
demonstrated that 7SK is not rate-limiting for the assembly of the inactive P-TEFb 
complex and HEXIM1-mediated inhibition of Tat activity is unlikely due to a global 
inhibition of P-TEFb activity.  
Human HEXIM1 consists of 359 aa and is divided into four regions (as depicted in 
figure 21):  a variable N-terminal region (1–149) that is suggested to have a self 
inhibitory function; a central nuclear localization signal (NLS, 150–177) that interacts with 
the nuclear transport machinery and directly binds to 7SK snRNA; a region of highest 
homology (185–220), including a negatively charged cluster that might be involved in P-
TEFb inhibition and a C-terminal CyclinT binding domain (TBD) (255–359) that leads to 
dimerization of HEXIM1 molecules (Yik et al., 2004; Michels et al., 2004; Shulte et al.,  
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Figure 35: The model for positive transcriptional regulation on the HIV-1-LTR 
 
  Only if the viral protein Tat is present and binds to the bulge of TAR the cellular transcription elongation 
factor P-TEFb is recruited. Upon phosphorylation of RNAPII, NELF and DSIF by the kinase component 
CDK9 of P-TEFb, antitermination takes place and TAR can be elongated to the full length viral RNA. 
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Figure 36: HEXIM1 functional domains 
In figure are indicated the relevant HEXIM1 functional domains and the position of the point mutants ILAA 
and PYND. 
 
 
 
 
 
 
 
 
 
 
 71
2005; Barbonic et al., 2005). It has been reported by Michels et al., the importance 
of two domains of HEXIM1 protein, involved in such interactions. Specifically, the 
HEXIM1 C-terminal domain (181–359) is involved in the binding to P-TEFb through 
direct interaction with CyclinT1 by the evolutionarily conserved motif (PYNT aa202–205) 
and the RNA-recognition motif (KHRR) that was identified in the central region of the 
protein (aa 152–155), involved in a direct binding of 7SK snRNA. I delineated the 
important structural domains of HEXIM1 required for repression of Tat, using two 
HEXIM1 mutants: PYND point mutant that is impaired in repression and binding either P-
TEFb or 7SK RNA in vivo, albeit it retains the ability to bind 7SK in vitro, and the 
HEXIM1-ILAA mutant which fails to interact in vivo and in vitro with 7SKsnRNA (Michels 
et al., 2004). The results obtained along with previous findings strongly suggest the 
crucial role of 7SK in the interaction between HEXIM1 and CyclinT1. In fact, I found that, 
unlike wild-type HEXIM1, both mutants were unable to respress Tat albeit they were 
expressed at levels comparable to the wild-type protein (figure 17). Thus it appears that 
HEXIM1 inhibition is strictly dependent upon the integrity of the protein to interact with P-
TEFb. It can be concluded that, because the point mutant ILAA abolished HEXIM1 
repression on Tat, HEXIM1-mediated inhibition of Tat required the formation of the P-
TEFb/HEXIM1/7SK complex. It was shown by Fraldi et al. that over-expression of 
HEXIM1 resulted in a modest reduction of P-TEFb activity (data no shown and Fraldi et 
al., 2005), thus the inhibition of Tat activity in unlikely due to a global reduction of cellular 
P-TEFb activity. Later on, I demonstrated that the ectopic expression of HEXIM1 did not 
affect Tat expression and that exogenous expression of this results in a small but 
detectable reduction in Tat-bound- P-TEFb (figure 18). 
Finally, because Tat and HEXIM1 interact with the cyclin-box region of CyclinT1 (figure 
37), it is plausible if not likely, that the mutually exclusive interaction of these two 
molecules with CyclinT1 is due to binding to the same domain or to a sterical hindrance. 
Collectively, these data demonstrated that over-expression of HEXIM1 resulted in a 
modest reduction of P-TEFb activity, the inhibition of Tat activity is unlikely due to a 
global reduction of cellular P-TEFb activity, rather over-expression of HEXIM1 appears to 
influence Tat-P-TEFb interaction as depicted in figure 38. 
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Figure 37: Diagram of human CyclinT1 
CyclinT1 is a 726 amino acid protein with a cyclin box, 7SKsnRNA-interacting domain, a Brd4 binding 
domain and a histidine rich domain for RNAPII domain. 
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Figure 38: Schematic model for inhibition of Tat-transactivation 
Over-expression of HEXIM1 results in an inhibition of Tat activity influencing Tat-P-TEFb interaction 
squelching the Tat protein from P-TEFb active complex. 
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Recent works have demonstrated that the integrated HIV-1 provirus is assembled 
into an ordered chromatin structure altered by external stimuli or inhibitors of HDACs 
activity (Van Lint et al., 1996; Ylisastigui et al., 2004; Williams et al., 2006). Dynamic 
changes in gene expression may affect chromatin structure and, consequently, the 
interaction of chromatin with regulatory factors as well as HDACs inhibitors (VPA and 
TSA). It has demonstrated that HMBA enhances HEXIM1 expression as well as 
endogenous HIV-1-LTR promoter (Zoumpourlis and Spandidos, 1992; Klichko et al., 
2006), so I investigated if HDACs inhibitors and HMBA could be enhances HIV-1-LTR 
basal transcription. In fact, I found that both VPA and HMBA activates basal as well Tat-
mediated HIV-1-LTR expression and that both of them act like TSA to induce a robust 
increase of basal and Tat-activated expression of the HIV-1-LTR promoter with a 
concomitant amounts of HEXIM1 levels unlikely the levels of CDK9 and CyCT1 proteins 
that remained largely unaffected (figure 4). Recent findings, shown that HMBA-treatment 
of virtually any cell line tested results in induction of HEXIM1 protein (Yik et al., 2005; 
Turano et al., 2006), however, induction of HEXIM1 is not restricted to HMBA treatment 
but it is up-regulated by various chemical inducers, such as Retinoic acid, DMSO 
(Turano et al., 2006), VPA and TSA. Subsequently, I checked the effect of over-
expression of HEXIM1 protein of the HIV-1 promoter activity in the presence of HDACs 
inhibitors and HMBA respectively resulting in an inhibition of the stimulatory effect 
exerted by these compounds, and, because both Tat and VPA stimulate basal 
transcription, I suggest that the inhibitory function of HEXIM1 might be due to interfering 
with Tat function and/or to inhibition of VPA action. In fact, I found that HEXIM1 
effectively debilitates the activity of HDACs inhibitors in a Tat-independent manner, but 
because has an important role the identification of HEXIM1 as a P-TEFb-associated 
factor and P-TEFb as a principal target of HEXIM1 (Yik et al., 2004; Michels et al., 2004) 
it suggest that P-TEFb could be play a key role in HIV-1 LTR activation mediated by 
HDACs inhibitors in the absence of Tat. I investigated this, using another specific 
inhibitor of P-TEFb activity based on OCR strategy (previously described in “Results” ). 
With this approach I demonstrated that the expression of cc-CDK9 molecules effectively 
inhibits VPA as well as HMBA activities (figure 21). It strongly suggests the crucial role of 
P-TEFb in HMBA or VPA induced activation of HIV-1-LTR promoter in the absence of 
Tat. These findings are in apparent contradiction with the activation of endogenous 
HEXIM1 protein levels observed after treatment with VPA or HMBA. However, it is 
pertinent to note that in human cell cultures almost half of HEXIM1 protein is not bound 
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to P-TEFb (Turano et al., 2006; Yik et al., 2004; Michels et al., 2004) , thus it is unlikely 
that the modest increase of endogenous HEXIM1 might affects P-TEFb activity. Several 
studies have highlighted the role of cis-acting DNA elements within the Long Terminal 
Repeat (LTR) in Tat transactivation. Although Tat stimulates mainly chain elongation, it 
requires cellular DNA-bound activators to stimulate transcription efficiently. In fact, 
mutation of cis-acting regulatory elements within HIV-1-LTR, such as Sp1 DNA-binding 
sites, strongly affect Tat transactivation (Cullen et al., 1993; Jones et al., 1994; Kamine 
et al., 1991).  To this end, monitoring the role of cis-acting sequences in HMBA or VPA 
activation of HIV-1-LTR expression, I shown that transiently basal transcription of three 
HIV-1-LTR mutants was activated by HMBA and VPA treatments either wild-type, albeit 
the relative basal levels of each reporter were significantly different (figure 12). 
Moreover, changes in chromatin conformation were also upon treatment with HDACs 
inhibitors (Wade 2001; De Ruijter et al., 2003). The Tat mediated recruitment of HAT 
proteins most likely explains the changes in chromatin conformation observed at the LTR 
upon transactivation (Verdin et al., 1993; Van Lint et al., 1996). In fact, HMBA and VPA 
treatments activate the transcriptional activity on HIV-1-promoter carried out by the 
powerful approach of chromatin immunoprecipitation (chIP): I found that VPA treatment 
leads to a clear increase of histone acetylation markedly in AcH3, whereas HMBA did 
not significantly modulates histone acetylation of HIV-1-LTR, but in both these 
treatments I looked a modest increased RNAPII recruitment on HIV-1-LTR promoter. 
Notably, in contrast, in the absence of treatments there was no detectable association of 
CDK9 (figure 13). However, following HMBA and VPA treatment, there was a robust 
increase in association of CDK9. These findings are consistent which the possibility that 
either HMBA or VPA induces a Tat-independent recruitment of CDK9 to the HIV-1 
promoter.  
 
 
 
 
 
 
 
 76
Acetylated chromatin Brd4
Pol II
2 P
2 P
2 P
2 P
CDK9
Hexim1
7SK snRNA
Cy
cli
n
T
Active complexInactive complex
CDK9
Cy
cli
n
T
 
 
Figure 39 : a model for Brd4 recruitment of P-TEFb 
P-TEFb is in a dynamic equilibrium between the Brd4 bound state and the inhibitory subunit bound state. 
Brd4 recruits P-TEFb to promoters in acetylated chromatin and liberates the kinase activity, allowing the 
transcriptional elongation. 
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Figure 40: a model for Brd4-HEXIM1 competition to P-TEFb complex 
HMBA or VPA treatments induce over –expression of HEXIM1 that may counteract the binding of Brd4 to P-
TEFb, through a competitive association between the ectopic expressed HEXIM1 and P-TEFb. 
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Moreover, chIP assays clearly demonstrated that P-TEFb is recruited at the HIV-1 
promoter after VPA treatment, in a Tat-independent manner. It remains obscure how P-
TEFb is recruited at HIV-1 promoter in the absence of Tat. It has been reported that Sp1 
directly interacts with CyclinT1 and that Sp1 is necessary and sufficient to recruit P-TEFb 
to the HIV-1LTR (Yedavalli et al., 2003). Moreover, P-TEFb has been shown to interact 
directly with the RNAPII CTD through a histidine rich region of CycT1 (Taube et al., 
2002). It remains to be shown whether VPA treatment might enhance such interactions. 
An alternative mechanism for Tat-independent recruitment of P-TEFb after VPA 
treatment might involve interaction between P-TEFb and Brd4. Brd4 is a bromodomain 
protein with an highly affinity for acetylated histone H4 and H3 (Dey et al., 2003). Most 
importanly, Brd4 can simultaneous interact with both acetylated histones and P-TEFb 
(Yang et al., 2005; Jang et al., 2005). It is plausible that VPA -induced acetylation of 
histone tails H3 and H4 might in turn increase binding to the Brd4-P-TEFb complex 
leading to efficient transcripton of HIV-1-LTR in the absence of Tat. Since Brd4 and 
HEXIM1/7SK snRNA associate in two mutually exclusive CycT1/CDK9 complexes (Yang 
et al., 2005), over-expression of HEXIM1 may counteract the binding of Brd4 to P-TEFb, 
through a competitive association between the ectopic expressed HEXIM1 and P-TEFb 
(figure 38 and 39). Finally I found that over-expression of exogenous HEXIM1, which is 
in association with 7SK snRNA, consituite the physiological inhibitor of P-TEFb (Turano 
et al., 2006; Yik et al., 2004; Michels et al., 2004) and inhibits HMBA, TSA and VPA-
mediated activation of HIV-1 promoter. The critical role of P-TEFb in VPA-induced 
activation of HIV-1 promoter has been further substantiated by the ability of the negative-
dominant cc-CDK9 fusion (Napolitano et al., 2003) to abolish HIV-1 expression in the 
presence of VPA. Reactivation of HIV-1 from post-integration latency by VPA has 
profound clinical implications, further experiments aimed at the specific study of VPA 
activation of HIV-1-LTR expression are necessary to elucidated this molecular 
mechanism. 
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 4.2 P-TEFb and cell cycle control 
 
While HMBA is structurally related to HDACs inhibitors, it does not inhibits HDACs 
or induces histone hyperacetylation (Richon et al., 1998). Indirect evidence suggests that 
HMBA and HDACs inhibitors induce cell differentiation by different pathways (Richon et 
al., 1996). It has demonstrated that HMBA induces cell cycle arrest, differentiation and/or 
apoptosis in various cell types (Marks et al., 1987). Moreover, treatment with HMBA 
blocks cell cycle progression in G1 (Byers et Al., 2005).  As shown in figure 9, treatment 
of huHL6 cells with HMBA induced a G1 arrest. It is  known that cycling cells are 
continuously monitoring both internal and external condition, and, if required, their cell 
cycle progression can be healted at so-called cell cycle checkpoint by arresting signals 
from outside or from inside the cells (Wade 2001). One of the best-known sensors and 
regulators of the internal cell cycle control pathway is the tumor suppressor p53 whose 
upregulation after DNA-damage leads to growth arrest al least partly via induction of p21 
(El Kharroubi et al., 1998). Consistent with this observation, I found a concomitant 
increase of p21 expression, whereas levels of p53 were modestly affected (figure 15). As 
expected, HEXIM1 expression was induced by HMBA, whereas did not produce 
significant differences in the expression of the core P-TEFb subunits.  
Collectively, my data strongly suggest that HMBA treatments lead to activation of HIV-1-
LTR and cellular p21 gene expression. In fact, HMBA treatment activates both p21 and 
HIV-1 promoters, co-expression of two P-TEFb’s inhibitors, as well as HEXIM1 and cc-
CDK9, effectively debilitated the activity of HMBA on both promoters constructs (figure 
11). Moreover, I found that HMBA is capable to modulates CDK9 activity. In fact, it 
demonstrated that a CDK9 activity in largely unaffected following 24h or longer HMBA 
treatment (Turano et al., 2006). Thus, I investigated a possible change in CDK9 kinase 
activity after HMBA treatment for short period. I found that HMBA treatment for 16 or 24 
hours did not result in detectable differences in CDK9-associated proteins. In contrast, 
cell extracts prepared after a short treatment with HMBA (1,2 and 4 hours) caused a 
significant reduction of HEXIM1 associated with the immunoprecipitated CDK9. Thus, 
HMBA treatment specifically induces a rapid and transient dissociaton of HEXIM1/P-
TEFb complex, without altering the CDK9/CycT1 heterodimer stability. Later on, I 
evaluated the relative amounts of associated HEXIM1 after HMBA treatments. I found 
that HMBA treatments caused a significant reduction of the amounts of HEXIM1 
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associated with the immunoprecipitated CDK9 (see figure 12), indicating that HMBA-
mediated dissociation of HEXIM1 from the P-TEFb complex could be attribuited to a 
direct interaction between HMBA and P-TEFb. Studies performed in collaboration with 
Dr.G.Napolitano, demonstrated an increase of kinase activity only seen in samples 
derived from short period of HMBA treatment (1 and 2 hrs) (data not shown and 
Napolitano et al., 2007). Altogheter, the results demonstrate that HMBA leads to a rapid 
and transient dissociation of HEXIM1 from P-TEFb with a concomitant enhancement of 
CDK9 kinase activity. 
 
As presented above, HMBA treatment leads to activation of p21 locus and G1 
arrest. Because the major molecular response to HMBA exposure is the rapid increase 
in the amounts as well as in the catalytic activity of the P-TEFb and it is well documented 
the activation of the p53-p21 axis in response to a variety of stimuli leading to cell cycle 
arrest. I found that P-TEFb interacts with p53 (figure 13) and it makes a coherent 
argument on the role of p53 in mediating P-TEFb recruitment on p21 locus after HMBA 
treatment. The absence of HEXIM1 protein in both endogenous and p53-over-expressed 
associated materials suggest that p53 interacts only with catalytic active P-TEFb “core” 
complex, a situation which is reminiscent of that observed with other P-TEFb-interacting 
factors such as Tat and Brd4 (Yang et al., 2005; Jang et al., 2005). Thus, I presented 
evidences shown in figure 14, that HMBA treatment induces activation of p21 and 
recruitment of P-TEFb to the p21 locus, throughout the active transcription unit, 
underlined by the presence of CDK9 in the distal region. It is not surprising that P-TEFb 
is recruited to the p21 locus it has been demonstrated that p21 is regulated at post-
initiation step (Espinosa et al., 2003). Thus, how P-TEFb is recruiting at p21 locus, is an 
important issue.  
It has demonstrated that P-TEFb is maintained in a functional equilibrium through 
alternately interacting with its positive and negative regulators (Jang et al. 2005) 
although the physiological significance of this phenomenon has not been demonstrated 
clearly. It was found that HMBA agent is known to affect the P-TEFb equilibrium; it  has 
been identified as the only one that can shift the P-TEFb balance toward the 
HEXIM1/7SK-bound state to increase the formation of the inactive P-TEFb complex 
(Chen et al. 2004). Nevertheless, the tight coupling of the P-TEFb equilibrium with the 
global control of cell growth and differentiation agrees well with the demonstrated 
growth-regulatory functions of the P-TEFb-associated factors (He et al., 2006). 
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Moreover, it has demonstrated that the HMBA induced dissociation of HEXIM1/7SK from 
P-TEFb is also reminiscent of the situations seen with HeLa cells treated with certain 
stress-inducing agents that globally disrupt transcription and suppress cell growth (Chen 
et al.,2004; Michels et al.,2003; Nguyen et al., 2001;Yang et al., 2001; Yik et al., 2003). 
Moreover, it has been shown that treatment of HeLa cells with the kinase inhibitor DRB 
causes a rapid dissociation of 7SK from P-TEFb (Nguyen et al., 2001 and Michels yet 
a.,2003) as well as Actinomycin D that distrupts P-TEFb/HEXIM1 by transcription arrest 
(Michels et al.,2003). Based on this observations and because HEXIM1 togheter with 
7SK RNA sequesters the core active P-TEFb in an inactive 7SK –HEXIM1/P-TEFb 
complex, I found that all treatments affect on P-TEFb/HEXIM1 complex in particular, 
treatments of huHL6 cells with DRB provoke a reduction of P-TEFb large form within the 
cells in a dose independent manner while ActinomycinD provoke a reduction of P-TEFb 
large form within the cells lightly, in a dose dependent manner (see figure 15). The 
results here presented suggest that treatment of huHL6 cells with DRB and 
ActinomycinD acts specifically (data no shown) and that upon these conditions, the cells 
are trying to compensate for the loss of P-TEFb activity by releasing more active P-TEFb 
from the inactive and large form. In highlight of results presented above, to address 
whether the huHL6 cells treatments with genotoxic insults could be shift the ratio of small 
to large P-TEFb complex by glycerol gradient assay that is the most commonly used 
method to separate different protein complexes by molecular weight. As shown in figure 
16, I demonstrated that upon these genotoxic insults, HEXIM1 is associated with the 
inactive P-TEFb complex but not with the small core P-TEFb. Consistently, when a 
lysate from huHL6 cells was treated with RNase A to destroy 7SK RNA and loaded onto 
a glycerol gradient, neither HEXIM1 nor CyclinT1 nor CDK9 remained in fractions 
revealing that, upon these genotoxic insults, levels of HEXIM1 were diminished greatly 
and that this effect were accompanied by a simultaneous reduction in the amounts of 
both CycT1 and CDK9 in the same fractions; this resulted in a shift of P-TEFb complex 
to inactive form. The results here presented suggest that treatment of huHL6 with DRB, 
Doxorubicin and ActinomycinD acts trying the cells to compensate for the loss of P-TEFb 
activity by releasing more active P-TEFb from the large form. Following severe genotoxic 
damage, cells undergo either rapid or delayed death. Sensitive cells undergo death 
within a few hours of genotoxic insult (if the damage is not so enormous as to cause 
immediate necrosis), whilst damage resistant cells execute death after a delay, 
precipitating either from the initial G2 arrest or after a number of cell divisions (Enerpeisa 
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2001). The observation that DNA-damaging agents induce levels of p53 in cells led to 
the definition of p53 as a checkpoint factor. While dispensable for viability, in response to 
genotoxic stress, p53 acts as an "emergency brake" inducing either arrest or apoptosis, 
protecting the genome from accumulating excess mutations. Consistent with this notion, 
cells lacking p53 were shown to be genetically unstable and thus more prone to tumors 
(Ko and Prives, 1996). DNA damage evokes a cellular damage response composed of 
activation of stress signalling and DNA checkpoint functions. These are translated to 
responses of replicative arrest, damage repair, and apoptosis aimed at cellular recovery 
from the damage. The significance of p53 in the DNA damage responses has frequently 
been reviewed in the context of ionizing radiation or other double strand break (DSB)-
inducing agents (Latonen 2005). I sought to investigate whether other genotoxic agents 
that acts on DNA damage and subsequently affect on p53 pathway, could act on 
association of HEXIM1 to P-TEFb.  To this end I performed gradient glycerol with anti-
tumor agents as well as, Doxorubicin, Apigenin, Pifithrin-α, Camptothecin and Mitomycin 
C. In particular, Doxorubicin is a compound, similary to DRB, that affects on DNA 
damage, but it not affects total RNAPII phosphorylation, whereas DRB treatments leads 
to a clear shift towards the unphosphorylated form because effectively it blocks CDK9 
activity (Gomes et al., 2007). Apigenin is an inhibitor of global kinase activity, inhibits 
topoisomeraseI and acts  arresting cell cycle in G2/M phase inducing  apoptosis related 
to induction of p53 (Torkin et al. 2005). Camptothecin is capable to bind irreversibly 
DNA-topoisomerase I complex leading at irreversible cleavage of DNA, induces 
apoptosis in many tumor cells, blocks the cell cycle cells in S-phase at low dose and 
cause single strand breaks in DNA that are converted in DS breaks which are lethal DNA 
lesion (Lansiaux et al, 2007;Ju et al, 2007 ); moreover, MitomycinC inhibits DNA 
synthesis, nuclear division and proliferation of cancer cells, leads to a gradual formation 
of DSBs chromosomal DNA, a slowdown of DNA synthesis and appearance of foci and  
although acts primarily during the late G1 and S phase, it is not cell cylce specific 
(Mladenov,2007; McKelvie 2007; Kang, 2005). In the end, Pifithrin-α, is a 
neuroprotective drug based on p53 inhibitors, enhances cell survival after genotoxic 
stress such as UV irradiation and treatment with Doxorubicin, ectopoxide etc, and a 
reversible inhibitor of p53 mediated apoptosis and p53-dependent gene transcription as 
p21 and Mdm2 (Downer et al 2007). As shown in figure 17, I found a P-TEFb shift versus 
inactive complex with all antitumor agents mentioned, unlikely Pifithrin-α. Notably, this 
compound is responsive to p53 inhibition and this suggest a heavy correlation between 
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p53 pathway and P-TEFb active/inactive equilibrium. Agents that cause cells to override 
the DNA-damage checkpoint are predicted to sensitize cells to killing by genotoxic 
agents. One such compound, Caffeine, uncouples cell-cycle progression from the 
replication and repair of DNA. Caffeine therefore serves as a model compound in 
establishing the principle that agents that override DNA-damage checkpoints can be 
used to sensitize cells to the killing effects of genotoxic drugs (Blasina et al., 1999). 
Caffeine may very be the most frequently ingested neuroactive drug in the world. It has 
been reported that Caffeine affects cell cycle function, induces programmed cells death 
or apoptosis and perturbs key regulatory proteins as well as p53 (He et al., 2003; Ito et 
al., 2003). Although the effects of caffeine have been investigated, much of the research 
data regarding caffeine’s effect on cell cycle and  proliferation seem ambiguous. One 
important factor may be that caffeine has been used in many cell types and under a 
variety of conditions and concentrations. In fact, it has found that at low concentration 
(1mM) it induces p53 posphorylation  and p53-dependent apoptosis, whereas at 1-2mM 
concentration  appeared  induces G1 arrest and at high concentration (2-5 mM) 
appeared to block G1 arrest and induce apoptosis (Bode and Dong, 2007).  Previous 
results demonstrated that caffeine overrides the cell cycle effects of various chemicals 
such as protease inhibitors, preventing apoptosis  inhibits cellular DNA repair 
mechanisms, but notably Mladenov et al. has been demonstrated that caffeine is 
capable to delay and reverse effect of MMC. In highlighted of this, I sought to determine 
if this effect could affects on P-TEFb equilibrium resulting in the same effect of Pifithryn-
α. I not found a P-TEFb shift versus inactive complex as shown in figure 17. Notably, 
because caffeine is capable to reverse the effect of DNA damage agents  I found in my 
experiment that this property is affected on MitomycinC and ActinomycinD too. To this 
end, I conclude that also this compound, as well as Pifithrin-α is responsive to p53 
inhibition, suggesting a heavy correlation between p53 pathway and P-TEFb 
active/inactive equilibrium.Therefore, the results here reported strongly suggest that P-
TEFb is activated in response to DNA damage and transcriptional block. In fact, 
treatments of cells with genotoxic insults (DXR, APG, MMC and CPT) that provoke DNA 
damage and activation of ATM/ATR-p53 pathway, and treatments with ActinomycinD 
that completely block transcription, affect the ratio of P-TEFb complex versus the small-
active one; furthermore, treatments with chemical compounds involved in inhibition of 
ATM/ATR-p53 pathway (Pifihrin-α and Caffeine), do not affect P-TEFb complex 
equilibrium. 
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In conclusion, as depicted in figure 26, I suggest that either transcriptional block 
(upon DRB and ActinmycinD treatments), UV exposure or genotoxic insults (upon DXR, 
MMC and CPT treatements) induce the P-TEFb complex activation. This activity is 
involved in the p53 pathway (Caffeine and Pifithrin-α treatments.). Indeed, the activated 
p53 recruits P-TEFb on the p21 promoter to induce cell cycle arrest.  
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Figure 41: Schematic model of P-TEFb recruitmenet on p21 promoter after transcriptional block and 
DNA damage. 
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5. Material and Method 
 
Plasimds 
The G5HIV-Luc contained the HIV-LTR sequences from –83 to +82 of LTR driven the 
Luc gene with 5 GAL4 DNA binding sites inserted at –83 (Majello et al.,1997).  
The pSV-Tat plasmid was described in Majello et al. 1999. 
Gal4-CycT1 was constructed by inserting the EcoRI ± NcoI fragment from GST-CyclinT 
containing the full-length CyclinT1 cDNA  into the SmaI site of pSG424  (Majello et al. 
1999).  
The HIV-1 long terminal repeat (LTR)-based luciferase plasmids G5-83-HIV and G5-38-
HIV contain the LTR sequences from 783 to +82 and from 738 to +82 respectively with 
five GAL4 binding sites inserted at position 783 (G5-83-HIV) and 738 (G5-38-HIV) 
(Majello et al.,1997).  
7SK snRNA plasmid was kindly provided by S.Murphy (Murphy et al. 1992).  
The Flag tagged HEXIM1 expression vector was constructed by insertion of the 
corresponding cDNA regions into the EcoRV site of 3xFlag-CMV10 vector (Clontech) 
(Michels et al., 2004). 
The wild-type of HEXIM1 plasmids were mutagenized by PCR to generate the deletion 
and point HEXIM1 mutants : ILAA, PDNT (Y203D), PYND (T205D) and PDND (Y203D,    
T205D) mutant proteins (Michels et al., 2004).  
The Flag tagged cc CDK9 (3F-cc-CDK9) expression vector was constructed by insertion 
of PCR amplified CC domain fragment from PCDNA3-PML into the  EcoRI and BglII 
vector (Napolitano et al., 2003). 
The 101 flag tagged PCDNA3-Tat (PCDNA3-Tat-101-flag) expression vector was kindly 
provided by Giacca. 
The p21-luciferase reporter contains the residues from 22329 to 111 of the p21 promoter 
(residues 2257 to 4595 of the sequence deposited in GenBank, no. U24170) subcloned 
from p21WWP into the HindIII site of pGL3 basic (Pagliuca et al., 2000). 
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Tissue culture and transfections 
  
Human 293T (Human Embryonic Kidney cells), CHO (Chibese Hamster Ovary cells) and 
huHL6 (a clonal cell line bearing an integrated HIV-LTR-Luc reporter derived from Hela 
cells) (Casse et al., 1999) cells were grown at 37°C in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum (Gibco Life Technologies). 
293T cells were used for transient transfection with HIV1-LTR-Luc reporter (100ng) in 
the presence of pSV-tat (50 ng) along with increasing (10, 100 and 500 ng) amounts of 
F:HEXIM1 and 7SK RNA (10, 100 and 500 ng). CHO cells were transfected with HIV-
LTR-luc reporter (50ng) in the presence of pSV-Tat (100ng) and togheter with CMV-
hCycT1 (200ng), in the presence of increasing amounts of F:HEXIM1 and 7SK. 
Moreover, 50ng of G5-HIVLuc reporter (Majello et al., 1994) was transfected into 293T 
cells along with Gal4-CycT1 (200 ng) or pSV-Tat (50 ng) along with increasing amounts 
of Flag:HEXIM1 wilt type and mutants (10, 100 and 500 ng). After further 24 hours, cells 
were harvested and lysed for luciferase assays. 
50ng of PCDNA3-Tat-101-flag plasmid were used for transient transfections of huHL6 
cells. 24 hours after transfection the culture medium was replaced with fresh one 
containing or not HMBA (10mM) and VPA (5mM). After further 24 hours, cells were 
harvested and lysed for luciferase assays.  HuHL6 cells harboring an integrated HIV-
LTR-Luc reporter were transfected with pcDNA3-Tat vector (50 ng) and 24 hours after 
transfection the culture medium was replaced with fresh one containing or not HMBA 
(10mM) and VPA (5mM). Cell lysates then prepared were analyzed for luciferase activities.  
Human 293T cells transfected with –83HIV-Luc reporter in the presence or absence of 
co-transfected PCDNA3-Tat-101flag vector (50 ng). As huHL6 cells, 24 hours after 
transfection the culture medium was replaced with fresh one containing or not HMBA 
(10mM), VPA (5mM) and TSA (100nM). Cell lysates then prepared were analyzed for 
luciferase activities. 
293T cells were co-transfected with –83HIV-Luc reporter together with pcDNA3-Tat 
vector (50ng), in the presence or absence of 1µg  of F:HEXIM1 vector (Fraldi et al., 
2005) or 1µg  of F:CC-CDK9 (Napolitano et al., 2003). After 24 hr cells were treated with 
VPA, TSA and HMBA for additional 24 hr as indicated. Cell lysates were then prepared 
and analyzed for luciferase activities. 
For all transfection assays 2,5x105 cells were transfected by a liposome method 
(Lipotectamine reagent; Life technologies, Inc.) in 2cm/dish in multiwells. 
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Whole cell extract 
Cells were harvested and washed in ice-cold PBS. After centrifugation, the cellular pellet 
were resuspended in BfrA (10mM HEPES pH 7,9, 1.5 mM MgCl2, 10mM KCl, 200 mM 
NaCl, 0.2 mm EDTA) and vortexed for 30 minutes on ice. The lysates were then 
centrifugated at 14000rpm for 30minutes at 4°C. 
 
Luciferase assay 
Luciferase activity was quantified using Dual-Luciferase Reporter assay (Promega) 
according to manifacture’s instructions and activity normalized in respect of the amount 
of protein cell extract.  
 
FACS analysis 
huHL6 cells were treated for 24hours for HMBA (10 mM). After was trypsinised and 
collected by centrifugation and washed in phosphated-buffered saline (PBS). Cells were 
resuspended in hypotonic solution (0.1% na-Citrate, 50g/ml Propidium iodide, 6.25 
g/ml Rnase and 0.00125% Nonident P40 (Sigma Chemical Co), incubated in absence 
of light for 30-60 minutes at room temperature. Cell cycle data acquisition and analyses 
were performed on Becton Dickinson flow cytometer using Cell Quest Pro and ModFit 
3.0 software. 
Western blotting and antibodies 
Cells were lysed in ice-chilled Buffer A (10mM HEPES pH 7,9, 1.5 mM MgCl2, 10mM 
Kcl, 200 mM NaCl, 0.2 mm EDTA), supplemented with 1mM dithiotreitol (DTT), 40U/ml 
of Rnasin (Promega), protease inhibitor cocktail (P-8340; Sigma), and 0.5% Nonident P-
40. Lysates were vortexed and incubated for 20 min on ice and clarifies by 
centrifugations. Western blotting were performed using the following antibodies: the 
rabbit polyclonal anti-HEXIM1 (C4) has been previously described (Michels et al., 2003); 
goat polyclonal anti-CycT1 (T-18), rabbit polyclonal anti CDK9 (H -169) and goat 
polyclonal anti-Actin (I-19) were from Santa Cruz. Anti-flag M2 monoclonal antobody 
were from Sigma.  Mouse monoclonal anti-p53 (DO-1) were from Santa Cruz and Rabbit 
polyclonal anti-p21 (N-20) were from Santa Cruz. Anti-Tat were from NIH AIDS 
Research Reagent Program. Binding was visualized by enhanced chemioluminescence 
(ECL-plus Kit, Amersham Bioscences). 
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ChIP assay 
For chip assay 10μg of –83HIV-Luc reporter DNA plasmid was transiently transfected 
into 293T cells, 24 hr after transfection cells treated with VPA (5mM) and HMBA  
(10mM). After further 24 hours chIP assays were carried out as described (Raha et al., 
2005). Briefly 24 hours after transfection, cell culture medium was replaced with fresh 
medium containing or not HMBA  (10mM) and VPA (5mM). After 24hrs cells were treated 
as described in Raha et al., 2005. Cells were cross-linked by adding formaldehyde to the 
medium (1% final concentration) and incubated for 10 minutes at room temperature. 
Cells were then washed with ice-cold PBS containing protease inhibitors. Cells were 
then lysed in SDS-lysis buffer (1% SDS, 50mM Tris-Hcl pH8, 10mM EDTA and protease 
inhibitors), and sonicated at least 6-8 times for 10 sec. with 2 minutes incubation on ice 
between. Lysates were centrifuged and 5% of the lysates were kept as input. Lysates 
were diluited 10-fold with chIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM 
EDTA, 16.7 mM Tris-Hcl pH8, 16.7 mM NaCl and protease inhibitors) and pre-cleared 
with 80μl of Salmon Sperm DNA/Protein G Sepharose 4 Fast-Flow (Amersham) for 4hrs 
at 4°C on a wheel and the supernatant was incubated overnight with the primary 
antibody : 10μg of goat polyclonal anti CDK9 L-19, anti-8WG16 (Babco, Richmond, CA) 
anti-AcH3 e AcH4 (Upstate Biotechnology), anti-p53 clone DO1 (Santa Cruz, Inc). After 
the overnight incubation with antibodies, 20μl of Salmon Sperm DNA/Protein G 
Sepharose were added, and the mixture was incubated for 1 hour at 4°C on a wheel. 
After extensive washes with low-salt immune complex wash buffer (0.1% SDS, 1%Triton 
X-100, 2mM EDTA, 20mMTris HCl pH8 and 150mM NaCl) and one with high-salt 
immune complex wash buffer (0,1%SDS, 1%Triton X-100, 2mM EDTA, 20mM Tris Hcl 
pH8 and 500mM NaCl), immuno-complexes were washed twice with TE buffer (10mM 
tris Hcl pH8 and 1mM EDTA). Chromatin was eluted with freshly prepared elution buffer 
(1%SDS and 0.1M CHNaO3). After reversal of the cross-links (at 65°C overnight), the 
samples were treated with proteinaseK for 2h at 55°C, extracted by phenol/chloroform 
and ethanol precipitated. The pellet was resuspended in TE buffer and PCR was 
permormed. IP DNA was quantizated with a Gel Doc instrument (Bio-Rad Laboratories) 
and presented as the ratio of IP to input.  
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Co-immunoprecipitation assay 
CoIP were carried out as previously described (Michels et al., 2004, Turano et al., 2006). 
Whole-cell extracts (1mg) were prepared from 293T cells co-transfected with pSV-Tat 
and F:HEXIM1. Extracts were obtained using buffer A  (10mM HEPES pH 7,9, 1.5 mM 
MgCl2, 10mM Kcl, 200 mM NaCl, 0.2 mm EDTA)  
 and were immunoprecipitated  with anti-CycT1 (H-245 from Santa Cruz) and normal IgG 
pre-adsorbed with proteinA/Sepharose beads, respectively. After extensive washes, the 
recovered materials were resolved on SDS-PAGE and immunoblotted with the anti-Tat 
(NIH AIDS Research Reagent Program), the rabbit polyclonal anti-HEXIM1 (C4) has 
been previously described (Michels et al., 2003); goat polyclonal anti-CycT1 (T-18), Anti-
flag M2 monoclonal antibody were from Sigma. To detect endogenous interaction 
between p53 and P-TEFb cell extracts from 293T cells (1,5mg) were prepared and 
processed as above.   
 
 
Glycerol Gradient 
huHL6 cells were grown in  DMEM  to a density of 4 × 105 cells/ml in 10cm pates The 
cells were treated for 2 hours with P-TEFb inhibitors (DRB100M, RNase 10 and ActD 
1mM) and anti-tumor agents (DXR 0,8M, CPT 12M, APG 60M, MMC 10/ml, CAF 
2mM, PFT 100nM) Cell lysates were prepared in Buffer A (10 mM KCl, 10 mM MgCl2, 
10 mM HEPES, 1 mM EDTA, 1 mM DTT, 0.1% PMSF and EDTA-free complete protease 
inhibitor cocktail (Roche) + RNAsin 1/ml Promega) containing 150 mM NaCl and 0.5% 
NP-40. The lysates were clarified by centrifugation at 14000 rpm for 30 minutes at 4°C. 
The supernatant was layered on top of a 5–45% glycerol gradient containing 150 mM 
NaCl. Gradients were spun at 39000 rpm for 16 hours using a SW-4Ti rotor. The 
fractions were analyzed for the presence of PTEFb complexes by immunoblotting with 
anti-CyclinT1, anti-HEXIM1 and anti-CDK9 antibodies (Santa Cruz) described above. 
Following incubation with the appropriate HRP-conjugated secondary antibodies, the 
blots were developed using enhanced chemioluminescence (ECL-plus Kit, Amersham 
Bioscences). The amount of P-TEFb in the large and free form was quantitated using a 
Gel Doc instrument (Bio-Rad Laboratories). 
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Abstract
Background: The positive transcription elongation factor b (P-TEFb) composed by CDK9/
CyclinT1 subunits is a dedicated co-factor of HIV transcriptional transactivator Tat protein.
Transcription driven by the long terminal repeat (LTR) of HIV involves formation of a quaternary
complex between P-TEFb, Tat and the TAR element. This recruitment is necessary to enhance the
processivity of RNA Pol II from the HIV-1 5' LTR promoter. The activity of P-TEFb is regulated in
vivo and in vitro by the HEXIM1/7SK snRNA ribonucleic-protein complex.
Results: Here we report that Tat transactivation is effectively inhibited by co-expression of
HEXIM1 or its paralog HEXIM2. HEXIM1 expression specifically represses transcription mediated
by the direct activation of P-TEFb through artificial recruitment of GAL4-CycT1. Using appropriate
HEXIM1 mutants we determined that effective Tat-inhibition entails the 7SK snRNA basic
recognition motif as well as the C-terminus region required for interaction with cyclin T1.
Enhanced expression of HEXIM1 protein modestly affects P-TEFb activity, suggesting that HEXIM1-
mediated repression of Tat activity is not due to a global inhibition of cellular transcription.
Conclusion: These results point to a pivotal role of P-TEFb for Tat's optimal transcription activity
and suggest that cellular proteins that regulate P-TEFb activity might exert profound effects on Tat
function in vivo.
Background
The positive transcription elongation factor b (P-TEFb)
composed by CDK9/CyclinT1, has emerged as a signifi-
cant co-factor of the HIV Tat protein. P-TEFb complex has
been shown to associate with and phosphorylate the car-
boxyl-terminal domain (CTD) of RNA pol II, thereby
enhancing elongation of transcription [1-3]. Tat protein
binds an uracil containing bulge within the stem-loop sec-
ondary structure of the Tat-activated region (TAR-RNA) in
HIV-1 transcripts [4-6]. Tat functions as an elongation fac-
tor and stabilizes the synthesis of full-length viral mRNAs
by preventing premature termination by the TAR-RNA
stem-loop. Physical and functional interactions between
Tat and P-TEFb have been well documented [7,8]. Tat
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Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42binds to P-TEFb by direct interaction with the human
cyclinT1, and the critical residues required for interaction
have been delineated [9,10]. The current model for
recruitment of P-TEFb to the LTR, predicts the formation
of the Tat-P-TEFb complex, which efficiently binds TAR,
allowing CDK9 to phosphorylate the CTD of RNAPII,
thereby, enhances processivity of the polymerase to pro-
duce full-length mRNAs [3,7-10].
Like other CDKs, the P-TEFb activity is regulated by a ded-
icated inhibitor. Two different P-TEFb complexes exist in
vivo [11,12]. The active complex is composed of two sub-
units, the CDK9 and its regulatory partners cyclinT1 or T2.
In addition, a larger inactive complex has been identified,
which comprises of four subunits, CDK9, cyclinT1 or T2,
the abundant small nuclear RNA 7SK and the HEXIM1
protein [13-17]. It has been recently shown that HEXIM1
has the inherent ability to associate with cyclin T1 and
binding of 7SK snRNA turns the HEXIM1 into a P-TEFb
inhibitor [15-17]. The relative presence of core and inac-
tive P-TEFb complexes changes rapidly in vivo [11,12].
Several stress-inducing agents trigger dissociation of the
inactive P-TEFb complex and subsequent accumulation of
kinase active P-TEFb [11]. Thus, the 7SK-HEXIM1 ribonu-
cleic complex represents a new type of CDK inhibitor that
contributes to regulation of gene transcription. A further
level of complexity of this system comes from the recent
identification of HEXIM2, a HEXIM1 paralog, which reg-
ulates P-TEFb similarly as HEXIM1 through association
with 7SK RNA [18,19].
It has been showed that Tat binds exclusively to the active
P-TEFb complex [13]. Thus the presence of HEXIM1/7SK
snRNA in P-TEFb complexes prevents Tat binding. Since
the association between 7SK RNA/HEXIM1 and P-TEFb
appears to compete with binding of Tat to cyclinT1, we
have speculated that the TAR RNA/Tat system may com-
pete with the cellular 7SK snRNA/HEXIM1 system in the
recruitment of the active P-TEFb complex [13]. Accord-
ingly, it has been shown that over-expression of HEXIM1
represses Tat function [14,17].
We show here that HEXIM1, or its paralog HEXIM2,
inhibits Tat trans-activation of HIV-LTR driven gene
expression, and more importantly, we demonstrated the
role of the 7SK snRNA recognition motif as well as the
binding to cyclin T1 as crucial elements for efficient Tat
inhibition.
Results
Tat activity is inhibited by HEXIM1
Tat activity involves direct interaction with CDK9/
CyclinT1 (P-TEFb) complex. However, two major P-TEFb-
containing complexes exits in human cells [11,12]. One is
active and restricted to CDK9 and cyclin T, the other is
inactive and it contains HEXIM1 or 2 and 7SK snRNA in
addition to P-TEFb [15,17]. We have previously shown
that Tat interacts only with the active P-TEFb complex
[13]. Because the two complexes are in rapid exchange, we
sought to determine the functional consequences of the
over-expression of HEXIM1 and 7SK snRNA on HIV-1
LTR-driven gene transcription. To this end we performed
transient transfections in human 293 cells using the HIV-
LTR-Luc reporter in the presence of increasing amounts of
Flag-taggeted HEXIM1 and 7SK snRNA, respectively.
Dose-dependent expression of F:HEXIM1 was monitored
by immunoblotting with anti-HEXIM1 antibody (Fig. 1
panel A). As presented in Fig. 1B, we found that basal tran-
scription from the LTR sequences was unaffected by the
presence of F:HEXIM1 or 7SK RNA. In contrast, Tat-medi-
ated transactivation of the HIV-1 LTR was inhibited by the
over-expression of F:HEXIM1 in a dose-dependent man-
ner. Ectopic expression of 7SK RNA did not significantly
affected HIV-LTR-Luc expression either alone or in combi-
nation with F:HEXIM1. Thus, it appears that HEXIM1 is
able to repress Tat-mediated activation. To further sub-
stantiate the inhibitory function of HEXIM1 we sought to
extend our analysis using the murine CHO cells. Tat pro-
tein is a potent activator of HIV-1 LTR transcription in pri-
mate cells but only poorly functional in rodent cells [6,7].
However, Tat-mediated activation can be rescued by
enforced expression of human cyclin T1 [6,7]. As pre-
sented in Fig. 1C we found that, while hCycT1 rescued Tat
function, ectopic expression of HEXIM1 effectively inhib-
its Tat activity. Most importantly, Tat enhancement medi-
ated by hCycT1 was effectively abrogated by co-expression
of HEXIM1 in a dose-dependent manner. Finally, like in
human cells, ectopic expression of 7SK snRNA did not
have any significant effect on Tat activity.
The results reported above suggested that ectopic expres-
sion of HEXIM1 inhibits Tat activity. A large number of
evidences indicate that Tat-transactivation is mainly due
to the recruitment of the cellular complex P-TEFb to the
LTR, causing phosphorylation of the RNAPII CTD [1,6-
10]. Accordingly, we and others have previously showed
that artificial recruitment of P-TEFb to the HIV-1 pro-
moter is sufficient to activate the HIV-1 promoter in the
absence of Tat [20,21]. We sought to determine the conse-
quences of ectopically expressed F:HEXIM1 on P-TEFb
induced transcription in the absence of Tat. We showed
that direct recruitment of CyclinT1 to a promoter template
by fusion to the GAL4 DNA binding domain, activates
transcription from an HIV-1 LTR (G5HIV-Luc) reporter
bearing GAL4 sites [20]. Human 293 cells were transfected
with the G5HIV-Luc reporter along with GAL4-fusion
expression vectors in the presence of F:HEXIM1. As shown
in Fig. 2A, we found that GAL4-CycT1 effectively activates
transcription from the HIV-1 LTR reporter, and co-expres-
sion of F:HEXIM1 resulted in a robust dose-dependentPage 2 of 11
(page number not for citation purposes)
Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42inhibition. The specific effect of HEXIM1 expression was
highlighted by the results shown in Fig. 2B. G5HIV-Luc
reporter was activated by co-expression of a GAL4-TBP,
and such activation was largely unaffected by co-expres-
sion of HEXIM1. Thus, it appears that while HEXIM1
represses P-TEFb activity, enforced expression of this pro-
tein does not have significant effects on TBP-mediated
basal transcription.
Definition of the HEXIM1 regulatory domains involved in 
repression
To investigate the structural determinants of HEXIM1 pro-
tein in repression, the activity of Gal4-CycT1 on G5HIV-
Luc was monitored in the presence of co-transfected Flag-
tagged deletion mutants of HEXIM1. We found that
removal of the C-terminal amino acids affected the inhi-
bition as shown by the HEXIM1 (1–300) and (1–240)
mutants (Figure 3 lanes 6–8 and 9–11). In contrast,
removal of the 119 N-terminal amino acids of HEXIM1
(120–359) did not abolished inhibition (lanes 12–14).
However, further deletion of the N-terminal amino acids
(181–359) completely abolished the inhibitory effect
(lanes 15–17). Thus, HEXIM1-mediated repression
required the presence of the C-terminal domain (300–
359aa) as well as a central region between residues 120
and 181. Finally, we found that HEXIM2, which like
Overexpression of HEXIM1 protein represses Tat transactivationFigure 1
Overexpression of HEXIM1 protein represses Tat transactivation. Panel A, Increasing amounts (10, 100 and 500 ng) of Flag-
taggeted HEXIM1 were transfected into 293, cellular extracts were prepared at 48 hr after transfection and the relative levels 
on endogenous and exogenous HEXIM1 proteins were visualized by immunoblotting with anti-HEXIM1 antibody. Panel B, the 
HIV-Luc reporter (50 ng) was transfected into 293 cells in the presence of pSV-tat (50 ng) along with increasing (10, 100 and 
500 ng) amounts of F:HEXIM1 and 7SK RNA (10, 100 and 500 ng), as indicated. Panel C, HEXIM1 decreases the co-operative 
effect of CycT1 on Tat activation in rodent cells. Chinese hamster ovary cells (CHO) were transfected with the HIV-LTR-Luc 
reporter (50 ng) in the presence of pSV-Tat (100 ng), lane 1, and together with CMV-hCycT1 (200 ng), lane 2, in the presence 
of increasing amounts of F:HEXIM1 and 7SK RNA as in panel B. Each histogram bar represents the mean of at least three inde-
pendent transfections after normalization to Renilla luciferase activity to correct for transfection efficiency with the activity of 
the reporter without effect set to one. Standard deviations were less than 10%.
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Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42HEXIM1, associates and inhibits P-TEFb activity, represses
Gal4-CycT1 activation in a dose dependent manner (lanes
18–20).
We have recently reported that the HEXIM1 C-terminal
domain (181–359) is involved in the binding to P-TEFb
through direct interaction with the cyclin-box of cyclinT1
[15], and the evolutionarily conserved motif (PYNT aa
202–205) is important for such interaction. The PYND
point mutant is impaired in repression and binding either
P-TEFb or 7SK RNA in vivo, albeit it retains the ability to
bind 7SK in vitro. In addition, we determined that
HEXIM1 binds 7SK snRNA directly and the RNA-recogni-
tion motif (KHRR) was identified in the central region of
the protein (aa 152–155). In fact, the HEXIM1-ILAA
mutant fails to interact in vivo and in vitro with 7SK
snRNA [15]. To test the importance of these motifs in
HEXIM1-mediated repression of Tat activity, HEXIM1
point mutants were co-transfected in 293 cells along with
Tat or Gal4-CycT1, respectively. As shown in Figure 4,
unlike wild-type HEXIM1, both mutants were unable to
repress Tat as well as Gal4-CycT activities, albeit they were
expressed at levels comparable to the wild-type protein.
Collectively, the results presented in figures 3 and 4
HEXIM1 represses GAL4-CycT1-mediated activationFigure 2
HEXIM1 represses GAL4-CycT1-mediated activation. Human 293 cells were transfected with 50 ng of G5-HIV Luc reporter 
DNA alone (lane 1) or in the presence of GAL4-expression plasmid DNA (200 ng), as indicated. The presence of the cotrans-
fected F:HEXIM1 (10, 100 and 500 ng) is indicated. Each histogram bar represents the mean of three independent transfections 
after normalization to Renilla luciferase activity. The results are presented as described in figure 1.
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Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42HEXIM1 regulatory domains involved in repressionFigure 3
HEXIM1 regulatory domains involved in repression. Human 293 cells were transfected with 50 ng of G5-HIV Luc reporter 
DNA alone (lane 1) or in the presence of 50 ng of pSV-Tat (lanes 2–20). The presence of increasing amounts (10, 100 and 500 
ng) F:HEXIM1 wild-type (lanes 3–5), various deletion mutants (lanes 6–17) and F:HEXIM2 wt(18–20) are indicated, respec-
tively. On the bottom, it is shown the western-blot of whole cells extracts from transfected cells probed with anti-Flag anti-
body from the indicated co-transfections. The results presented are from a single experiment after normalization to Renilla 
luciferase activity with the activity of the reporter without effect set to one. This experiment was performed three times with 
similar results.
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Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42strongly suggest that HEXIM1-mediated inhibition of Tat
activity requires interaction with P-TEFb as well as bind-
ing to 7SK snRNA.
P-TEFb activity in the presence of enhanced expression of 
HEXIM1
Next we sought to determine whether enhanced expres-
sion of HEXIM1 might directly affect the P-TEFb activity.
293 cells were transfected with F:HEXIM1 and cellular
extracts from mock and transfected cells were prepared. P-
TEFb activity was assayed using as substrate the CTD4
peptide consisting of four consensus repeats of the
RNAPII CTD, and time-course kinase assays were per-
formed [15]. Briefly, P-TEFb and its associated factors
were affinity purified with anti-CycT1 antibody from
mock and F:HEXIM1 transfected cell extracts. Immuno-
precipitates were analyzed by immunoblotting for evalu-
ation of CDK9, cyclin T1 and HEXIM1 proteins,
respectively. The immunoprecipitates were then treated or
not treated with RNase A (Fig. 5). The RNase treatment
will degrade the 7SK snRNA thereby relieving the P-TEFb
inhibition by HEXIM1/7SK snRNP. In fact, samples
treated with RNase showed a robust increase in kinase
activity compared those not treated with RNase,
On top the relevant HEXIM1 functional domains are depictedFigure 4
On top the relevant HEXIM1 functional domains are depicted. Position of the point mutants ILAA and PYND are indicated. 
G5-HIVLuc reporter (50 ng) was transfected into 293 cells along with Gal4-CycT1 (200 ng) Panel A, or pSV-Tat (50 ng) panel 
B along with increasing amounts of Flag:HEXIM1 wilt type and mutants (10, 100 and 500 ng) as indicated. Each histogram bar 
represents the mean of three independent transfections after normalization to Renilla luciferase activity. The results are pre-
sented as described in figure 1. Panel C, western-blot with anti-HEXIM1 antibody demonstrated that the HEXIM1 effectors 
were expressed at comparable levels.
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Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42indicating that 7SK snRNA had been effectively degraded.
We found that the kinase activities of samples that were
treated with RNase were quantitatively the same in both
mock and F:HEXIM1 transfected extracts indicating equal
amounts total of P-TEFb in both samples. A modest, but
reproducible reduction of P-TEFb kinase activity (2-fold)
was observed in extracts from F-HEXIM1 transfected cells.
Altogether, these results demonstrated that over-expres-
sion of HEXIM1 resulted in a modest reduction of P-TEFb
activity, thus the inhibition of Tat activity is unlikely due
to a global reduction of cellular P-TEFb activity.
To further investigate the mechanism of inhibition of Tat-
mediated transcription by HEXIM1, we tested the relative
levels of transfected Tat protein in the presence of
F:HEXIM1. We found that ectopic expression of HEXIM1
did not affected Tat expression (Figure 6A). Next, we
sought to determine whether exogenous expression of
HEXIM1 might result in a decrease in Tat-bound CycT1.
To this end 293 cells were transfected with pSV-Tat in the
presence or absence of F-HEXIM1 using the same transfec-
tion conditions used in the Luciferase assays. Cells extracts
were immunoprecipitated with CycT1 antibody and the
P-TEFb activity in F:HEXIM1 transfected cellsFigure 5
P-TEFb activity in F:HEXIM1 transfected cells. Human 293 cells were transfected with 100 ng of F:HEXIM1 and cell extracts 
were prepared from mock and F:HEXIM1 expressing cells at 48 hr after transfection. Cell extracts were immunoprecipitated 
with anti-cycT1 antisera. The relative amounts of immunopreicipitated cyclinT1, CDK9 and HEXIM1 were quantitated by 
immunoblotting. Samples were treated or not treated with RNase, as indicated. Kinase assays were performed using a CTD4 
peptide and 32P incorporation was quantified in arbitrary units and plotted versus time (min). This experiment was performed 
four times with similar results. A typical experiment is shown.
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Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42immunoprecipitates were analyzed by immunoblotting
for evaluation of Tat, CycT1 and HEXIM1 proteins,
respectively. In two different experiments we found a
modest, but reproducible decrease in Tat-bound cyclin T1
(Fig. 6B). Thus, it appears that exogenous expression of
HEXIM1 results in a decrease of Tat-bound P-TEFb.
Discussion
Several lines of evidence have suggested that Tat function
is largely dependent upon the physical and functional
interaction with the cellular transcription factor P-TEFb.
The recruitment of P-TEFb to the LTR, involves the forma-
tion of the Tat-P-TEFb complex which efficiently binds
TAR, allowing CDK9 to phosphorylate the CTD of
RNAPII, thereby, enhances processivity of the polymerase
to produce full-length mRNAs [6-10]. Two different P-
Tat-CyclinT1 binding in the presence of HEXIM1Figure 6
Tat-CyclinT1 binding in the presence of HEXIM1. Panel A. 293 cells were transfected with 50 ng of pSV-Tat in the presence or 
absence of F:HEXIM1 (100 ng) as indicated and at 48 hrs after transfection cell extracts were probe by Western blotting with 
anti-Tat. For accurate comparison increasing amounts of material (µl) were loaded on the gels. Panel B. 293 cells were trans-
fected as in Panel A, and cell extracts were immunoprecipitated with anti-CycT1. Immunocomplexes were analyzed on West-
ern blots as indicated. I, input, B; bound, FT; flow through. This experiment was performed two times with similar results.Page 8 of 11
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Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42TEFb complexes exist in vivo. The core active P-TEFb com-
prises two subunits, the catalytic CDK9 and a regulatory
partner cyclin T, and a larger inactive P-TEFb complex
comprised by CDK9, cyclin T, HEXIM1 protein and the
7SK snRNA [11-17]. The relative presence of core and
inactive P-TEFb complexes changes rapidly in vivo [11].
We have previously shown that the presence of HEXIM1/
7SK snRNA in P-TEFb complexes prevents Tat binding to
P-TEFb [13]. Since the association between 7SK RNA/
HEXIM1 and P-TEFb competes with binding of Tat to
cyclinT1, we have speculated that the TAR RNA/Tat system
may compete with the cellular 7SK snRNA/HEXIM1 sys-
tem [13]. Accordingly, it has been shown that over-expres-
sion of HEXIM1 represses Tat function [14,19] We show
here that HEXIM1 inhibits Tat function, while expression
of 7SK snRNA does not influence Tat activity. It is perti-
nent to note that 7SK RNA is an abundant snRNA [23],
and it is unlikely that 7SK might be rate-limiting for the
assembly of the inactive P-TEFb complex.
We have delineated important structural domains of
HEXIM1 required for repression of Tat. First, we found
that the C-terminal region is required for inhibition. Pre-
vious findings indicated that the C-terminal region of
HEXIM1 is involved in binding with cyclinT1 as well as
for homo and hetero-dimerization with HEXIM2
[15,18,19]. Second, point mutations in the evolutionarily
conserved motif PYNT (aa 202–205) abolished inhibi-
tion. It has recently shown a critical role of threonine 205
in P-TEFb binding [15]. Moreover, deletion mutants una-
ble to bind P-TEFb failed to repress Tat (Figure 3). There-
fore, it appears that HEXIM1 inhibition is strictly
dependent upon the integrity of the protein to interact
with P-TEFb. Third, a point mutant in the central part of
HEXIM1 (KHRR motif aa 152–155) strongly affects Tat
repression. Since this basic motif has been previously
shown as the 7SK snRNA recognition motif [15], we con-
clude that interaction between HEXIM1 and 7SK snRNA is
required for Tat repression. Collectively, these findings
strongly suggested that HEXIM1-mediated inhibition of
Tat required the formation of the P-TEFb/HEXIM1/7SK
complex.
We determined that enhanced expression of HEXIM1
resulted in a modest inhibition (2-fold) of P-TEFb activity
in vivo. Thus, HEXIM1-mediated inhibition of Tat activity
is unlikely due to a global inhibition of P-TEFb activity.
Moreover, we found that basal transcription from the LTR
sequences was largely unaffected by over-expression of
HEXIM1. Finally, ectopic expression of this protein does
not have significant effects on TBP-mediated basal
transcription. Thus, it appears that P-TEFb is specifically
required for Tat-dependent HIV LTR transcription. Our
results differ somewhat from those obtained in the Zhou
lab who found that exogenous expression of HEXIM1
affects both basal as well as Tat-induced transcription
[13]. These apparent discrepancies are possible due to dif-
ferent transfection conditions in which the relative
amounts of the over-expressed exogenous proteins are
likely different. We found that Tat expression which is
under the control of SV40 promoter remains largely unaf-
fected by co-expression of HEXIM. Our findings suggest a
dedicated role of P-TEFb in Tat activity. Recent studies
point to a specific role of P-TEFb for certain promoters. It
has recently found that P-TEFb is recruited to the IL-8 but
not to the IkBα promoter [23], and it also represses tran-
scription of regulators such as the nuclear receptor
coactivator, PGC-1, in cardiac myocytes [24]. The specific
HEXIM-mediated inhibition of Tat activity underlines the
pivotal role of P-TEFb in the HIV LTR transcription.
The repression exerted by the HEXIM1 protein is likely the
results of a competition between Tat and HEXIM1 in
binding the P-TEFb. Since Tat binds only to the active P-
TEFb complex, it has been suggested that Tat might trap
the active form of P-TEFb as the PTEFb/7SK RNA/HEXIM1
complex appears to undergo continuous formation and
disruption in vivo. In this scenario over expression of
HEXIM1 may counteract the binding of Tat to P-TEFb,
through a competitive association between the ectopic
expressed HEXIM1 and P-TEFb. Accordingly, we found
that exogenous expression of HEXIM1 results in a small
but detectable reduction in Tat-bound- P-TEFb. Our co-
immunoprecipitation results are consistent with recent
findings showing a mutually exclusive interaction of
HEXIM1 and Tat with cyclinT1 using recombinant puri-
fied proteins [25]. Because Tat and HEXIM1 interact with
the cyclin-box region of cyclinT1, it is plausible if not
likely, that the mutually exclusive interaction of these two
molecules with cyclinT1 is due to binding to the same
domain or to a sterical hindrance. However, these studies
have been performed in vitro in the absence of 7SK
snRNA.
The results reported here along with previous findings
strongly suggest the crucial role of 7SK in the interaction
between HEXIM1 and cyclinT1. In fact, HEXIM1 ILAA
mutant does not associate with 7SK in vivo and in vitro,
and co-immuprecipitation of cyclinT1 and 7SK RNA was
markedly reduced with ILAA mutant compared to wild
type [15]. Finally, as shown here ILAA mutant failed to
repress Tat activity, suggesting an important role of
HEXIM1/7SK interaction in Tat inhibition. Thus, associa-
tion between HEXIM1 and 7SK snRNA appears an impor-
tant determinant for Tat inhibition. Future in vitro and in
vivo interaction studies, in the presence of 7SK snRNA
may be instrumental to elucidate the role of 7SK/HEXIM1
complex in Tat activity.Page 9 of 11
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Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42Conclusion
The studies described in this provides further support to
the pivotal role of P-TEFb for the optimal transcription Tat
activity and highlight the importance of the P-TEFb cellu-
lar co-factors HEXIM1/7SK snRNA complex in Tat activity.
Methods
Tissue culture and transfections
Human 293 and rodent CHO cells were grown at 37°C in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% fetal calf serum (Gibco, Life Technolo-
gies). Subconfluent cell cultures were transfected cell
cultures were transfected by a liposome method (Lipo-
fectAMINE reagent; Life Technologies, Inc.) in 2 cm/dish
in multiwells, using 100 ng of reporter DNA and different
amounts of activator plasmid DNA as indicated in the text
and 20 ng of Renilla luciferase expression plasmid (pRL-
CMV, Promega) for normalization of transfections effi-
ciencies. Cells were harvested 48 h after DNA transfec-
tions, and cellular extracts were assayed for luciferase
activity using Dual-Luciferase Reporter assay (Promega)
according to the manufacturer's instructions. The experi-
mental reporter luciferase activity was normalized to
transfection efficiency as measured by the activity deriving
from pRL-CMV.
Plasmids
The G5HIV-Luc contained the HIV-1 LTR sequences from
-83 to +82 of LTR driven the Luc gene with 5 GAL4 DNA-
binding sites inserted at -83. The pSV-Tat, GAL4-TBP,
GAL4-CycT1, have been described [20]. 7SK snRNA plas-
mid was kindly provided by S. Murphy [22]. All Flag-
taggeted HEXIM1 and HEXIM2 expression vectors were
constructed by insertion of the corresponding cDNA
regions into the EcoRV site of p3xFlag-CMV10 vector
(Clontech). Description of the deletion and point
HEXIM1 mutants have been described previously [15].
Full description of the expression vectors used in this
work is available upon request.
Western blotting and antibodies
Cells were lysed in ice-chilled buffer A (10 mM HEPES pH
7.9, 1.5 mM MgCl2, 10 mM KCl, 200 mM NaCl, 0.2 mM
EDTA), supplemented with 1 mM dithiothreitol, 40 U/ml
of RNasin (Promega), protease inhibitor cocktail (P-8340;
Sigma), and 0.5 % Nonidet P-40. Lysates were vortexed
and incubated for 20 min on ice and clarified by centrifu-
gations. Western blottings were performed using the fol-
lowing antibodies: the rabbit polyclonal anti-HEXIM1
(C4) has been previously described (6); anti-FLAG M2
Monoclonal Antibody (Sigma), goat polyclonal anti-
CycT1 (T-18), rabbit polyclonal anti-CDK9 (H-169) from
Santa Cruz, anti-Tat (NIH AIDS Research Reagent Pro-
gram). Binding was visualized by enhanced chemilumi-
nescence (ECL-plus Kit, Amersham Biosciences).
Co-immunoprecipitation and kinase assay
293 cells were transfected with pSV-Tat in the presence or
absence of F:HEXIM1 and cell extracts were prepared at 48
hrs after transfection. CycT1 was immunopurified from
cell extracts (1 mg) using anti-CycT1 (H-245) (sc-10750,
Santa Cruz). Input, immunoprecipited and flow through
materials were used in western blottings using anti-cycT1,
anti-HEXIM1 and anti-Tat, respectively. For kinase assays
293 cells were transfected with F:HEXIM1 and after 48 hr
P-TEFb complex was immunopurified from cell extracts (1
mg) using anti-CycT1 (H-245) (sc-10750, Santa Cruz) as
previously described [13,15]. Briefly, whole cell extracts
from mock and F:HEXIM1 transfected 293 cells were used
in immunoprecipitations together with 40µl of slurry
beads (protein G-Sepharose 4 Fast Flow, Amersham Bio-
sciences) pre-adsorbed with anti-CycT1 and the interac-
tions were carried out in buffer A for one hour at 4°C on
a wheel. After extensive washes one half of the immunop-
urified materials was used in western blotting to ensure
the presence of equal amounts of CDK9, HEXIM1 and
CycT1, respectively. The remaining material was sus-
pended and stirred at room temperature and split in two
equal aliquots. One of the aliquot was treated with 10U of
RNase A for 15 min at 30°C. Samples treated or not with
RNase were stirred at room temperature for three minutes
in 65 µl of buffer A containing [γ-32P]ATP (0,1 µCi/µl), 40
mM ATP, 0,1 µg/ml (YSPTSPS)4 peptide CTD4 (6, 8) and
RNasin (40 U/ml). Aliquots (20 µl) of the suspension
were mixed with SDS-PAGE loading buffer at intervals of
three minutes to stop the reaction. The phosphorylated
CTD4 substrate was separated on a 15% SDS-PAGE and
visualized by radiography. Incorporation of [32P] into
CTD peptide was quantified on a Bio-Rad
phosphoimager.
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Research Paper
p14ARF Directly Interacts with Myc Through the Myc BoxII Domain
ABSTRACT
Myc is a well known proto-oncogene encoding for a transcription factor whose activity
is tightly regulated in the cellular context. Myc was the first oncogene recognized to activate
the ARF tumor suppressor gene which suppresses cell proliferation partly through stabiliza-
tion of the p53 tumor suppressor protein but which also has p53-independent growth-
suppressive functions. Recent studies have indicated that mouse p19ARF negatively
regulates Myc’s transcriptional activity. We here show that the human p14ARF directly
associates with Myc and relocates Myc from the nucleoplasm to the nucleolus. We found
that p14ARF interacts with the Myc-Max complex and the binding of p14ARF does not
interfere with Myc-Max interaction in vitro. Protein interaction assays define the Myc BoxII
as a critical domain required for interaction with p14ARF. Moreover, we identify 30 amino
acids encompassing Myc BoxII domain required for p14ARF interaction and colocalization
in vivo. Finally, we show that p14ARF down regulates Myc activated transcription and
that this activity cannot be addressed to an intrinsic p14ARF repressor domain.
INTRODUCTION
Deregulated expression of Myc protein contributes to several aspect of tumor cell biology.
Enhanced expression of Myc can drive unrestricted cell proliferation, inhibition of cell
differentiation and vasculogenesis, reduce cell adhesion, promotes metastasis and genomic
instability. Conversely loss of Myc protein not only inhibits cell proliferation and growth,
but can also increase cell differentiation and adhesion.1,2,3 High levels of Myc activity are
required for ARF induction and Myc enhancing effect on cell proliferation is inhibited by
the ARF-Mdm2-p53 pathway.4,5
The Myc protein contains a transactivation domain (TAD) at the amino terminus and
a basic region directly followed by a basic helix loop helix leucine zipper motif (bHLH-LZ)
at its carboxyl terminus. The bHLH-LZ domain is responsible for DNA binding and
heterodimerization with partner proteins. Myc partner is the Max protein that also has a
bHLH-LZ domain through which forms a Myc-Max complex that specifically binds to
E-box sequences on gene targeted promoters. The TAD of Myc contains two regions, Myc
BoxI and II that are highly conserved in sequence among Myc family members. Both of
these regions appear fundamental for optimal transcriptional transactivation.3
On the other end, in a context independent from the E-box recruitment, high levels of
Myc have been correlated with transcriptional repression of a number of genes including
p15 and p21.1,6 A regulated transition between the activating and repressing role of the
Myc protein might depend from the physiological status of the cell. The ARF protein has
been recently found to associate with Myc independently from p53 and to inhibit tran-
scription but not repression by Myc.4,7,8
The ARF tumor suppressor (p19ARF in mouse or p14ARF in human) antagonizes the
occurrence of various tumors. ARF up-regulates the p53 tumor-suppressing activity by
interacting with Mdm2 and increasing protein expression of p53.9,10 In addition, several
evidences support the involvement of ARF in the inhibition of cell proliferation independ-
ently of p53.10,11 Mouse and human ARF proteins share a limited homology at the cDNA
and protein levels (132aa for p14ARF versus 169aa for p19ARF).11 These differences at
the structural level have consequences whose functional relevance still is obscure. Different
partners, according to the species, have been found, while p19ARF is able to interact with
5.8S rRNA, the p14 human protein has never been found in a 5.8S rRNA complex.12,13
The structural differences between the murine p19ARF and the human p14ARF proteins
led us to investigate if also the human p14ARF tumor suppressor protein associated with
the Myc protein and if this association was a direct binding between the two proteins.
 
MATERIALS AND METHODS
Plasmids. GAl4-KRAB and G5-83HIV-Luc plasmids have been previ-
ously described.14 Gal4-p14ARF was constructed by inserting an EcoRI/SalI
fragment containing the ARF cDNA obtained from the GFP-p14ARF into
the pSG424 vector. The same insert was subcloned in pPROEX HTa vector
(GIBCO Life Technologies) to obtain the pHis-ARF vector. GFP-p14ARF,
GST-p14ARF, GST-Max, His-Max, pcDNA3-Max, pHA-Myc-FLAG,
pcDNA3-FLAG-Myc, pcDNA3-FLAG-Myc∆123-151, pMT2T-Myc,
pcDNA-p14ARF-HA, GST-Myc deletion mutants, hTERT-Luc were kindly
provided by G. La Mantia and R. Dalla Favera.
In vitro proteins binding assays. Bacterial cells were lysed in PBS 1X
Buffer with 1mM PMSF and protease inhibitors and subsequently sonicated.
The lysates were centrifuged and recombinant proteins were affinity purified:
the GST-fusions (GST; GST-ARF; GST-Max; GST-Myc 1-42; GST-Myc
1-103; GST-Myc 1-143; GST-Myc 1-228; GST-Myc 151-340; GST-Myc
262-349) were purified as previously described15 using glutathione-
sepharose (Amersham Biosciences) and subsequently eluted from the beads
by 20 mM glutathione incubation. The His-Max and His-ARF proteins were
affinity purified by using Ni-NTA Agarose (Invitrogen life technologies) and
subsequently eluted in Buffer C (20 mM Tris-HCl; 100 mM KCl; 5 mM
2-mercaptoethanol, 10% glycerol, 100mM imidazole). The HA-Myc-FLAG
protein was double purified in two steps: in the first step the recombinant
protein was affinity purified with ANTI-FLAG M2-Agarose Affinity Gel
(Sigma) and subsequently eluted by incubation with the FLAG peptide; in
the second step the resulting protein was incubated with Monoclonal
Anti-HA Agarose Conjugate (Sigma) and eluted from these beads by using
HA Peptide (Sigma). For the individual experiments 600 ng of each recom-
binant protein were incubated in a final volume of 1 ml of Binding Buffer
(50 mM Tris-HCl pH 7.4; 150–500 mM NaCl; 1 mM MgCl2; 1 mM DTT;
0.2% NP40). After extensive washing in Binding Buffer, the bound proteins
were eluted by 2X Laemmli buffer, separated on SDS PAGE followed by
Western Blotting.
Cell culture, Luciferase assays and immunofluorescence. Human 293T
and U2OS cell lines were grown in DMEM supplemented with 10% fetal
calf serum. For the luciferase assay, cells were transfected with lipofectamine
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Figure 1. p14ARF directly interacts with Myc in vitro. In the in vitro pull-down assays all the GST-fusions were purified using glutathione-sepharose and
subsequently eluted from the beads by 20 mM glutathione incubation. The His-Max and His-p14ARF proteins were affinity purified by using Ni-NTA Agarose
(Invitrogen life technologies) and subsequently eluted according to the manufacturer’s instructions. The HA-Myc-FLAG protein was double purified first with
ANTI-FLAG M2-Agarose Affinity Gel (Sigma) followed with Monoclonal ANTI-HA Agarose Conjugate (Sigma). (A) The GST, GST-Max or GST-p14ARF proteins
(600 ng) were incubated in presence (lanes 1–3) or absence (lanes 4–6) of HA-Myc-FLAG bait protein (600 ng). Protein complexes were recovered by
immunoaffinity with ANTI-FLAG M2-Agarose and analyzed by WB with anti-FLAG (top panel) and anti-GST (bottom panel) (Santa Cruz Biotechnology, Inc.).
In lanes 8, 9, 10 and 5% of the inputs were loaded. (B) GST-p14ARF and GST-Max proteins (600 ng) were incubated with equal amounts of GST (lane 1)
or HA-Myc-FLAG (lane 2). Affinity complexes (AC) were analyzed by WB using anti-GST (top panel) and a mixture of anti-Myc plus 6xHis Monoclonal
Antibody (BD Biosciences, bottom panel). (C) Mapping of the Myc domains involved in ARF interaction. His-p14ARF was incubated with GST and GST-Myc
deletion mutants (lanes 1–7) proteins. In lane 8, as positive control of Myc interaction, GST-Myc 262-439 was incubated with the His-Max. The protein
complexes were recovered using glutathione-sepharose and the copurified proteins revealed with anti-His (top panel) and anti-GST (bottom panel). In lane
9 and 10, 5% of the proteins inputs were loaded. (D) Schematic representation of the Myc full-length protein and deletion mutants. The relative strengths of
interactions with p14ARF is indicated.
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2000 (Invitrogen Technologies) and pRL-CMV (Promega) was cotransfected
for normalization. The amounts of transfected plasmids DNAs are indicated
in the legend to figures. For immunofluorescence analysis U2OS cells were
transfected with lipofectamine 2000 with 200 ng of the pcDNA3-FLAG-Myc,
pcDNA3-FLAG-Myc∆123-151, GAL4-KRAB, and Gal4-ARF plasmid
and cells processed as described16 using the anti-GAL4 (Upstate Bio,Inc)
and anti-Myc (9E10, Santa Cruz Biotechnology, Inc.) antibodies.
Antibodies and coimmunoprecipitations. The following antibodies
were used for the immunological techniques: anti-Myc (N262 for IP and
9E10 for WB, Santa Cruz Biotechnology, Inc.), anti-Max (C17, Santa Cruz
Biotechnology, Inc.), anti-ARF (C-18, Santa Cruz Biotechnology, Inc.),
anti-FLAG M2 Monoclonal Antibody-Peroxidase Conjugate (Sigma), anti-
GST (B-14, Santa Cruz Biotechnology, Inc.), 6xHis Monoclonal Antibody
(BD Biosciences), anti-GST (B-14, Santa Cruz Biotechnology, Inc.), anti-
Gal4 (Upstate Bio,Inc.). Coimmunoprecipitations from transiently transfected
cells was carried out as previously described.15 For c-Myc IP, 5 µg of antibody
or IgG plus 25 µl of preequilibrated protein G-Sepharose 4 Fast Flow
(Amersharm Biosciences) was used; for Max IP, 3 µg of antibody or IgG was
used plus 25 µl of preequilibrated protein G-Sepharose 4 Fast Flow
(Amersharm Biosciences) was used. For FLAG IP, 25 µl of pre-equilibrated
anti-FLAG M2-Agarose Affinity Gel (Sigma) was used. All interactions were
carried out overnight at 4˚C. Beads were washed at least five times using
buffer F (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 30 mM Na4O7P2, 50
mM NaF, 5 µM ZnCl2, 0.1 mM Na3VO4, 1% Triton, 0.1 mM PMSF)
before loading on SDS-PAGE.
RESULTS
p14ARF directly interacts with cMyc. Recent studies have indicated that
mouse p19ARF interacts and negatively regulates Myc’s transcriptional
activity. The structural differences between the murine p19ARF and the
human p14ARF proteins prompt us to determine if also the human
p14ARF tumor suppressor protein associated with the human Myc protein.
To this end we performed in vitro interaction assays using highly purified
bacterial expressed HA-Myc-FLAG and GST-p14ARF proteins. Equal amounts
of the two purified proteins were incubated for three hours and subsequently
the HA-Myc-FLAG protein complex was recovered with M2-FLAG beads
and analyzed by western blotting with the GST antibody for the presence of
the GST-p14ARF copurified protein. In addition, the HA-Myc-FLAG was
incubated with GST and GST-Max proteins as negative and positive interaction
controls, respectively (Fig. 1A, lane 1 and 2). The result showed in Figure 1A,
demonstrates that Myc directly interacts with p14ARF (lane 3).
Interaction between Myc and p19ARF has been shown to alter the tran-
scription activity of Myc.4,7,8 Since Myc binds to target promoters as het-
erodimer with Max, we sought to determine if p14ARF was able to bind to
the Myc-Max heterodimer, and most importantly to determine a possible
mutually exclusive interaction of p14ARF and Max with Myc. Purified
GST-p14ARF, HA-Myc-FLAG and His-Max proteins were incubated and
the GST-affinity complex was purified. The affinity-purified complex (AC)
was then analyzed for the presence of Myc and Max proteins by
immunoblotting with anti-Myc and anti-His antibodies, respectively. The
result in Figure 1B, lane 2, shows that the GST-p14ARF pull-down both
Myc and Max, demonstrating that p14ARF interacts with the Myc-Max
complex and that the binding of p14ARF does not interfere with Myc-Max
interaction in vitro.
Myc BoxII is required for Myc-ARF interaction in vivo and in vitro. To
identify Myc protein sequences that are essential for association with p14ARF,
we performed in vitro GST pull-down assays using the His-p14ARF protein
and various GST-Myc deletion mutants. The different GST-Myc deletion
mutants were mixed with the His-p14ARF protein and the complexes were
affinity-purified by GST beads; the presence of p14ARF was monitored by
immunoblotting with His antibody. Aliquots of each sample were assayed
with the GST antibody for the presence of the different GST-Myc mutants
used as baits. The results in Figure 1C show that the Myc deletion mutants
1-143 and 1-228 (lane 4 and 5) retain the ability to bind the His-p14ARF
protein. In particular, the GST-Myc 1-228 shows stronger interaction. In
contrast, the N-terminal deletion mutants, GST-Myc 151-340 and
GST-Myc 262-439 fail to bind His-p14ARF (lanes 6 and 7). As positive
control of interaction the GST-Myc 262-439 interacts with His-Max (lane 8).
Thus, the Myc residues 103 to 151, including the Myc BoxII domain, are
required for association with p14ARF in vitro.
To determine whether Myc/Max heterodimer interacts with p14ARF in
vivo, CoIP assays were performed with protein extracts from transiently
transfected 293T cells that express low levels of endogenous Myc and ARF
proteins. The cells were transfected with CMV-based Myc and Max expression
vectors in the presence and absence of p14ARF, and immunoprecipitations
were performed using anti-Myc or anti-Max antibodies. Immunoblot analysis
was then performed using ARF antibody. The results reported in Figure 2A
show that either the p14ARF or Max proteins coimmunoprecipitated with
Myc. In parallel the extracts were immunoprecipitated with the Max antibody
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Figure 2. p14ARF interacts with Myc in vivo. (A) 293T cells were cotransfected by the calcium–phosphate method with of pcDNA3-FLAG-Myc, pcDNA3-Max
and pcDNA-ARF-HA as indicated. Protein extracts were immunoprecipitated with the anti-Myc N262 antibody (lanes 3–5), anti-Max antibody (Santa Cruz
Biotechnology, Inc; lanes 6–8), and IgG antibody (lanes 5,8). and the copurified complexes analyzed by WB with anti-Myc 9E10, anti-Max and anti-ARF
antibodies, as indicated. 5% of the proteins inputs were loaded in lanes 1 and 2. (B) U2OS cells were cotranfected with the indicated vectors and protein
extracts were IP with anti-ARF antibody (lanes 4–6) and the CoIP complexes analyzed by WB with anti-Myc (top) and anti-ARF (bottom). 5% of the proteins
inputs were loaded in lanes 1–3. (C) Myc BoxII is required for the Myc-ARF interaction in vivo. 293T cells were cotransfected with pcDNA-p14ARF-HA along
with pcDNA3-FLAG-Myc or pcDNA3-FLAG-Myc∆123-151 indicated. Protein extracts from the transfected cells were IP with ANTI-FLAG M2-Agarose followed
by WBs with anti-Myc (top), anti-Max (middle) and anti-ARF (bottom).
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followed by immunoblotting with Myc, Max and ARF antibodies,
respectively. As shown in Figure 2A, Max immunoprecipitated
extracts contained both the Myc and the ARF proteins (lane 7).
Collectively these findings demonstrate that p14ARF associates
with Myc/Max heterodimer in vitro and in vivo and that Myc
binding to Max and p14ARF is not mutually exclusive. To further
validate the Myc-ARF interaction the U2OS cell line, which do
not express the ARF protein, were transfected with CMV-based
Myc and ARF expression vectors and cellular extracts were
immunoprecipitated with the ARF antibody. Immunoblotts
confirmed the presence of the Myc protein in the immunopre-
cipitated extracts (Fig. 2B, lane 6).
To corroborate the requirement of the Myc BoxII in the inter-
action with the p14ARF, we performed CoIP assays with protein
extracts prepared from 293T cells that were transiently cotrans-
fected with a CMV driven p14ARF expression vector along with
the pCDNA3-FLAG-Myc vector expressing the full-length protein
or an isogenic vector, pcDNA3-FLAG-Myc∆123-151, expressing
a protein with an in-frame deletion of the Myc BoxII domain.
Protein extracts were immunoprecipitated with the FLAG anti-
body followed by immunoblot with the ARF and Max antibody,
respectively. The result shown in Figure 2C), illustrate that while
the full-length Myc protein interacts with both p14ARF and
Max, the deletion of a 123 to 151, including the Myc BoxII,
severely invalidates the Myc-ARF binding, without significant
effects on Max binding. Collectively, these results substantiated
the physical interaction between ARF and Myc and demonstrate
that the region encompassing the Myc BoxII is involved in the interaction
between Myc and p14ARF both in vitro and in vivo.
Myc-p14ARF nucleolar colocalization is abrogated by Myc BoxII dele-
tion. The Myc protein localizes in the cellular nucleus while the p14ARF
protein has a predominantly nucleolar localization. Depending from the cell
line in which the Myc-ARF interaction has been investigated, it has been
reported that, upon ectopic expression of ARF, Myc colocalizes with ARF in
nucleoli.7 Consequently, we sought to analyze the contribution of the Myc
BoxII region, required for in vivo and in vitro binding, in the sub-cellular
colocalization of Myc and p14ARF. U2OS cells were cotransfected with a
green fluorescent protein (GFP) fusion, GFP-p14ARF, along with the Myc
expression vector or the deletion mutant Myc∆123-151. In agreement with
previous observations, we found that the GFP-p14ARF accumulates pre-
dominantly into the nucleolus whereas Myc displayed a typical nucleopla-
matic localization (data not shown). When ARF and Myc were cotransfect-
ed in a 1-to1 ratio, 82% of the cotransfected cells exhibited colocalization
of Myc and ARF protein into the nucleoli (Fig. 3). In contrast, a significant
reduction of colocalization into the nucleoli (22%) was observed when
GFP-p14ARF was cotransfected with the Myc∆123-151 deletion mutant.
These findings underlie the relevance of the Myc BoxII domain in the phys-
iological interaction between the ARF and Myc protein.
It has been shown that mouse p19ARF is able to block Myc’s ability to
activate transcription.4,8 To extend these results to the human ARF
homolog, we next investigated if p14ARF expression in the U2OS cell line
was able to inhibit Myc ability to transactivate the Telomerase Reverse
Transcriptase (hTERT) promoter.17 As reported in Figure 4A, Myc exoge-
nous expression in U2OS cells activates the hTERT-Luc promoter expression
and cotransfection of p14ARF inhibits Myc-activation in a dose dependent
manner.
p14 ARF does not possess an intrinsic repressor domain. Several models
can be envisaged to explain how ARF might repress Myc mediated transcrip-
tion. For example ARF may possess an intrinsic repressor domain. In order
to evaluate if the p14ARF protein is able to repress transcription when arti-
ficially recruited on a targeted promoter, the human ARF cDNA was fused
to the yeast GAL4 DNA binding domain and the activity of the resulting
plasmid, GAL4-p14ARF, assayed on a targeted promoter bearing 5xGAL4
DNA binding sequences. As control, the GAL4-KRAB expression vector,16
bearing the well described KRAB repressor domain was used. As shown in
Figure 4B, artificial recruitment of GAL4-p14ARF has no significant effects
on G5-83HIV-Luc expression, while GAL4-KRAB effectively repressed the
G5-83HIV-Luc promoter’s activity. Immunofluorescence of transfected cells
with a GAL4 antibody, indicated that both GAL4 fusion proteins are
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Figure 3. Myc-ARF nucleolar colocalization is impaired by Myc BoxII deletion. U2OS
cells were cotransfected with GFP-p14ARF and pcDNA3-FLAG-Myc or pcDNA3-FLAG-
Myc∆123-151 by Lipofectamine 2000 as indicated. An example of immunofluorescence
microscopy of the cells immunostained with anti-Myc 9E10 and analyzed by fluores-
cence microscopy as previously described, is shown. At least 150 cells were analyzed
in each experiment. Values are means from three independent experiments. All images
were digitally processed using Adobe Photoshop.
Figure 4. ARF expression down regulates Myc
activated transcription of the human TERT
promoter. (A) U2OS cells were cotransfected
with 100 ng of hTERT-Luc, 200 ng pMT2T-Myc
and different amounts (0.1; 0.5 and 1 µg,
respectively) of pcDNA-p14ARF-HA as indicated.
(B) Left panel, GAL4-p14ARF fusion protein
artificial recruitment. Cos cells were cotrans-
fected by Lipofectamine with 100 ng the G5-
83HIV-Luc vector, GAL4-p14ARF (0.5 and
1µg) and GAL4-KRAB (0.5 and 1µg) as indicat-
ed. In the right panel, the immunostaining with
anti-GAL4 of transfected cells is shown. Each
histogram bar represents the mean of three
independent transfections made in duplicate
with a standard deviation less than 10%.
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expressed at comparable levels (percentage of GAL4 positive cells) and both
proteins display a prominent nuclear localization (Fig. 4B, right panel).
Thus, p14ARF does not appear to possess an intrinsic repression capability.
DISCUSSION
It has been recently shown that mouse p19ARF negatively regu-
lates Myc’s transcriptional activity. Even though 14ARF and p19ARF
are only 50% identical, their biological function, and interaction
with Myc appears to be very similar. We show here by in vitro pull
down assays and in vivo CoIPs that c-Myc binds directly to p14ARF
and that Myc Box II is critical for the interaction. We also found that
that p14ARF does not interfere with the binding between c-Myc
and Max. In addition, p14ARF inhibits the activation of the hTERT
promoter by Myc, without having any intrinsic repression activity
itself. While Myc protein is a nucleoplasmatic protein the p14ARF
protein has a predominantly nucleolar localization. When both
proteins were expressed we found that the majority of cotransfected
cells exhibited colocalization of Myc and ARF protein into the
nucleoli. Previous studies have shown that, depending from the cell
line in which the Myc-ARF interaction has been investigated, upon
ectopic expression of p19ARF, Myc colocalizes with p19ARF in
nucleoli.7
It remains largely unknown how ARF downregulates Myc tran-
scription activity. It is quite unlikely that ARF could affect recruitment
of Myc-Max heterodimer on DNA target promoters. Gels retardation
experiments indicated that expression of the p14ARF protein in the
U2OS cells does not reduce the association of the Myc-Max complex
to the target DNA sequence (Amente S, Gargano B, unpublished
observation). Accordingly, ChIP analysis on Myc targeted promoters
indicate that Myc binds to the elF4E and nucleolin genes promoters
whether or not p19ARF is present indicating that p19ARF does not
affect recruitment of Myc on these target genes.8
Our findings strongly suggest the critical role of Myc BoxII in
ARF interaction. In fact, we identify 30 amino acids encompassing
Myc BoxII domain required for p14ARF interaction and colocaliza-
tion in vivo. A large number of evidences demonstrated that Myc
BoxII is required for activation and repression of most target
genes.1,3 In addition to ARF, four proteins can bind directly to this
region: the TRRAP, a core subunit of the TIP60 and GCN5 histone
acetyltransferase complex (HAT),18 the ATPases TIP48 and TIP49
found in chromatin remodeling complexes,19 and the SKP2 protein
involved in ubiquitilation.20 However, it is not known if these proteins
bind Myc simultaneously or Myc forms separate complexes with
some of them. We speculate that ARF binding may alter the associa-
tion of Myc to dedicated cofactors either trough sterical hindrance
or to a mutually exclusive interaction due to binding to the same
domain.
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The	 positive	 transcription	 elongation	 factor	 (P‑TEFb)	 is	 a	 cyclin‑dependent	 kinase	
responsible	 for	 phosphorylation	 of	 the	 carboxyl‑terminal‑domain	 (CTD)	 of	 the	 larger	
subunit	of	RNA	polymerase	II	as	well	as	the	negative	elongation	factors	NELF	and	DSIF	
for	a	recent	review	(see	ref.	1	and	refs.	therein).	P‑TEFb	activity	is	controlled	in	vivo	by	
negative	 as	 well	 as	 positive	 factors.	 In	 cultured	HeLa	 cells	 two	 equivalent	 amounts	 of	
different	 P‑TEFb	 complexes	 exist	 in	 vivo.2‑5	The	 core	 active	 P‑TEFb	 is	 a	 heterodimer	
composed	 of	 CDK9	 and	 cyclin	T1	 or	T2	 (CycT1	 and	CycT2).	 P‑TEFb	 is	 negatively	
regulated	 by	 HEXIM1,	 which	 in	 association	 with	 7SK	 snRNA	 hold	 P‑TEFb	 in	 a	
kinase‑defective	large	7SK‑HEXIM1/P‑TEFb	snRNP	complex.6,7
Following	cellular	stress	such	as	genotoxic	insults,	UV	irradiation,	cardiac	hypertrophic	
stimuli	or	treatments	that	induce	transcriptional	arrest,	7SK	and	HEXIM1	dissociate	from	
the	ribonucleo‑protein	complex,	causing	the	rapid	accumulation	of	the	catalytically	active	
P‑TEFb.2,3	In	contrast	with	a	plethora	of	positive	P‑TEFb	cofactors,	HEXIM1	is	the	only	
known	negative	 regulator.	HEXIM1	has	 the	 inherent	 ability	 to	 associate	with	P‑TEFb	
and	binding	of	7SK	snRNA	turns	 the	HEXIM1	 into	a	P‑TEFb	 inhibitor.6,7	HEXIM1	
has	been	originally	isolated	as	a	protein	which	is	induced	in	smooth	muscle	cells	following	
exposure	to	Hexamethylene	bisacetamide	(HMBA).	Moreover,	HMBA	treatment	leads	to	
enhanced	expression	of	HEXIM1	in	virtually	all	cell	 lines	 tested,	and	overexpression	of	
HEXIM1	inhibits	P‑TEFb	activity.5,8	Recently,	we	reported	that	HEXIM1	causes	growth	
inhibition	 and	 promotes	 neuronal	 differentiation.9	 Collectively,	 these	 findings	 provide	
circumstantial	evidences	on	a	putative	role	of	HEXIM1	in	cell	proliferation.
HMBA	is	widely	known	to	induce	cell	cycle	arrest,	differentiation	and/or	apoptosis	in	
various	cell	types.10,11	However,	it	remains	unclear	whether	these	effects	are	mediated	by	
functional	variations	of	the	HEXIM1/P‑TEFb	equilibrium.	Here,	we	addressed	this	issue	
by	 analyzing	 the	 functional	 consequences	of	HMBA	on	P‑TEFb	activity	 and	cell	 cycle	
progression.
We	 sought	 to	 determine	 changes	 in	 the	 cell	 cycle	 profile	 of	 a	 clonal	HeLa	 cell	 line	
(huHL6)	bearing	an	integrated	HIV‑LTR‑Luc	reporter,	exposed	to	HMBA.	As	shown	in	
Figure	1A,	treatment	of	huHL6	cells	with	HMBA	induced	a	G1	arrest.	Consistent	with	
this	observation,	western	blot	analysis	revealed	a	concomitant	increase	of	p21	expression,	
whereas	levels	of	p53	were	modestly	affected	(Fig.	1B).	As	expected,	HEXIM1	expression	
was	induced	by	HMBA,	whereas	did	not	produce	significant	differences	in	the	expression	
of	the	core	P‑TEFb	subunits	(CDK9	and	CycT1).	Moreover,	accordingly	with	previous	
studies,12	HMBA	activated	expression	from	the	endogenous	HIV‑LTR	(data	not	shown).	
Because	HEXIM1	together	with	7SK	RNA	sequesters	the	core	active	P‑TEFb	in	an	inactive	
7SK‑HEXIM1/P‑TEFb	complex	we	examined	the	association	of	HEXIM1	to	P‑TEFb	by	
co-immunoprecipitation.	Cell	extracts	prepared	from	huHL6	cells	were	immuprecipitated	
with	 anti‑CDK9	 and	 the	 presence	 of	 the	 associated	 CycT1	 and	HEXIM1	 was	 evalu-
ated	by	western	blotting.	HMBA	treatment	for	16	or	24	hr	did	not	result	in	detectable	
differences	in	CDK9‑associated	proteins9,13	and	data	not	shown.	In	contrast,	cell	extracts	
prepared	after	a	short	treatment	with	HMBA	(1,	2	and	4	hr)	caused	a	significant	reduc-
tion	 of	 HEXIM1	 associated	 with	 the	 immunoprecipitated	 CDK9	 (Fig.	 1C).	 Notably,	
the	CDK9‑CycT1	complex	was	unaffected.	Thus,	HMBA	treatment	specifically	induces	
a	 rapid	 and	 transient	 dissociation	 of	HEXIM1/P‑TEFb	 complex,	 without	 altering	 the	
CDK9/CycT1	heterodimer	stability.
Next	we	investigated	a	possible	change	in	CDK9	kinase	activity	after	HMBA	treatment	
for	short	period	of	time.	P‑TEFb	activity	was	assayed	using	as	substrate	the	CTD4	peptide	
consisting	of	four	consensus	repeats	of	the	RNAPII	CTD,	and	for	an	accurate	comparison	
time‑course	kinase	assays	were	performed	as	previously	described.4,6,9	Briefly,	P‑TEFb	and	
its	associated	factors	were	affinity	purified	with	anti‑CDK9	antibody	from	cell	extracts	at	
various	time	after	treatment.	Immunoprecipitates	were	analyzed	by	immunoblotting	with	
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anti‑CDK9	antibody	 for	 evaluation	of	CDK9	protein.	The	 immu-
noprecipitates	 were	 then	 treated	 or	 not	 treated	 with	 RNase	 A.	 As	
shown	in	Fig.	1D,	an	increase	in	CDK9	kinase	activity	was	observed	
in	the	samples	prepared	from	HMBA‑treated	cells.	Increased	kinase	
activity	 was	 only	 seen	 in	 samples	 derived	 from	 short	 period	 of	
HMBA	treatment	(1	and	2	hr).	Moreover,	the	kinase	
activities	 of	 samples	 that	 were	 treated	 with	 RNase	
were	quantitatively	the	same	at	all	time	points	indi-
cating	 that	 the	bulk	of	P‑TEFb	present	 in	 the	 cell	
during	 treatment	 remained	 constant.	 Altogether,	
these	 results	 demonstrate	 that	 HMBA	 leads	 to	 a	
rapid	 and	 transient	 dissociation	 of	HEXIM1	 from	
P‑TEFb	with	a	concomitant	enhancement	of	CDK9	
kinase	activity.
As	 presented	 above	 HMBA	 treatment	 leads	 to	
transient	 enhancement	 of	 P‑TEFb	 activity	 with	 a	
concomitant	activation	of	p21	expression.	Because,	
it	is	well	documented	the	activation	of	the	p53‑p21	
axis	 in	 response	 to	 a	 variety	 of	 stimuli	 leading	
to	 cell	 cycle	 arrest,	 we	 investigated	 whether	 p53	
might	mediate	 the	 P‑TEFb	 recruitment	 at	 p21.	 A	
prerequisite	 for	 such	 hypothesis	 is	 the	 interaction	
between	 p53	 and	 P‑TEFb.	 To	 test	 such	 premise,	
p53‑/‑	H1299	cells	were	transiently	transfected	with	
CMV‑p53	 and	 CMV‑CycT1	 expression	 vectors	
and	 cell	 extracts	 were	 prepared	 and	 subjected	 to	
CoIP	 with	 anti‑CycT1	 or	 anti‑p53,	 respectively.	
As	reported	in	Fig.	2A,	in	addition	to	the	expected	
CDK9	and	HEXIM1	proteins,	p53	was	found	in	the	
immunoprecipitated	CycT1	materials.	Reciprocally,	
anti‑p53	 antibody	 coprecipitated	 CycT1	 and	
CDK9	 proteins,	 however,	 no	 HEXIM1	 protein	
was	 detectable	 in	 the	 p53‑containing	 complex.	
Next,	 to	 ascertain	 whether	 endogenous	 p53	 inter-
acts	 with	 P‑TEFb,	 CoIP	 analysis	 was	 carried	 out	
with	 cell	 extracts	 from	p53‑expressing	U2OS	cells.	
In	 Figure	 2B,	 anti‑p53	 antibody	 coprecipitated	
CycT1	and	CDK9,	but	preimmune	serum	did	not.	
Reciprocally,	anti‑CycT1	coprecipitated	endogenous	
p53,	 as	 well	 as	 the	 expected	 partners	 CDK9	 and	
HEXIM1,	whereas	control	IgG	did	not.	The	absence	
of	 HEXIM1	 protein	 in	 p53‑associated	 materials	
suggest	 that	 p53	 interacts	 only	 with	 the	 catalytic	
active	P‑TEFb	‘core’	complex.
The	 foregoing	 observations	 suggest	 that	
HMBA‑activation	 of	 p21	 expression	 involves	
P‑TEFb.	Thus,	 we	 sought	 to	 investigate	 the	 pres-
ence	 of	 P‑TEFb	 at	 the	 target	 promoter	 using	
chromatin	 immunoprecipitation	 (ChIP)	 (Fig.	 2B).	
After	 treatment	 of	 huHL6	 cells	 with	 HMBA	 for	
10h,	chromatin	was	prepared	and	subjected	to	ChIP	
assays	with	antibodies	specific	for	CDK9,	and	p53.	
Precipitated	DNA	was	analyzed	by	PCR	with	primers	
spanning	four	p21	sequences13	i.e.,	the	high‑affinity	
p53‑binding	site	(‑2283),	two	regions	proximal	to	the	
transcription	start	site	(‑20	and	+182)	and	the	distal	
amplicon	at	+5794.	The	semiquantitative	nature	of	
these	 assays	 was	 taking	 in	 account	 by	 performing	
PCR	 amplification	 using	 serial	 dilutions	 of	 DNA	
template	as	well	as	by	repeating	the	experiments	(3–4	
times)	 using	 different	 chromatin	 preparations.	 Normal	 serum	 and	
input	DNA	values	were	used	to	subtract/normalize	the	values	from	
ChIP	 samples.	 ChIPs	 from	 treated	 cells	 reveal	 p53	 recruitment	 at	
the	major	p53‑binding	site	(‑2283),	while	p53	recruitment	increases	
only	modestly	 at	 proximal	 core	 promoter	 (‑20),	 and	 it	was	 absent	
Figure 1. (A) Cell cycle distribution of huHL6 cells treated with HMBA (10mM) for 24 hr, using 
propidium iodide staining. (B) huHL6 cell extracts were prepared after HMBA treatments for 
indicated times (hr) and analyzed by Western blots with the indicated antibodies. (C) huHL6 
cell extracts were prepared from cells treated with HMBA for the indicated time periods (hr), 
and immunoprecipitated with anti‑CDK9 and analyzed by Western blots with the indicated 
antibodies. Panel D, huHL6 cells were treated with HMBA and after 1, 2 and 16 h of treat-
ments, cell extracts were prepared and immunoprecipitated with anti‑CDK9. The relative 
amounts of immunoprecipitated CDK9 were quantitated by immunoblotting. Kinase assays 
were performed using the CTD4 peptide and 32P incorporation was quantified in arbitrary 
units and plotted versus time (min). Samples were treated or not treated with RNase, as indi-
cated. This experiment was performed three times with similar results.
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at	the	3'	portion	of	the	gene.	As	compared	to	untreated	cells,	ChIP	
experiments	indicated	that	CDK9	levels	rise	significantly	around	the	
core	 promoter	 (‑20	 and	 +182	 amplicons).	 Moreover,	 accordingly	
with	previous	 studies13	 the	presence	 of	CDK9	 in	 the	distal	 region	
(+5794)	 is	 suggestive	 of	 the	 presence	 of	 P‑TEFb	 throughout	 the	
active	transcription	unit.
Because	gene	transcription	is	the	endpoint	of	signal	transduction	
pathways	 that	mediate	 the	 cellular	 response	 to	 different	 stimuli,	 it	
is	not	 surprising	 that	 several	 agents	 that	 affect	 cellular	homeostasis	
impinge	on	 the	P‑TEFb	activity.	The	major	mechanism	 regulating	
P‑TEFb	is	the	dynamic	association	of	the	active	eterodimer	CDK9/
CyCT1	to	HEXIM1	or	2	and	7SK	snRNA,	for	a	recent	review	(see	
ref.	1).	HEXIM1	was	originally	isolated	as	a	protein	up‑regulated	by	
HMBA,	which	is	a	potent	inducer	of	growth	arrest	of	a	wide	variety	
of	 transformed	 cells,	 and	 it	 consistently	 induces	 murine	 erythro-
leukemia	 cells	 to	 terminal	 erythroid	 differentiation	 and	 cell	 cycle	
arrest.9,10
Despite	 the	 overall	 increase	 in	HEXIM1	 protein	 level,	HMBA	
induces	 a	 transient	 dissociation	 of	 P‑TEFb	 from	 the	 negative	
HEXIM1/P‑TEFb	 complex	 leading	 to	 enhanced	 kinase	 activity	 of	
CDK9.	 Notably,	 such	 effects	 were	 not	 restricted	 to	 HeLa	 cells	 as	
similar	 responses	 were	 seen	 using	 293T	 and	MEL	 cells	 (data	 not	
shown).	 While	 this	 work	 was	 in	 progress	
we	 learned	 that	 HMBA‑mediated	 revers-
ible	 disruption	 of	 the	 HEXIM1/P‑TEFb	
complex	was	shown	by	another	laboratory;12	
although,	 only	 the	 association	 of	HEXIM1	
to	P‑TEFb	has	been	monitored	in	this	study.	
Moreover,	 in	 this	 report,12	 only	 a	 minor	
effect	 on	 cell	 proliferation	 was	 observed,	
while	we	found	cell	growth	arrest	in	response	
to	 HMBA	 treatment	 of	 different	 cell	 lines	
(HeLa,	 293T,	 H1299,	 MEL,	 U2OS	 data	
not	shown).	We	don’t	know	how	to	explain	
the	discrepancy	between	these	data;	however,	
both	 sets	 of	 experiments	 confirmed	 the	
reversible	disruption	of	the	HEXIM/P‑TEFb	
interaction.
We	 presented	 evidences	 showing	 that	
HMBA	treatment	induces	activation	of	p21	
and	recruitment	of	P‑TEFb	to	the	p21	locus.	
It	is	not	surprising	that	P‑TEFb	is	recruited	
to	the	p21	locus	as	it	has	been	demonstrated	
that	p21	is	regulated	at	post‑initiation	step.13	
How	P‑TEFb	is	recruited	to	p21	locus	is	an	
important	 issue.	 Because	 HMBA	 does	 not	
inhibit	 HDACs	 or	 induce	 histone	 hyper-
acetylation,10	it	is	unlikely	a	role	of	Brd4	in	
recruiting	 P‑TEFb.	 Accordingly,	 we	 found	
that	 exposure	 to	 HMBA	 does	 not	 induce	
hyperacetylation	 at	 the	 p21	 as	 well	 as	 at	
HIV‑LTR	promoter	 (data	 not	 shown).	The	
major	molecular	 response	 to	HMBA	 expo-
sure	 is	 the	 rapid	 increase	 of	 the	 catalytic	
activity	 of	 the	 P‑TEFb.	 The	 finding	 that	
P‑TEFb	interacts	with	p53	makes	a	coherent	
argument	on	the	role	of	this	master	p21‑reg-
ulator	 in	 mediating	 P‑TEFb	 recruitment.	
Moreover,	 it	 has	 recently	 been	 shown	 that	
CDK9	 phosphorylates	 p53	 in	 vitro	 on	 Ser	
33,	315	and	392,	although	the	biological	role	of	this	phosphorylation	
remains	to	be	elucidated.14,15
The	biochemical	consequences	of	HMBA	treatment	are	reminis-
cent	of	 the	 rapid	 release	of	active	P‑TEFb	complex	after	 treatment	
with	stress‑inducing	agents	such	as	UV	irradiation	and	with	general	
inhibitor	of	transcription	as	Actinomycin	D	or	DRB.2,3	It	is	conceiv-
able	 that	 increased	 availability	 of	 active	 core	P‑TEFb	will	 help	 the	
execution	of	 the	transcriptional	response	 leading	to	cell	cycle	arrest	
though	activation	of	selected	target	genes.
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